Regulation of DNA (Cytosine-5) Methyltransferase 1 in the cell cycle and its role(s) in doxorubicin-mediated micronuclei formation by TAN HWEE HONG
 REGULATION OF DNA (CYTOSINE-5) 
METHYLTRANSFERASE 1 IN THE CELL CYCLE AND 













NATIONAL UNIVERSITY OF SINGAPORE 
2008 
 
 REGULATION OF DNA (CYTOSINE-5) 
METHYLTRANSFERASE 1 IN THE CELL CYCLE AND 






TAN HWEE HONG 
(B.Sc, Murdoch University) 
 
 
A THESIS SUBMITTED FOR THE DEGREE OF 
DOCTORATE OF PHILOSOPHY 
INSTITUTE OF MOLECULAR AND CELL BIOLOGY 
AND DEPARTMENT OF PHYSIOLOGY 
NATIONAL UNIVERSITY OF SINGAPORE 
2008 
ACKNOWLEDGEMENTS 
I would like to thank my supervisor, Associate Professor Benjamin F.L.Li, for having 
faith in my ability to undertake graduate studies and for his guidance and 
encouragement throughout the years. 
 
I would also like to thank Professor Alan Porter, Associate Professor Cai Mingjie and 
Dr Linda Chuang, members of my supervisory committee, for their advice and 
discussion. 
 
I would like to extend my sincere appreciation to; 
Prof Alan Porter for his willingness to guide me through the last year of my PhD. I am 
most grateful to him for giving me constructive suggestions for my project, and for 
reading and editing my thesis.  I really appreciate his constant encouragement.   
A/Prof Manoor Prakash Hande for his kindness in helping me cross the final hurdle. 
Dr Linda Chuang for teaching me many useful techniques and for sharing with me her 
invaluable knowledge on DNA methylation. I am grateful for her guidance and her 
friendship all these years. 
To Miss Yeo Wanlin and Dr Vinay Badal for their friendship and encouragement. 
To Dr Oh Hue Kian and Miss Swa Li Foon for their collaborations. 
Members of Prof Porter’s laboratory for sharing their knowledge in cell death. 
 
Special thanks to my husband for his support and understanding throughout the years. 
 
Finally, I would like to dedicate this thesis with great love to my parents and my 




DNA methyltransferase 1 (DNMT1) is the major methyltransferase involved in 
maintenance methylation of newly synthesized DNA. The regulation of DNMT1 
expression is critical in coordinating DNMT1 activity with biological processes and 
therefore must be tightly regulated in the cell cycle. Interestingly, DNMT1 expression 
is inversely correlated with the cell cycle inhibitor p21WAF1 protein in mammalian 
cells, which is independent of the tumor suppresser p53 as shown here. Using a 
combination of experimental protocols including cell synchronization studies, 
transient over-expression, siRNA-mediated depletion and luciferase reporter assays, 
the roles of the transcription factors E2F1 and Sp1, and the transcriptional co-
activator p300 in the regulation of DNMT1 expression were investigated. 
Transcription from the human DNMT1 promoter was shown to be dependent on E2F1 
and Sp1. In addition, this study has identified p300 as a crucial transcriptional co-
activator for E2F1 and Sp1 in regulating DNMT1 expression. Most importantly, this 
report demonstrates for the first time that p21WAF1 negatively regulates DNMT1 at the 
transcriptional level. The up-regulation of p21WAF1 by in-vitro over-expression or by 
treatment with Trichostatin A led to the corresponding down-regulation of DNMT1, 
which consistently coincided with the reduction of p300. Although p21WAF1 is known 
to inhibit the transcriptional activity of E2F1, my data show that p21WAF1 may 
potentially inhibit p300, either directly or indirectly. Surprisingly, DNMT1 was 
down-regulated by TSA treatment in the absence of p300, which may be due to the 
selective depletion of Sp1 that only occurs when p300 is absent. Nevertheless, my 
findings provide the outline of a mechanistic explanation for the inverse relationship 
between DNMT1 and p21WAF1 in mammalian cells. This novel p21WAF1-E2F1/p300-
 ii
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DNMT1 pathway may play a pivotal role to ensure regulated DNMT1 expression and 
DNA methylation in mammalian cell division. 
 
De-regulated DNMT1 expression is often associated with tumorigenesis, and there are 
reports suggesting that DNMT1 acts as a potential target for cancer therapy. I 
attempted to compare the genotoxic effects of doxorubicin, a Topoisomerase II poison 
commonly used in chemotherapeutic treatments, on normal and cancer human cell 
lines, and the potential involvement of DNMT1 in this doxorubicin-induced 
cytotoxicity. The physiological significance of the relationship between p300 and 
DNMT1 was further highlighted in the doxorubicin-mediated DNA damage response, 
which consistently depleted p300, and consequently DNMT1, in non-tumorigenic but 
not tumorigenic cells. My data further show that doxorubicin selectively induces 
micronucleation preceded by senescence-like morphological changes in transformed 
or tumorigenic cells only, and this consistently correlates with a decrease in cell 
viability and an increase in cell death. Importantly, I discovered for the first time a 
positive link between DNMT1 protein expression and micronuclei formation. 
However, although I provide strong evidence that DNMT1 plays a significant role in 
doxorubicin-induced micronucleation, which may lead to cellular demise; it remains 
unclear to what extent DNMT1 contributes to the ultimate cell death. Nevertheless, 
my findings strongly support DNMT1 as one molecular target for doxorubicin-
induced cytotoxicity in mammalian cancer cells. I proposed that the expression levels 
of DNMT1 in tumor cells may potentially determine the effectiveness of doxorubicin 
in chemotherapy. This novel observation enhances the understanding of drug response 
during doxorubicin administration in cancer therapy. 
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Chapter 1: INTRODUCTION 
 
1.1 Historical Overview of DNA Methylation 
The genome is encoded by four fundamental base residues, Adenine (A), Guanine 
(G), Cytosine (C) and Thymine (T). In addition, minor base residues in the form of 
hydroxylated and methylated bases are also present in nucleic acids. Of all DNA 
modifications, two methylated base residues, namely 5-methyl-cytosine (5MeC) 
(Hotchkiss, 1948) and N6-methyladenine (6MeA) (Dunn and Smith, 1955), are 
extensively studied as both serve important functions in both prokaryotic and 
eukaryotic cells. They are formed by the enzymatic transfer of a methyl group from S-
Adenosyl-L-Methionine (SAM) onto the DNA by specific DNA methyltransferases. 
 
1.1.1 DNA methylation in prokaryotic cells 
Both 5-methyl-cytosine (5MeC) (1%) and N6-methyladenine (6MeA) (2%) are found 
in the prokaryote Escherichia coli (E. coli) genome (Doskocil and Sormo'Va, 1965; 
Hattman et al., 1978).  DNA cytosine methylase (dcm) methylates the internal 
cytosine residue in the palindromic CCA/TGG sequence, and DNA adenine 
methylase (dam) methylates the adenine residue in the palindromic GATC sequences 
(Razin et al., 1980). 
 
While the function of dcm methylation still remains to be established, dam serves 
vital roles related to DNA replication, mismatch repair as well as the host-defense 
restriction endonuclease system in E. coli. A time lag between DNA replication and 
methylation by dam results in hemi-methylation of the DNA at the replication fork of 
the genome (Szyf et al., 1982). Since E. coli OriC has 11 GATC sites that can be 
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methylated by dam, and hemi-methylated OriC demonstrated a higher affinity for 
binding to cell membranes (Ogden et al., 1988), this allows preferential binding of the 
SeqA protein to GATC sequences, hence delaying premature methylation and re-
initiation from the OriC until DNA replication is completed (Bakker and Smith, 1989; 
Kang et al., 1999). 
 
Apart from DNA replication, several lines of evidence point to the pivotal roles of 
Dam methylation in post-replication mismatch repair and genetic recombination in 
bacteria. It has been shown that the DNA-binding activity of the MutL mismatch 
protein is needed for dam methylation-directed mismatch repair in E. coli (Robertson 
et al., 2006). Importantly, deficiency of methylation at CCA/TGG by dam is 
associated with increased genetic recombination events (Korba and Hays, 1982). 
Another important role of dam methylation in the bacterial genome is the restriction 
endonuclease system that cleaves foreign DNA to confer protection to the host DNA 
from infection. Interestingly, while the mismatch repair system is well conserved in 
living organisms, dam methylation system mainly functions in prokaryotes but not in 
eukaryotes (Wilson and Murray, 1991).   
 
1.1.2 DNA methylation in eukaryotic cells 
The most striking difference between prokaryotes and eukaryotes is the negligible 
level of 6MeA in eukaryotic DNA, suggesting the non-essential role of adenine 
methylation in eukaryotes. In contrast, 5MeC, mainly located in CG and CNG 
sequences, is non-randomly distributed in higher eukaryotic genomes (Gruenbaum et 
al., 1981; Ramsahoye et al., 2000) . These DNA methylation patterns play important 
roles in gene regulation in diverse organisms including sea urchins (Bird et al., 1979), 
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fungi, plants, protozoa and mammals, with the exception of Saccharomyces cerevisiae 
and Caenorhabditis elegans which do not display methyltransferase activities despite 
the existence of putative DNA methyltransferase genes, as reviewed by Bestor (Goll 
and Bestor, 2005).  
 
Mammalian DNA methylation 
The mammalian genome contains about 3 X 107 residues of 5MeC which represent 
1% to 3% of the total cytosine content of mammalian DNA (Bestor and Tycko, 1996). 
Even though 5-methylcytosine has been observed in CpA, CpT and CpC 
dinucleotides, CpG is the major methylated dinucleotides that accounts for 40% to 
80% of the cytosine methylation in different mammalian genomes (Woodcock et al., 
1987). 
 
While the functional roles of CpA, CpT and CpC methylation remain unresolved, 
methylation of CpG in mammalian cells has been implicated in epigenetic 
modifications of chromatin such as genomic imprinting, X-chromosome inactivation, 
aging and mammalian development (Bird, 2002). However, imprinted genes and 
genes subjected to X-chromosome inactivation only account for <10% of the 5-
methylcytosine content in the genome, with the majority residing in transposons 
(Walsh and Bestor, 1999; Yoder et al., 1997). This is in agreement with the fact that 
transposable elements are generally abundant in the genome (>40%) and are relatively 
rich in CpG dinculeotides (Goll and Bestor, 2005; Smit and Riggs, 1996). Genomic 
imprinting has been proposed to involve allele and tissue-specific methylation 
patterns which are heritable in somatic cells (Wigler et al., 1981). These parental-
specific methylation patterns are erased in primordial germ cells, but are re-
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established during gametogenesis or early embryogenesis (Chaillet et al., 1991). 
Additionally, DNA methylation patterns may also alter during development and 
differentiation. Disruption of DNA methylation patterns leads to abnormal 
development and recessive embryonic lethality, as demonstrated in the mouse system 
by gene targeting mutation of the murine DNA methyltransferase gene (Li et al., 
1992). Knockout of the murine oocyte-specific DNMT1o gene was also shown to 
result in the disruption of genomic imprinting in homozygous embryos, further 
demonstrating the importance of DNA methylation in mammalian development 
(Howell et al., 2001).  
 
1.1.3 Demethylation of 5MeC 
DNA methylation in mammals was also shown to be a reversible biochemical process 
and the mechanism for DNA demethylation involves DNA demethylases that encode 
a methyl-CpG-binding domain (Patra et al., 2008). One such protein identified earlier 
in the chick embryo is the 5MeC DNA glycosylase (5-MCDG) which requires RNA 
for its demethylating function (Jost et al., 1997). Interestingly, methylcytosine binding 
protein MBD4 has also been shown to act as a demethylase with similar 5-MCDG 
activity (Hendrich et al., 1999; Zhu et al., 2000). Similarly, MBD2 was shown to 
possess dual functions as a transcription repressor and as a DNA demethylase that 
target demethylation and activation of specific gene promoters (Detich et al., 2002). 
This novel finding was however heavily disputed by others (Ng et al., 1999; Hendrich 
et al., 2001).  
 
Demethylation of DNA can also occur by the treatment of cells with demethylating 
agents such as 5-azacytidine (5AzaC) and 5-aza-deoxycytidine (5AzadC) (Wolffe et 
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al., 1999). Their incorporation into the DNA causes DNMT1 to become irreversibly 
bound to these cytosine structural analogues. This leads to rapid loss of DNMT1 upon 
repeated replications, resulting in significant demethylation (Ghoshal et al., 2005). 
Similarly, procainamide, a local anesthetic, has been shown to demethylate genes by 
inhibiting the maintenance activity of DNMT1 (Lee et al., 2005), and constrained 
analogues of procaine targeting DNMT1 have recently been synthesized (Castellano 
et al., 2008). In addition, an anti-sense oligodeoxynucleotide to DNMT1, identified as 
MG98, has been discovered to effectively deplete DNMT1 expression in mammalian 
cells. Though MG98 was shown to have therapeutic potential, clinical studies are still 
extensively carried out in patients with myelodysplastic syndrome (MDS) and acute 
myeloid leukemia (AML) to determine the efficacy of this drug in targeting aberrant 
epigenetics in MDS/AML (Klisovic et al., 2008). 
 
1.1.4 Host defense versus DNA methylation 
Cytosine methylation is part of a genome defense system involved in the inactivation 
of parasitic sequences such as transposable elements and proviral DNA, and most of 
these elements are found to be methylated and transcriptionally inert as 
heterochromatin in mammalian, plants and fungi genomes (Bestor and Tycko, 1996). 
Indeed, the majority of cytosine methylation in plants and mammals, and all cytosine 
methylation in the ascomycete fungus Neurospara crassa, reside in repetitive 
elements such as transposons (Goll and Bestor, 2005; Smit and Riggs, 1996). 
Strikingly, Drosophila which is deficient in 5meC suffers significantly larger numbers 
of insertion mutations (50% to 85%) than mammals, suggesting that cytosine 
methylation may have a primary role in regulating the activities of transposons (Yoder 
et al., 1997).  
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RNA interference (RNAi) which occurs in plants, mammals and some fungi, is also 
capable of directing DNA methylation. Several plant RNA viruses have been shown 
to trigger de novo methylation and co-suppression of homologous DNA sequences 
during the course of infection (Jones et al., 1998a). The viral double-stranded RNAs 
(dsRNAs) are cleaved by the dicer class of ribonuclease into small 21-26 nucleotides 
RNAs termed RNAi, which are then degraded by the argonaute protein of the RISC 
complex (Liu et al., 2004). Methylation of homologous DNA sequences in the host 
results in the formation of a transcriptionally silent heterochromatin, and therefore 
confers protection against cleavage and resistance to further infection as a means of 
host defense (Mathieu and Bender, 2004). RNAi was also shown to induce DNA 
methylation and histone H3 methylation in human cells, as demonstrated by the 
silencing of the E-cadherin gene using synthetic RNAi targeted to the CpG islands of 
the E-cadherin promoter (Kawasaki and Taira, 2004). However, the importance of this 
pathway in mammals is unknown. 
 
Other than host defense, the ability of DNA methyltransferases to recognize 
secondary structures may also lead to genomic defects. During DNA replication, 
slippage of replication intermediates can result in the extrusion of a segment of 
GGC/GCC triplet sequences, which form stable three-way junctions associated with 
DNA instability; and this can lead to chromosome fragility (Usdin and Woodford, 
1995). Furthermore, this abnormal DNA structure can be preferentially recognized by 
DNA methyltransferases for de novo methylation. In such a scenario, the host defense 
system attacks an innocuous alteration of an endogenous gene because of its similarity 
to a parasitic sequence element. As a result, the GGC/GCC repeats expansions may 
lead to diseases related to auto-immune disorders (Bestor and Tycko, 1996). 
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1.2 Mammalian DNA Methyltransferases 
DNA (cytosine-5) methyltransferases (DNMT) catalyze the enzymatic transfer of 
methyl groups from S-adenosyl-methionine (SAM) to the 5-carbon position of 
cytosine residues, predominantly in CpG dinucleotides, to form 5MeC bases 
(Robertson, 2001). DNMTs bear ten characteristic sequence motifs, Motifs I to X. 
Most of these motifs are discernable in the DNA cytosine-methyltransferases from 
bacteria, fungi and plants to mammals (Bestor, 2000). In mammals, three families of 
DNA (cytosine-5) methyltransferases have been identified, namely DNMT1, 
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Diagram 1: Schematic diagram of the 1616 amino acid human DNA methyltransferase 1 
(DNMT1) protein showing the binding sites for proteins (Robertson, 2001). 
 
 
DNA methyltransferase 1 (DNMT1) was the first eukaryotic DNA methyltransferase 
to be purified and cloned from the mouse (Bestor et al., 1988). The human homologue 
was identified in 1992 (Yen et al., 1992), and the full-length DNMT1 gene encoding 
1616 amino acids was mapped to chromosome 19p13.2 (Yoder et al., 1996). The 
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human gene is composed of 40 exons and 39 introns spanning 60 kilobases. 
Alternative splicing of the C-terminal region may generate DNA methyltransferase 
isoforms (Ramchandani et al., 1998). DNMT1 adopts a global structure consisting of 
the C-terminal catalytic domain linked to the N-terminal regulatory domain through a 
lysine- and glycine-rich (KG) linker domain. The C-terminal catalytic domain is 
highly conserved among species while the N-terminal domain of DNMT1 contains a 
number of functional domains that have accrued over the course of evolution. 
Importantly, it was demonstrated that the N-terminal region is also responsible for the 
regulation of the catalytic activity at the C-terminal region (Fatemi et al., 2001).  
 
The first 126 codons at the N-terminus of DNMT1 interact with DNA 
methyltransferase associated protein-1 (DMAP1), and are responsible for forming a 
repressor complex with HDAC2 at replication foci (Rountree et al., 2000). Codons 
163 to 174 of DNMT1 also interact with PCNA, an auxillary factor for DNA 
replication and repair, and this DNMT1-PCNA complex serves as a target for p21WAF1 
protein (Chuang et al., 1997). The target recognition domain of DNMT1 for hemi-
methylated DNA resides within codons 122 to 417 in close proximity with the PCNA-
binding site, and the binding of DNA substrates to this region can disrupt the 
DNMT1-PCNA interaction (Araujo et al., 2001). A nuclear localization sequence 
(NLS) is located at codons 194 to 213, and a fork targeting region required for 
association with replication foci has been identified (Leonhardt et al., 1992). A 
cysteine-rich (CXXC) zinc-binding domain is located at the center of the N-terminal 
region, but its function remain unknown (Bestor, 1992). Interestingly, this cysteine-
rich domain, which shows homology to the repressor domain of HRX, was found to 
possess transcriptional repressor activity by its association with HDAC and histone 
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deacetylase activity (Fuks et al., 2000). Two independent zinc-binding domains were 
also characterized and were shown to be responsible for modulating the DNA-binding 
domain of DNMT1 (Chuang et al., 1996). DNMT1 has been demonstrated to form a 
complex with HDAC1, RB and E2F1 to repress transcription from E2F-responsive 
promoters; and indeed, amino acids 653-812 of DNMT1 protein can directly interact 
with RB proteins to mediate repression (Fuks et al., 2000; Robertson et al., 2000). 
Two bromo-adjacent homology (BAH) domains proposed to act as a protein-protein 
interaction motif are found at the end of the N-terminal domain (Callebaut et al., 
1999). More recently, DNMT1 was also shown to interact with p53 in regulating p53-
repressed promoters, and the interaction domain was mapped to amino acids 1081-
1409 of the C-terminal region of DNMT1 (Esteve et al., 2005). 
 
Human DNMT1 is the most abundant methyltransferase in somatic cells. It has a 10-
to 40-fold preference for hemi-methylated substrates, and is therefore known as the 
maintenance methyltransferase (Hermann et al., 2004). DNMT1 has been implicated 
in a variety of epigenetic events related to genomic imprinting (Li et al., 1993), X-
chromosome inactivation (Beard et al., 1995) and mammalian development. Targeted 
disruption of the DNMT1 gene leads to embryonic lethality and hypomethylation of 
several genes, strongly suggesting that DNMT1 is crucial for embryonic development 
(Li et al., 1992). DNMT1 knockout in somatic cells leads to decreased cell viability, 
further demonstrating that DNMT1 is necessary for cell survival (Egger et al., 2006). 
 
DNMT1 variants 
An alternative splice variant of human DNMT1 containing an extra 48 bp between 
exons 4 and 5 was identified in somatic cells and termed DNMT1b (Hsu et al., 1999). 
DNMT1b mRNA is ubiquitiously expressed in all mammalian cells. Although 
DNMT1b has an additional 16 amino acids, it possesses an enzymatic activity similar 
to DNMT1 in vitro (Bonfils et al., 2000). Even though DNMT1b is evolutionarily 
conserved in human and mouse, the biological role is still unknown (Lin et al., 2000). 
Alternative splicing of the 5’ exons of the DNMT1 gene also produces two sex-
specific forms of DNMT1 mRNA variants termed DNMT1o and DNMt1p. 
 
1.2.2 DNMT2 
The DNA methyltransferase 2 (DNMT2) gene was cloned in 1998 based on its 
homology to the pmt1 gene of Schizosaccharomyces pombe (Yoder and Bestor, 
1998). Although the human DNMT2 gene encoding the 391 amino acid DNMT2 
protein was mapped to chromosome 10p12-10p14, the human genome project 
revealed that its actual location is at chromosome 10p15.1 (Yoder and Bestor, 1998). 
The DNMT2 protein is unique among all other eukaryotic methyltransferases as it 
lacks the N-terminal regulatory domain (Cheng et al., 1993) but the motifs 
characteristic of all DNA methyltransferases, including the conserved proline-cysteine 
dipeptide at the active site, are well-conserved in the human and murine DNMT2 
genes (Robertson, 2002). DNMT2 can form stable DNA-protein complexes in vitro 
(Dong et al., 2001), and was found to possess weak residual DNA (cytosine-5) 
methyltransferase activity for methylation of CpG in a loose ttnCGga(g/a) consensus 
sequence (Hermann et al., 2003). Surprisingly, novel work identified methylation of 
cytosine 38 in modified tRNAAsp by DNMT2, suggesting that small RNA molecules 




1.2.3 DNMT3a and DNMT3b 
The mammalian genome encodes two functional DNMT3 cytosine methyltransferases 
- DNMT3a and DNMT3b - which are essential for embryonic development and de 
novo methylation during embryogenesis (Okano et al., 1999). DNMT3a is ubiquitious 
expressed but is present in lower amounts than DNMT1. Genetic studies indicate that 
global methylation patterns remained intact in Dnmt3a-deficient mice. These Dnmt3a-
deficient mice can survive to term, but they suffer severe developmental defects and 
die by early adulthood with loss of germ cells, suggesting a role of DNMT3a in 
mammalian development (Okano et al., 1999). Although DNMT3a is highly specific 
for CpG methylation, there is increasing evidence highlighting the role of DNMT3a in 
de novo methylation of non-CpG sites (Gowher and Jeltsch, 2001). Compared with 
DNMT3a, DNMT3b is present in low amounts in most tissues but highly expressed in 
the testis, suggesting a crucial role in spermatogenesis (Xie et al., 1999). DNMT3b 
also appears to be crucial for the de novo methylation of minor satellite repeats 
adjacent to centromeres, particularly at satellites 2 and 3 on human chromosomes 1, 9 
and 16; and mutations in the DNMT3b gene are associated with the human genetic 
immunodeficiency disorder, centromere instability and facial abnormalities syndrome 
(ICF) syndrome (Hansen et al., 1999; Jin et al., 2008).  
 
A third homologue DNMT3L which lacks cytosine methyltransferase activity was 
identified and functions as a regulatory factor in germ cells (Aapola et al., 2000). 
DNMT3L can interact with the amino terminus of histone H3 tails when the lysine 4 
residue is not methylated. This interaction promotes the recruitment and activation of 
DNMT3A2, a germ-cell specific isoform of DNMT3A, thereby inducing de novo 
DNA methylation (Ooi et al., 2007).  
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1.2.4 Cooperation among the DNMTs 
Conditional knockouts of DNA methyltransferases have been generated to examine
their roles in mammalian cells. Interestingly, the functional role of DNMT1 as the 
sole maintenance methyltransferase in human colorectal cancer cells has been 
contested, as Rhee et al reported that approximately 80% of methylation is retained in 
colorectal cancer HCT116 cells upon elimination of up to 95% of DNMT1 
methyltransferase activity by gene targeting (Rhee et al., 2000). Similarly, negligible 
demethylation of hypermethylated gene promoters was also observed when colorectal 
cancer cells were treated with siRNA oligonucleotides to deplete DNMT1, strongly 
suggesting that DNMT1 activity is dispensable in colorectal cancer cells (Ting et al., 
2004). 
 
However, contrary to the genetic study, complete demethylation of the Cdkn2a locus 
was observed upon depletion of 70% of methyltranseferase activity in HCT116 cells 
treated with antisense and siRNA oligonucleotides to deplete DNMT1 (Robert et al., 
2003). As such, the authors concluded that DNMT1 is essential for maintaining CpG 
island hypermethylation in colorectal cancer cells, casting doubts to the presumed role 
of DNMT1 in previous studies. These conflicting findings were resolved by a recent 
study that identified a truncated DNMT1 protein in the DNMT1 HCT116 knockout 
cells (Egger et al., 2006). Surprisingly, even though part of the N-terminal domain of 
DNMT1 was deleted in the construct, the catalytic C-terminal domain was preserved 
and maintained hemi-methytransferase activity. Treatment with RNAi targeting 
DNMT1 resulted in decreased cell viability in both the wild-type and DNMT1 
knockout HCT116 cells. This finding may address the discrepancies arising from 
different experimental methods and cell types used in each study.  
However, DNA methylation is a complex process and several in-vivo and in-vitro
studies have instead indicated a mechanistic interplay among DNA methytransferases 
in DNA methylation process. Indeed, DNMT3a and DNMT3b were found to form 
complexes with DNMT1, and this cooperative interaction is crucial for the 
establishment and maintenance of methylation patterns in the genome (Fatemi et al., 
2002; Kim et al., 2002). Similarly, the maintenance of methylation in repetitive 
elements such as the LINE-1 promoter was found to involve the cooperative functions 
of DNMT1, DNMT3a and DNMT3b in mouse embryonic stem cells (Liang et al., 
2002). The cooperative functions of DNMT1 and DNMT3a/b were further 
demonstrated by complete absence of methyltransferase activity and > 95% reduction 
in genomic methylation in DNMT1-deficient cells upon the deletion of 20 exons of 
the DNMT3b locus to generate double knockout cells (DKO) (Rhee et al., 2002). 
 
1.3 Roles of DNA Methylation 
In addition to its important roles in mammalian development, DNA methylation is 
also implicated in genomic imprinting, X-chromosome inactivation, epigenetic 
regulation of genes and transcription regulation. 
 
1.3.1 Genomic imprinting 
Genomic imprinting refers to the gamete-specific differential modification of parental
genomes that are maintained in somatic tissues throughout embryonic development, 
but are erased in primordial germ cells (Diagram 2) (Morgan et al., 2005). DNA 
methylation plays a critical role in genomic imprinting and is required for the 
maintenance of monoallelic expression of imprinted genes such as H19, insulin-like 
growth factor 2 (Igf-2) and Igf-2 receptor (Igf-2r). The CpG islands of the H19, Igf-2
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Diagram 2: Epigenetic reprogramming cycle (adapted from Morgan et al, 2005). The first round 
of reprogramming occurs during gametogenesis. During gametogenesis, primordial germ cells (PGCs) 
arise from somatic tissue and develop into mature gametes. The genomes of the mature gametes 
undergo DNA demethylation. Following DNA demethylation, the genomes of the gametes are actively 
de novo methylated and acquire genomic imprints. Fertilization of the paternal and maternal gametes 
then signals another round of reprogramming during implantation development. The paternal 
pronucleus (PN) undergoes active DNA demethylation. During early cell cycle and before blastulation, 
the embryo’s genome is passively DNA demethylated. On the other hand, imprinted genes maintained 
their methylation throughout the preimplantation reprogramming events. De novo methylation occurs 
during the differentiation of the first two lineages of the blastocyst stage, and the inner cell mass (ICM) 
become hypermethylated as compared to the trophectoderm (TE). (Morgan et al., 2005). 
 
 
and Igf-2r genes are differentially methylated in embryos depending on their parental 
origin, and the reciprocal imprinting of IGF2 and H19 is mainly controlled by the 
Imprinting Centre 1 (IC1) on chromosome 11p15.5. Demethylation of these three 
genes in mice deficient in DNA methyltransferase activity resulted in altered
expression, leading to disruption of genomic imprinting in the mutant embryos 
(Sasaki et al., 2000). The finding that Dnmt3a/Dnmt3b-deficient females fail to 
establish maternal methylation imprints suggests that de novo methylation by Dnmt3a 
and Dnmt3b is crucial for establishing imprinting marks in oocytes (Okano et al., 
1999). Interestingly, Dnmt3L-deficient oocytes are also unable to establish maternal-
specific methylation imprints even though Dnmt3L does not exhibit enzymatic 
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activity, suggesting that Dnmt3L might cooperate with Dnmt3a and Dnmt3b to 
regulate gamete-specific methylation of imprinted genes in oocytes (Hata et al., 
2002). Though not crucial for the establishment of imprinting, the somatic form of 
DNMT1 is responsible for the maintenance of genomic methylation patterns in pre-
implantation embryos (Branco et al., 2008; Kurihara et al., 2008). In addition to the 
role in genomic imprinting of female oocytes, DNA methylation is also shown to be 
crucial for spermatogenesis in mammalian cells (Kato et al., 2007).  
 
1.3.2 X-chromosome inactivation 
In female mammals, X-chromosome dosage compensation is achieved by a process 
known as X-chromosome inactivation, which silences one of the two X chromosomes 
during early embryogenesis by converting it into a transcriptionally inert and highly 
condensed heterochromatin (Ng et al., 2007). The involvement of DNA methylation 
in the initiation of X inactivation from the X inactivation centre (XIC) is unclear but 
de novo methylation by DNMT3a and DNMT3b is thought to facilitate the spreading 
of the activation signal (Li, 2002). Hypermethylation of Xi (inactive X chromosome) 
may recruit methyl-CpG-binding proteins (MBPs) such as MeCP2 and Mbd2, which 
in turn recruit chromatin-remodelling and histone deacetylase complexes for gene 
silencing (Barr et al., 2007).  
 
Work on DNMT1-/- knockout mouse embryos also shows that even though DNMT1 is 
not required for the initial establishment of Xist silencing, it is essential for the 
stability of the silent state (Sado et al., 2004). Similarly, in human ICF patients who 
suffer from a mutation in DNMT3b, global demethylation and reactivation of some 
genes on the inactive X suggests that DNMT3b is responsible for establishing CpG 
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methylation on the Xi (Hansen et al., 2000). Together, these findings indicate that 
gene silencing of chromosomes requires the synergistic action of several epigenetic 
mechanisms. Surprisingly, studies on human HCT116 DNMT1/DNMT3b double 
knockout cells demonstrated that despite global DNA demethylation in the genome, 
methylation and transcription repression of the Xist is sustained, suggesting that 
DNMT1 and DNMT3b are not crucial for the maintenance of Xist methylation in 
mammalian cells (Vasques et al., 2005). However, it is important to note that further 
studies provided evidence that the HCT116 DNMT1-/- cells do retain a truncated form 
of DNMT1 protein which possesses methyltransferase activity (Egger et al., 2006).  
 
1.3.3 Epigenetic regulation of genes 
In higher eukaryotes, DNA methylation is the major epigenetic regulation of genomes
as the methylation status of genes correlates with their transcriptional silencing. 
Transcriptionally active euchromatin regions such as CpG islands in the first exons 
and promoters of housekeeping and tissue-specific genes are usually unmethylated 
(eg. X chromosome-linked housekeeping genes). In contrast, high levels of CpG 
methylation and histone deacetylation are associated with transcriptional silencing of 
condensed heterochromatin regions of the genome, which is thought to be stabilized 
by the binding of heterochromatin protein 1 (HP1) (Li, 2002). Transcriptionally 
inactive chromatin is typically assembled into nucleosomal structures consisting of an 
octamer of core histone proteins wrapped around a 160bp DNA segment, and adjacent 
nucleosomes are linked by a single molecule of histone H1. DNA methylation can 
influence the structure and function of the chromatin by altering the histone-DNA 
association through methylation-specific DNA-binding proteins such as MeCP2 and 
histone deacetylases (Nan et al., 1997). This allows for stable transcriptional silencing 
through the condensation of higher-order nucleosomal structures (Mellor, 2006).  
 
1.3.3a DNMT1 interacts with G9a histone methylase 
It was shown that DNMT1 directly interact with G9a, a H3K9 histone methylase, and 
the complex is recruited to the chromatin as a ternary complex with PCNA during 
DNA replication (Esteve et al., 2006). Depletion of DNMT1 leads to inhibition of 
DNA methylation, G9a loading and H3K9 methylation, demonstrating the crucial role 
of DNMT1 as the primary loading factor. In vitro studies showed that DNMT1 and 
G9a cooperatively promote each other’s enzymatic activities in the complex, and 
therefore enhance DNA and histone methylation. This cooperative interaction 
provides evidence of a mechanism in coordinating DNA and H3K9 methylation 
during cell division. Interestingly, dimethylation of H3K9 by G9a also promotes the 
recruitment of HP1, which stabilizes the chromatin structure. DNMT1 can physically 
interact with HP1, which stimulates DNMT1 activity and enhances DNA methylation, 
thus providing a positive feedback loop for gene silencing (Smallwood et al., 2007). 
 
1.3.3b DNMT1 interacts with Polycomb Group (PcG) proteins 
Other than DNA methylation, the Polycomb Group (PcG) proteins represent crucial 
epigenetic systems involved in heritable gene repression. These proteins exist in two 
protein complexes, namely the Polycomb repressive complex 1 and 2 (PRC1 and 
PRC2). An additional EZH1/EED complex identified as PRC3 was recently reported 
in human cells (Kuzmichev et al., 2004). The Polycomb protein EZH2, a histone 
methyltransferase associated with transcription repression, was recently found to 
associate and recruit DNMTs to EZH2-target gene promoters, suggesting that the 
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Polycomb protein may act as a recruitment platform for DNA methylation (Vire et al., 
2006). The fact that EZH2 can directly interact with DNMTs suggest that it can 
possibly influence DNA methylation events. Indeed, increased expression of EZH2 
during prostate cancer progression is correlated with escalated DNA methylation 
alterations (Hoffmann et al., 2007). In addition, EZH2 and EED (PRC2 members) 
appear to be essential for the recruitment of PRC1 core component BMI1 to PcG 
bodies for chromatin silencing (Hernandez-Munoz et al., 2005). Interestingly, loss of 
DNMT1 by siRNA perturbs BMI1 recruitment and results in extensive loss of 
methylation at pericentric major satellite regions independent of HDAC activity. 
These data clearly illustrate the role of DNMT1 as a recruitment factor for BMI1 to 
PcG bodies independent from DNMT1-associated HDAC activity, thus providing a 
glimpse of a mechanistic link between PcG proteins and DNA methylation systems. 
 
1.3.3c DNMT1 interacts with UHRF1 
The disruption of the interaction between DNMT1 and its recruitment factor PCNA 
resulted in a negligible decrease in the efficiency of maintenance methylation, 
suggesting the existence of other recruitment factors (Spada et al., 2007). Mammalian 
UHRF1, also known as ICBP90 (Inverted CCAAT box binding protein of 90kDa) or 
NP95, has recently been identified as a factor for recruitment of DNMT1 to the 
chromatin (Bostick et al., 2007). UHRF1 protein peaks during the S phase of cell 
cycle similar to DNMT1 protein, and is found to be elevated in cancer cell lines 
correlated with a higher expression of Topoisomerase IIα. The SET and RING finger-
associated (SRA) domain of UHRF1 shows preferential binding to hemimethylated 
CG sites and is responsible for the binding and recruitment of HDAC1 to methyl-CpG 
sites (Unoki et al., 2004). In addition, UHRF1 can also tether DNMT1 to the 
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chromatin through its direct interaction with the DNMT1 protein (Bostick et al., 
2007).  
 
Conversely, a recent report demonstrates that UHRF1 recruits DNMT1 to methylated 
DNA at heterochromatin regions and is essential for maintaining global and local 
DNA methylation, as well as for the repression of retro-transposons and imprinted 
genes (Sharif et al., 2007). In line with this, murine UHRF1 was shown to localize to 
chromocenters during pericentromeric heterochromatin replication, and that the PHD 
domain of UHRF1 is essential for the stabilization of the chromocenter structures and 
recruitment of modifying enzymes (Papait et al., 2008). Similar to PCNA, these novel 
findings clearly describe UHRF1 as a recruitment factor for DNMT1 that facilitates 
efficient maintenance CpG methylation and mediates epigenetic inheritance. 
 
1.3.4 Transcriptional suppression   
Transcriptional suppression by DNA methylation may involve at least two molecular 
mechanisms. The presence of methyl-CpG residues on the DNA may affect histone 
modification processes and nucleosome occupancy within the promoter regions of 
genes. As such, DNA methylation can impede the binding of basal and ubiquitous 
transcription factors such as AP-2 (Comb and Goodman, 1990), c-Myc (Prendergast 
and Ziff, 1991), CTCF (Bell and Felsenfeld, 2000; Renaud et al., 2007) and E2 
promoter binding factors (E2F) (Kovesdi et al., 1987) to their cognate sites on gene 
promoters due to alteration of the chromatin structure. However, this is not a global 
mechanism as some transcription factors do not have CpG in their binding sites and 
therefore are insensitive to DNA methylation. Furthermore, most methylation-
sensitive transcription factors generally associate with CpG islands of gene promoters, 
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which are mainly unmethylated in most cell types, and therefore DNA methylation is 
unlikely to play a role in their regulation (Kass et al., 1997; Tate and Bird, 1993). 
Transcription of methylated DNA has been observed in the absence of chromatin or 
methyl-binding proteins, suggesting that DNA methylation can silence genes by other 
mechanisms involving the chromatin structure (Miranda and Jones, 2007).   
 
DNA methylation can also suppress transcription by recruiting proteins that bind to 
methylated CpGs to form a repressor complex on the DNA, thereby providing a 
means of global transcription control of the genomes (Kass et al., 1997; Tate and 
Bird, 1993). A family of proteins that share a 70-residue methyl-CpG-binding domain 
(MBD) has been identified in mammalian cells, members of which include the 
MeCP1, MeCP2 and MBDs proteins (Ballestar and Wolffe, 2001). MeCP-1 is a large 
multi-subunit complex containing HDAC1/2, RbAp46/48 and MBD2 proteins that 
specifically binds to DNA sequences containing multiple symmetrically methylated 
CpGs (Ng et al., 1999). The MeCP-1 complex preferentially binds to methylated 
nucleosomes, whereas the MBD2 component recruits nucleosome remodeling factor 
and histone deacetylase NuRD to deacetylate the nucleosomal structures, leading to 
stable transcription repression (Feng et al., 2007). MeCP-2 is considerably more 
abundant than MeCP-1 and is also able to bind DNA containing single symmetrically 
methylated CpG pairs (Nan et al., 1997). The transcription repression domain (TRD) 
identified in MeCP-2 associates with a corepressor complex containing the 
transcription repressor mSin3A and histone deacetylases in transcription silencing 
(Nan et al., 1998).  
 
A recent report showed that LSH, a protein related to the SNF2 family of chromatin
 remodeling ATPases, serves as a recruiting factor for DNMT1 and DNMT3B, and 
cooperates with HDAC1 and HDAC2 to establish transcriptionally repressive 
chromatin at targeted gene promoters (Myant and Stancheva, 2008). In addition, 
DNMT1 co-localizes with the transcription repressor Hesx1 in the nucleus. The N-
terminal and C-terminal regions of DNMT1 interact with Hesx1 in vivo, suggesting a 
role for DNMT1 in Hesx1-dependent transcriptional repression (Sajedi et al., 2008). 
 
1.4 DNMT1 in the Cell Cycle  
DNMT1 is constitutively expressed in mammalian cells but the expression level is 
cell cycle-regulated. The interplay between DNMT1 and other cellular proteins is 
important in regulating its activity at different stages of the cell cycle.  
 
1.4.1 Regulation of DNMT1 expression 
The DNMT1 protein peaks during DNA replication in the S phase of the cell cycle, 
but is present at very low levels in non-cycling Go cells due to its degradation (Ding 
and Chaillet, 2002). Degradation may possibly occur via the proteosomal degradation 
pathway involving the KEN Box, Bromo-Adjacent Homology Domain and Nuclear 
Localization Signal (NLS) domains, as demonstrated by treatment with 5AzadC 
(Ghoshal et al., 2005). Interestingly, the N-terminal domain of DNMT1 plays a role in 
the stabilization of the protein. This has been shown by the deletion of the first 118 aa 
to force initiation of translation at the second AUG codon, thereby producing a shorter 
DNMT1 which is stable during the Go phase (Ding and Chaillet, 2002). Indeed, 
DNMT1 levels are elevated in several cancer cell lines due to defective degradation 
through its N-terminal destruction domain (Agoston et al., 2005). Further work 
showed that inactivation of the RB pathway, commonly observed in cancer cells, 
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resulted in the over-expression of MAD2 which stabilizes DNMT1, leading to 
DNMT1 dysregulation in cancer cells (Agoston et al., 2007).  
 
The regulation of DNMT1 gene expression is critical in coordinating DNMT1 activity 
with biological processes. Despite the importance of DNMT1, the extent of the 
transcriptional regulatory region of both the murine and human DNMT1 genes is not 
very clear. In 1992, Rouleau et al identified putative promoter and enhancer regions 
upstream of the murine Dnmt1 gene (Rouleau et al., 1992). However, the discovery of 
new 5’ regions in the murine and human DNMT1 genes inevitably positioned a new 
transcription initiation site upstream of the previously identified promoter (Yoder et 
al., 1996). Following this, putative binding sites for transcription factors such as TCF-
1, AP-1 (Activator Protein 1), E2F1 and Sp1/Sp3 were identified in the human 
DNMT1 gene upstream of this newly characterized AUG intiation site (Bigey et al., 
2000). These findings directed new interest in resolving how DNMT1 is regulated. 
Kishikawa et al went on to demonstrate that transcription of the murine Dnmt1 
promoter is independently controlled by Sp1 and Sp3, and that p300 is involved in co-
activation of the Sp3 transcriptional activity (Kishikawa et al., 2002a). Both Sp1 and 
Sp3 are controlled in a cell cycle-dependent manner and are mainly recruited to the 
Dnmt1 promoter during the late G1 and S phase in somatic cells. p300/CBP has been 
shown to associate with the Sp3 at the Dnmt1 promoter during S phase to direct 
transcriptional co-activation, resulting in high levels of Dnmt1 protein in S phase cells 
(Kishikawa et al., 2003). Furthermore, work by McCabe et al demonstrated that the 
E2F-binding site located within the transcription initiation region is critical for the 
regulation of DNMT1 transcription in proliferating cells via the pRB/E2F1 pathway 
(McCabe et al., 2005).  
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However, although p300 is a well-documented co-activator for Sp1/3 and E2F1 and 
that it was shown to be involved in transcriptional co-activation of the murine Dnmt1 
promoter, its activity on human DNMT1 promoter was not studied to date. The fact 
that the regulation of DNMT1 gene is not fully resolved limits the understanding of 
how DNMT1 expression is coordinated in cells. As such, the exact roles of E2F1, Sp1 
and p300 in DNMT1 transcription and the functional interplay among these proteins 
need urgent investigation. 
 
1.4.2 E2F1/RB pathway  
The E2F family of transcription factors comprises heterodimeric proteins composed 
of one of the eight E2F proteins (E2F1 to 8) bound to a DP family member (DP1, DP2 
or DP3). E2F1, the best studied member of the family, plays an important role in the 
regulation of the expression of genes essential for DNA replication and cell cycle 
progression (DeGregori and Johnson, 2006; Trimarchi and Lees, 2002). In quiescent 
cells, E2F1 is bound to the hypophosphorylated RB to form the inactive E2F1/DP-
1/pRB complex which inhibits transcription. During late G1 phase, activation of 
CDKs and phosphorylation of pRB by CDK2/Cyclin E leads to the release of RB 
from the complex. The ‘free’ E2F1/DP1 can then bind to target gene promoters and 
recruit co-activators such as p300/CBP or p300/CBP-associated factors (P/CAF) and 
histone acetyltransferase activity to initiate the transcription of genes involved in 
G1/S transition such as DNA polymerase, cyclins and c-Myc (Trouche et al., 1996).  
 
The level of E2F1 can be regulated by ubiquitination-dependent proteasome 
degradation involving the SCFSKP2 ligase (Marti et al., 1999). Furthermore, the 
phosphorylation of the DP1 subunit by cyclin A/CDK2 can abolish the DNA-binding 
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activity of the E2F1 heterodimer during S phase (Krek et al., 1995). The cell cycle 
inhibitor p21WAF1 negatively regulates the activity of E2F1 by preventing CDK-
dependent phosphorylation of pRB. p21WAF1 can also bind to E2F subunits, and this is 
associated with the down-regulation of the transcriptional activity of E2F via a 
CDK/RB-independent pathway (Delavaine and La Thangue, 1999). Interestingly, the 
E2F1/RB pathway is responsible for the up-regulation of DNMT1 expression, which 
is inversely related to p21WAF1, in the S phase. This may be necessary to maintain 
DNA methylation patterns on the newly synthesized DNA (Kimura et al., 2003). 
Conversely, RB can also interact with DNMT1 and disrupt the DNMT1-DNA binary 
complex, which modulates DNMT1 activity and provides negative feedback 
regulation on DNA methylation (Pradhan and Kim, 2002). 
 
Other than regulating cell growth, E2F1 also participates in cell survival and 
apoptosis via p53-dependent and p53-independent mechanisms (Matsumura et al., 
2003). E2F1-induced cell cycle progression and apoptosis is negatively regulated by 
pRB, and the regulation involves separate E2F1-specific interaction domains on the 
pRB protein (Ding and Chaillet, 2002; Julian et al., 2007). During DNA damage, 
dephosphorylation of pRB at the CDK phosphorylation sites and phosphorylation of 
pRB at serine 612 by Chk1/2, promotes pRB-E2F1 complex formation and inhibits 
G1/S cell cycle progression (Inoue et al., 2007). Conversely, phosphorylation of E2F1 
at the amino terminus by ATM in response to DNA damage results in the stabilization 
and accumulation of E2F1 protein, which can then selectively augment p53-
dependent and p53-independent apoptosis (Ianari et al., 2004; Lin et al., 2001). 
Although both p300/CBP and P/CAF can induce acetylation of E2F1 in vitro at the 
same lysine residues, acetylation and stabilization of E2F1 by P/CAF was 
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preferentially induced upon Dox-mediated DNA damage (Ianari et al., 2004). This 
presents an alternative in the regulation of the E2F1/pRB pathway in response to 
specific DNA damage which may have broad implications in tumorigenesis. 
 
1.4.3 p300/CBP co-activator 
The p300/CREB-Binding proteins (p300/CBP) are a group of transcriptional co-
activators that exist as part of a larger co-activator complex, and the components of 
this complex, including p300/CBP and p300/CBP-associated factors (P/CAF), exhibit 
histone acetyltransferases (HAT) activity (Liu et al., 2008). The p300 and CBP 
proteins are highly conserved homologues that play important functions in cell cycle 
regulation, apoptosis and the DNA damage response. p300 also plays an important 
role in G1/S control by inhibiting the phosphorylation of RB at early G1 and 
preventing cells from premature S phase entry (Iyer et al., 2007). Phosphorylation of 
p300/CBP by cyclin E/CDK2 in a cell cycle-dependent manner stimulates its intrinsic 
HAT activity and leads to the activation of S phase genes that is otherwise repressed 
in early G1 phase (Ait-Si-Ali et al., 1998). On the other hand, phosphorylation of 
p300 by p38 mitogen-activated protein kinases (MAPKs) upon Dox-mediated DNA 
damage response results in the degradation of p300 in cardiac cells (Poizat et al., 
2005). Interestingly, p300 transactivation activity is stimulated by the de-repression of 
its sumoylation-dependent transcriptional repression domain CRD1 by p21WAF1 
(Snowden et al., 2000); and this regulation is independent of the binding of p21WAF1 
with Cyclin/CDK and PCNA (Garcia-Wilson and Perkins, 2005). 
 
p300 is a well-documented co-activator for both p53 and E2F1 sequence-specific 
transcription factors (Lee et al., 1998). Phosphorylation of the transactivation domains 
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of p53 was shown to increase the binding affinity of p53 for p300 (Polley et al., 
2008). The association with p300 is required for p53-dependent transcriptional 
activation of p21WAF1, and the concomitant increase in p21WAF1 further enhances p53-
dependent transcription by potentiating the p53/p300 interaction (Lambert et al., 
1998). E2F1 negatively regulates p53-dependent transcriptional activity by competing 
with p53 for p300, and this effect can be antagonized by pRB (Lee et al., 1998). 
Consistent with the role of p21WAF1 in the auto-regulation of p53-dependent 
transcription, the induction of p21WAF1 negatively regulates E2F1 activity by 
inhibiting the CDK-dependent phosphorylation of pRB and promoting the interaction 
between pRB and E2F1, thus acting as a positive feedback mechanism (Delavaine and 
La Thangue, 1999). As p300 can facilitate cell cycle arrest governed by p53 as well as 
enhance the apoptotic activity of E2F1, the levels of p53 and E2F1 in cells may have 
a profound impact on cell cycle progression.  
 
Other than transcriptional regulation, p300 is also responsible for modulating the 
stability of p53 protein. The interaction between p300 and p53 enhances the stability 
of p53 by sequestering p53 in the nucleus and preventing its degradation by MDM2 
(Yuan et al., 1999). In addition, p300 can promote the acetylation of specific lysine 
residues in the C terminus of p53 and enhance the DNA-binding capability of p53 
(Dornan et al., 2003; Liu et al., 1999). Conversely, p300 positively regulates MDM2 
expression and enhances the ability of MDM2 to target p53 for degradation (Kawai et 
al., 2001). The contradicting roles of p300 in the stabilization of p53 and MDM2 
proteins and in promoting the degradation of p53 by MDM2 may be necessary for the 




1.4.4 DNMT1 and DNA replication 
Earlier work on DNA methylation identified the recruitment of DNMTs to sites of 
active DNA synthesis in S phase nuclei of mouse fibroblasts through a targeting 
sequence at the N-terminal region of DNMTs (Leonhardt et al., 1992). In support of 
this, the N-terminus of DNMT1 was shown to interact directly with PCNA and this is 
required for association with the replication machinery during DNA replication 
(Chuang et al., 1997). The isolation of a fraction of DNMT1 from a multi-protein 
DNA replication complex, termed the DNA synthesome, in an asynchronous 
population of human cervical and breast carcinoma cells further demonstrates that 
DNA methylation and DNA replication are tightly coupled (Vertino et al., 2002). This 
synthesome-associated DNMT1 exhibits both maintenance and de novo methylation 
activity necessary for the methylation of newly replicated DNA in semi-conservative 
DNA replication. However, an alternative splice variant of DNMT1 that lack the 
PCNA-binding domain retained reduced levels of maintenance DNA methylation 
activity in human cells, suggesting that direct coupling to replication is not necessary 
for maintenance DNA methylation (Spada et al., 2007). Importantly, a specific 
targeting sequence on the DNMT1 protein was found to associate with chromatin and 
constitutive heterochromatin during G2 and M phases of the cell cycle (Easwaran et 
al., 2004). This interaction is independent of DNA replication and heterochromatin-
specific histone trimethylation, thus indicating the possibility of a replication-
independent role of DNMT1, such as DNA repair, in maintaining DNA methylation 
via a novel pathway.   
 
1.4.5 DNMT1 and PCNA 
PCNA functions as a processivity factor for DNA Polymerases δ and β by forming a
trimeric ring structure that clamps and then slides along the DNA duplex during DNA 
replication (Krishna et al., 1994). The binding of PCNA to DNA apparently facilitates 
the recruitment of DNMT1 and methylation of hemi-methylated DNA in S phase 
nuclei in vitro, thus demonstrating a role of PCNA for the recruitment of DNMT1 to 
active DNA replication sites (Iida et al., 2002). Binding of PCNA does not alter the 
enzymatic activity of DNMT1; and DNMT1 lacking the PCNA-binding motif remains 
active, strongly suggesting that the interaction with PCNA is not essential for 
DNMT1 activity per se, but enhances the efficiency of DNA methylation in vivo 
(Chuang et al., 1997). In addition, disrupting the interaction between DNMT1 and 
PCNA resulted in only a negligible decrease in the efficiency of maintenance 
methylation, suggesting the existence of other recruitment factors such as the UHF1 
protein as discussed earlier (Spada et al., 2007).  
 
PCNA participates in repair processes such as nucleotide excision repair (NER) 
(Mocquet et al., 2008) and directly interacts with MLH1, an MMR component 
necessary for DNA mismatch repair at a step preceding DNA resynthesis (Masih et 
al., 2008). Hence, PCNA is a potential physical link between DNMT1 and MMR 
complexes. PCNA has also been shown to co-localize with p21WAF1 protein at DNA 
repair sites during DNA damage (Cazzalini et al., 2008), and a 39 amino acid peptide 
derived from p21WAF1 protein inhibits DNA replication in vivo by binding to PCNA 
(Chen et al., 1996). Interestingly, Chuang et al demonstrated an inverse relationship 
between p21WAF1 and DNMT1 protein expression in mammalian cells, and that 
p21WAF1 can inhibit DNA methylation by competing with DNMT1 for binding to 
PCNA upon DNA damage (Chuang et al., 1997). However, the molecular mechanism 
and functional significance of their association have yet to be confirmed.   
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1.4.6 DNMT1 and p21WAF1 
A casual inverse relationship has also been reported between DNA methylation of the 
p21WAF1 promoter and p21WAF1 silencing during tumorigenesis and senescence (Chen 
et al., 2000; Zheng et al., 2006). p21WAF1 is a cell cycle protein that is rarely mutated 
or deleted in tumours and cancer cell lines; whereas CpG island hypermethylation of 
the p21WAF1 promoter has been associated with transcriptional silencing of the p21WAF1 
gene in acute lymphoblastic leukemia (Roman-Gomez et al., 2002), gastric cancer 
cells (Shin et al., 2000) and human lung cancer cell lines (Zhu et al., 2003). 
Methylation of CpG dinucleotides may repress gene expression of the p21WAF1 
promoter by the recruitment of MeCp2 proteins and the HDAC repressor complex, 
preventing the binding of transcription factors (Jones et al., 1998b; Nan et al., 1998). 
Methylation of CpG dinucleotides within the Sp1/Sp3 consensus sequence on the 
p21WAF1 promoter will not influence Sp1/Sp3 binding and transcription activity. By 
contrast, methylation of CpG sites outside the consensus Sp1/Sp3 binding sites has 
been shown to significantly reduce Sp1/Sp3 binding by 50-95%, thereby inhibiting 
p21WAF1 transcription (Zhu et al., 2003).  
 
The depletion of DNMT1 protein during senescence corresponds to reduced 
methylation of the p21WAF1 promoter and an increase in the expression of p21WAF1 
mRNA and protein, leading to cell cycle arrest and cellular senescence (Zheng et al., 
2006). Similarly, inhibition of DNA methyltransferase activity correlates with a 
significant increase in p21WAF1 expression as observed in several independent studies 
(Fournel et al., 1999; Milutinovic et al., 2000; Young and Smith, 2001). In addition, 
the induction of p21WAF1 protein expression in response to DNA demethylating 
treatments leads to cell cycle withdrawal in normal human fibroblasts, suggesting a 
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functional role of the inverse relationship under physiological conditions (Young and 
Smith, 2001). Strikingly, the depletion of DNMT1 by antisense knockout resulted in 
induction of p21WAF1 expression without affecting the methylation status of the 
promoter, suggesting that DNMT1 may also affect the transcriptional regulation of the 
p21WAF1 promoter independent of DNA methylation activity, possibly via an 
alternative mechanism involving p53 (Milutinovic et al., 2004). This finding provides 
an important clue in understanding the role of DNMT1 in transcription control 
independent of its DNA methyltransferase activity. Treatment with a histone 
deacetylase (HDAC) inhibitor resulted in transcription activation of the p21WAF1 
promoter, and this observation indicates the presence of a repressor complex 
consisting of HDAC in the transcription repression of the p21WAF1 promoter (Xiao et 
al., 2000).  Following that, Zhou et al demonstrated that a HDAC inhibitor promotes 
ubiquitination of DNMT1, which resulted in ubiquitin-dependent proteasomal 
degradation of DNMT1 protein in human breast cancer cells (Zhou et al., 2008). This 
observation further supports the inverse relationship such that the down-regulation of 
DNMT1 (by HDAC inhibition) conversely leads to the up-regulation of p21WAF1 
expression. Despite the fact that DNMT1 is associated with HDAC activity in 
transcriptional repression (Fuks et al., 2000), it remains to be investigated how the 
p21WAF1 promoter can be negatively regulated by DNMT1, either via methylation-
dependent or methylation-independent mechanisms.   
 
1.5 Regulation of p21WAF1 Expression  
p21WAF1 protein belongs to a family of cyclin-dependent kinase (CDK) inhibitors 
involved in the regulation of cell cycle progression. The p21WAF1 protein is 
ubiquitiously expressed in mammalian cells (Vidal and Koff, 2000), and the stability 
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of the protein is regulated by the proteosomal activator REGγ (Li et al., 2007). 
p21WAF1 is a short-lived protein and changes in its stoichiometry can be regulated at 
both the transcription and translational levels. 
 
1.5.1 p53-dependent trancriptional regulation of p21WAF1 
p53 protein binds to its consensus sequence located on the distal region of the p21WAF1 
promoter and is responsible for transcriptional regulation of p21WAF1 expression (el-
Deiry et al., 1993). p53 may act as a transcriptional co-activator by physically 
interacting with the transcription factor Sp1 bound at the proximal promoter region 
(Elements 1 to 6) of the p21WAF1 promoter, thus resulting in enhanced transactivation 
(Koutsodontis et al., 2001). In addition, p53 can directly interact with and recruit 
p300 to the basal transcription machinery thus stimulating transcription of the p21WAF1 
promoter (Liu et al., 2003). Even though p300 was shown to collaborate with Sp1/Sp3 
in the transactivation of the p21WAF1 promoter upon treatment with histone deacetylase 
inhibitor Trichostatin (TSA), no direct interaction was detected between the two 
proteins (Xiao et al., 2000). As such, the molecular basis for this relationship may 
involve the recruitment of p300 by p53 to a common multi-protein complex that 
resides at the basal transcription region near to the Sp1 binding elements on the 
p21WAF1 proximal promoter. Targeted mutation of element 3 on the p21WAF1 promoter 
disrupted the synergistic interactions of Sp1 and Sp3 with the upstream p53-binding 
enhancer region and perturbed transactivation (Koutsodontis et al., 2002).  
 
1.5.2 p53-independent transcriptional regulation of p21WAF1 
Breast Cancer Susceptibility Gene 1 (BRCA1) is a tumor suppressor gene involved in 
the cellular differentiation and proliferation of mammary glands. BRCA1 has also 
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been implicated in the cellular response to DNA damage as well as in transcriptional 
regulation (Mullan et al., 2006). Indeed, BRCA1 has been identified as a potent 
inducer of p53-dependent transcriptional activity (MacLachlan et al., 2002). Although 
the amino terminus of BRCA1 was identified as the region for binding to p53 (Zhang 
et al., 1998), the second BRCT domain of BRCA1 seems to be crucial for the 
interaction with p53 required to stimulate transcription of the p21WAF1 promoter (Chai 
et al., 1999). In addition, binding of p300 to the BRCT domain in a cell cycle 
dependent but phosphorylation-independent manner was shown to enhance BRCA1-
mediated transactivation of genes (Pao et al., 2000). Interestingly, deletion mapping 
within the human p21WAF1 promoter has identified a 50bp region within the Sp1 
elements in the proximal promoter region that seems to mediate the transcriptional 
activation of p21WAF1 by the direct binding of BRCA1 independent of p53 
(Somasundaram et al., 1997). In line with this, Fabbro et al highlighted the role of 
BRCA1 in the transactivation of p21WAF1 expression via a p53-independent 
mechanism leading to p21WAF1 induction and BRCA1-mediated cell cycle arrest 
(Fabbro and Henderson, 2008). More recently, transcription factor NFκB/p65 
(Nuclear Factor-κB) has been shown to be involved in the induction of p21WAF1 
expression in response to Dox treatment, and this occurs via the direct binding of 
NFκB/p65 to the p21WAF1 promoter independent of p53 (Ma et al., 2008). 
 
1.5.3 Translational regulation of p21WAF1  
Other than transcription regulation, p21WAF1 can also be regulated at the post-
translation level. Several lines of evidence indicated that the turnover of p21WAF1 
protein occurs via a proteasomal degradation pathway that is independent of 
ubiquitination (Lee et al., 2006). Recent work further demonstrated that this 
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ubiquitination-independent degradation of p21WAF1 involves the REGγ complex (also 
known as 11S or PA28) (Chen et al., 2007b; Li et al., 2007). The REGγ complex is an 
ATP- and ubiquitination-independent proteasome activator that enhances the catalytic 
activity of proteasomes. REGγ directly binds to free p21WAF1 protein and targets it for 
ubiquitin-independent degradation by the 20S proteasome, leading to cell cycle arrest 
in the G2/M phase. In addition, phosphorylation of p21WAF1 within the Cdk-binding 
domain by Glycogen Synthase Kinase-3 (GSK-3) triggers the proteosomal 
degradation of the p21WAF1 protein. In contrast, the PI3K/Akt signal transduction 
pathway mediates p21WAF1 expression by promoting the inhibitory phosphorylation of 
GSK-3 and hence prevents p21WAF1 degradation (Rossig et al., 2002). Yeast two 
hybrid screen has also identified a novel protein, WISp39, which binds to the amino 
terminus of p21WAF1 and enhances its protein stability (Jascur et al., 2005). WISp39 
contains a tetraricopeptide repeat (TRP) domain that allows the recruitment of heat 
shock response protein Hsp90 to the p21WAF1 protein to form a trimeric complex 
which enables correct folding and enhances p21WAF1 protein. 
 
1.6 DNA Damage Response 
Cellular DNA is a highly reactive molecule and its structural integrity is constantly 
threatened by genotoxic agents. Fidelity of the eukaryotic genome is maintained by 
the coordinated interplay of functionally linked cellular pathways such as cell cycle 
checkpoints and DNA repair pathways. 
 
1.6.1 ATM/ATR signaling pathways 
Both ATM and ATR belong to the PI3-Kinase superfamily (Abraham, 2004). In 
general, ATR is activated by stalled replication forks and genotoxic agents that 
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produce bulky DNA adducts following UV irradiation (Unsal-Kacmaz et al., 2002), 
while ATM is activated by ionizing radiation and genotoxic agents that produce 
double strand DNA breaks (Lavin, 2007; Lavin and Kozlov, 2007). Earlier work on 
ATM/ATR pathways demonstrated that ATM and ATR phosphorylate Chk2 and 
Chk1, respectively, upon DNA damage (Matsuoka et al., 2000; Zhao and Piwnica-
Worms, 2001). However, there is increasing evidence to show some overlap between 
the two pathways. One example is the recent report showing ATR-mediated 
phosphorylation of Chk2 in response to cisplatin-induced DNA damage, strongly 
suggesting that these two parallel damage response pathways may not be mutually 
exclusive (Pabla et al., 2008). Several reports have identified the MRN complex as an 
upstream activator of the ATM pathway (Carson et al., 2003; Uziel et al., 2003). The 
MRN complex, composed of Mre11, Rad50 and Nbs1 proteins, can bind directly to 
the site of double strand breaks (DSB). Mre11 processes the ends of the damaged 
DNA and allows the recruitment of ATM to the sites of DSB. This results in the 
activation of ATM by autophosphorylation at serine1981 and monomerization. Active 
ATM monomers can phosphorylate substrates at the site of DSB or may be released 
from the site to phosphorylate distal substrates such as chromatin-bound histone 
H2AX, which is a marker for DSBs (Lee and Paull, 2007). Although the MRN 
complex can function upstream of ATM in signaling, Nbs1 itself is a substrate for 
ATM phosphorylation (Wu et al., 2000), and it plays a role in the activation of 
downstream events which leads to cell cycle arrest (Girard et al., 2002). 
 
1.6.2 Cell cycle checkpoints 
Depending on the type of DNA damage, ATM/ATR and Chk2/Chk1 kinases play 
pivotal roles in the G1/S phase checkpoints. When DNA damage occurs in the G1 
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phase, ATM/ATR is activated, and they phosphorylate a range of substrates including 
p53 and Chk2/Chk1 proteins (Zhou and Elledge, 2000). Activated Chk2 and Chk1 
also phosphorylate p53 on serine 20, which leads to stabilization and accumulation of 
p53, and efficient transactivation of cell cycle inhibitors such as p21WAF1 and p27CIP1 
(Chehab et al., 2000; Hirao et al., 2000). Additionally, gradual accumulation of 
p16INK4A disrupts the Cyclin D-Cdk4/6-p21WAF1 complex, thereby releasing a pool of 
p21WAF1 (Agami and Bernards, 2000). At a high threshold level, p21WAF1 binds the 
Cyclin E-Cdk2 complex and inhibit its activity, leading to G1/S phase arrest by two 
parallel pathways; repression of RB-regulated E2F transcription (Harbour and Dean, 
2000) and inhibition of c-Myc dependent transcription (Santoni-Rugiu et al., 2000). 
 
However, the silencing of Cyclin E-Cdk2 activity in late G1 occurs even in cells 
lacking p53 and p21 proteins, arguing for the existence of a more rapid p53-
independent response mechanism at the G1/S checkpoint. This mechanism involves 
the phosphorylation of Cdc25A phosphatases by Chk2 and Chk1, which signals the 
ubiquitination and degradation of Cdc25A by proteasomes, resulting in the 
phosphorylation of Cdk2 on tyrosine 15 and inhibition of the Cyclin E-Cdk2 activity 
and G1 entry (Falck et al., 2001). Interestingly, the ATM-Chk2-Cdc25A-Cdk2 
pathway also emerges as a key mechanism in the transient intra-S-phase arrest. 
During DNA damage in the S phase, ATM signals an intra-S-phase arrest through at 
least two parallel pathways, one involving ATM-Chk2-Cdc25A-Cdk2, and another 
involving the trimeric protein complex Mre11-Nbs1-Rad50 (Falck et al., 2002). 
SMC-1 protein, a component of the RC-1 protein complex that promotes DNA repair 
by homologous recombination, has also been identified as one of its downstream
effectors (Wakeman et al., 2004).   
1.6.3 DNMT1 and p53 
A p53 consensus binding site was identified in exon 1 of the human DNMT1 gene.
Phosphorylation of p53 upon DNA damage leads to diminished binding to this site 
and de-repression of the DNMT1 gene, suggesting a mechanistic link between the two 
proteins in the DNA damage response (Peterson et al., 2003). This is supported by the 
observation that DNMT1 and p53 co-localize in the nucleus, and a p53 interaction 
domain was identified from amino acids 1081 to 1409 at the C-terminal region of 
DNMT1 (Esteve et al., 2005). Following doxorubicin assault, repression of the anti-
apoptotic survivin gene by p53 is mediated by the recruitment of DNMT1 to the 
survivin gene promoter (Esteve et al., 2005). The survivin gene promoter is CG-rich 
and contains several Sp1 canonical and p53 binding sites involved in the regulation of 
its gene expression. Recent studies show that Sp1 may act as a platform for the 
recruitment of transcriptional repressors consisting of p53, DNMT1 and HDAC for 
the repression of the survivin gene after DNA damage (Esteve et al., 2007).  
 
Similarly, down-regulation of Cdc25C and Cdc2 following DNA damage involves the 
functional cooperation of p53 and DNMT1, which form a complex with the 
transcriptional repressors HDAC and H3K9me2 on the Cdc25C and Cdc2 promoters 
(Le Gac et al., 2006). This finding strongly highlights the interplay of DNMT1 and 
p53 proteins in gene suppression upon DNA damage. On the contrary, DNA damage 
induced by sulfonate-derived methylating agents such as methylmethanesulfonate 
(MMS) results in the depletion of DNMT1 protein in human cells by the activation of 
a p53-independent DNA damage response pathway, suggesting the existence of other 
mechanisms for the regulation of DNMT1 protein (Chuang et al., 2002). 
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1.6.4 DNMT1 in DNA damage and repair 
Other than maintaining the methylation patterns of newly replicated DNA, increasing
evidence suggest that DNMT1 also play important roles in DNA damage response 
pathways in mammals. DNMT1 has been shown to accumulate at DNA damage sites 
by binding to PCNA, and this may be necessary for DNMT1 to maintain DNA 
methylation pattern during the repair process, thus minimizing aberrant methylation 
events that may lead to de-regulation of gene expression and genomic instability 
(Mortusewicz et al., 2005). Inhibition of DNMT1 leads to an intra-S-phase arrest and 
induction of stress response genes, demonstrating a link between DNA methylation 
and cell cycle checkpoints. This mechanism was proposed to prevent the 
accumulation of DNA methylation errors that could arise if replication proceeds in the 
absence of DNMT1, thereby maintaining the epigenomic information of cells 
(Milutinovic et al., 2003). Indeed, loss of DNMT1 leads to reduced fidelity of 
maintenance methylation, enhanced genomic instability and decreased cell viability 
(Brown and Robertson, 2007). This finding may provide a mechanistic explanation 
for the role of DNMT1 in cancer.  
 
By correcting replication errors, mismatch repair (MMR) acts as a genome
surveillance system that plays an important role is reducing mutations and 
maintaining genomic stability in the newly synthesized DNA helix. Impaired MMR 
can lead to microsatellite instability (MSI) which manifests itself as alterations in the 
length of simple repetitive DNA sequences. Interestingly, several lines of evidence 
also suggest an association between the MMR pathway and DNA methylation in 
mammals. Firstly, PCNA proved to be a physical link between MMR complexes and 
DNMT1 proteins. PCNA was shown to directly interact with MLH1 necessary for 
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DNA mismatch repair at a step preceding DNA resynthesis (Lee and Alani, 2006), 
and it also participates in repair processes such as nucleotide excision repair (NER) 
(Mocquet et al., 2008) and MMR pathways (Masih et al., 2008). Additionally, PCNA 
interacts and co-localizes with DNMT1 at replication foci, suggesting a possible 
linkage between DNA repair and methylation pathways. Secondly, MBD4 (MED1) 
methyl-binding protein binds to fully and hemi-methylated DNA and forms a 
complex with MLH1. MBD4 has high homology to bacterial DNA repair 
glycosylase/lyases and was reported to display endonuclease activity that may be 
involved in the MMR process (Bellacosa et al., 1999). Supporting this, MBD4 was 
found to be mutated in human carcinomas with microsatellite instability (Riccio et al., 
1999). Both studies suggested that MBD4, and possibly DNMTs, may play an 
important role in the mismatch repair pathway.  
 
The role of DNMT1 in the MMR pathway was further confirmed by independent 
studies that show DNMT1 deficiency in mouse embryonic stem cells leads to 
impairment of DNA replication and mismatch repair, resulting in an increase in MSI 
(Kim et al., 2004). In agreement with this, DNMT1 was also identified as a potential 
component of the MMR pathway in a genetic screen for MMR mutants using 
Bloom’s syndrome protein (Blm)-deficient mouse embryonic stem cells (Guo et al., 
2004). 
 
1.6.5 The nucleolus – a DNA damage response center  
The nucleolus is the site of ribosome-subunit biogenesis in eukaryotic cells. Apart 
from its role in rRNA synthesis and ribosome assembly, the nucleolus has also been 
implicated in viral replication, cell cycle regulation, aging, nuclear export pathways 
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and telomerase functions (Olson et al., 2002). The functions of the nucleolus were 
also found to be tremendously modified in human cancer cells. Impairment of 
nucleolus function is linked to diseases such as Diamond-Blackfan anaemia 
(Choesmel et al., 2007), Werner syndrome, Bloom syndrome and Rothmund-
Thomson syndrome (Brosh et al., 2001; Marciniak et al., 1998; Woo et al., 2006). 
 
The role of DNMT1 in maintaining the integrity of the nucleolar structure was 
demonstrated by the hypomethylation of ribosomal RNA genes and epigenetic 
disruption of the nucleolar structure in human DNMT1 knockout cells (Espada et al., 
2007). Surprisingly, the nucleolus has been proposed as a stress response center, and 
this is highlighted by its ability to regulate p53 during DNA damage (Horn and 
Vousden, 2004). Early work demonstrated that inhibition of Topoisomerase II by 
doxorubicin leads to nucleolar disruption as identified by the translocation of 
nucleophosmin/B23 from the nucleolus into the nucleoplasm in human and murine 
cells (Bor et al., 1992; Chan et al., 1987). The translocation of nucleophosmin/B23 
upon stress and DNA damage has been proposed as a mechanism to retain p53 in the 
nucleoplasm, thereby mediating its stabilization and accumulation (Rubbi and Milner, 
2003). The mechanism involves the rapid interactions of B23 with p53 and HMD2 
proteins which lead to the dissociation of the HDM2-p53 complexes and relief of 
HMD2-mediated p53 protein degradation (Colombo et al., 2002; Kurki et al., 2004). 
The impairment in nucleolar functions frequently observed in viral infections is also 
associated with stabilization of p53, thus providing an important example of this 
model in viral transformation (Hiscox, 2002).  
 
Several proteins such as DNA damage-dependent poly(ADP-ribose) polymerases 1
and 2 (PARP-1 and PARP-2) have also been shown to associate with the nucleolus by 
the interaction with B23 (Meder et al., 2005). Importantly, DNMT1 was also found to 
associate with B23 in the nucleolus of cultured cells (my unpublished data). Hence, it 
will be interesting to elucidate the possible interplay among these proteins in response 
to DNA damage.  
 
1.7 Micronuclei 
DNA damaging agents, particularly those that induce DNA double strand breaks 
(DSBs), can enhance genomic instability resulting in the formation of micronuclei 
structures in mitotic cells (Dhawan et al., 2003; Emri et al., 2000; Hatayoglu and 
Orta, 2007).  
 
1.7.1 Micronuclei – what are they? 
Micronuclei structures are defined as chromatin-containing bodies that lag due to the 
failure of sister chromatids to segregate properly in anaphase. These bodies fail to 
incorporate into daughter cells during telophase and are extruded into the cytoplasm 
of either, or both, daughter cells as extranuclear bodies (Lindholm et al., 1991). Since 
micronuclei can only be formed during telophase, cell division is a pre-requisite to the 
formation of micronuclei. There are two main categories of micronuclei, namely, 
clastogenic micronuclei containing acentric chromosomes or chromatid fragments, 
and aneugenic micronuclei containing whole chromosomes or chromatids (Norppa 
and Falck, 2003). Clastogenic and aneugenic micronuclei can be distinguished by 
their centromere-specific DNA sequences or centromeric proteins using 
immunofluorescent staining with anti-kinetochore antibody which specifically detects 
aneuploidy (Degrassi and Tanzarella, 1988; Hennig et al., 1988). Some micronuclei 
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may also be derived from broken anaphase bridges resulting from chromosome 
rearrangements (Cornforth and Goodwin, 1991). The loss of DNA fragments as 
micronuclei may eventually lead to genetic imbalances and cell death. 
 
The analysis of micronuclei has gained popularity as an in vitro genotoxicity test and 
as a biomarker assay for human exposure to genotoxic agents (Hongping et al., 2006; 
Norppa and Falck, 2003; Orsiere et al., 2006). Since micronuclei are formed during 
cell division, an accurate estimation of micronuclei frequency can be obtained from 
the first post-mitotic interphase after exposure to genotoxic agents by using the 
cytokinesis inhibitor Cytochalasin B (Norppa and Falck, 2003). Whilst micronuclei 
analysis is a useful tool, little is known about the mechanisms of micronuclei 
generation and the proteins involved in their formation. 
 
1.7.2 DNMT1 and micronuclei  
5-azacytidine (5AzaC), a structural analogue for cytidine, has been shown to induce 
the formation of clastogenic micronuclei in mouse lymphoma cells (Stopper et al., 
1993). Similarly, DNA methyltransferase inhibitors such as 5-aza-2’-deoxycytidine 
(5AzadC) and (-)-epigallocatechin-3-gallate (EGCG) were shown to exhibit 
significant genotoxic effects on human cancer cell lines by the induction of 
micronuclei (Stresemann et al., 2006). These reports suggest a potential involvement 
of DNMT1 and/or DNA methylation in DNA damage-induced micronuclei formation. 
DNMT1 deficiency in mouse embryonic stem cells leads to impairment of DNA 
replication and mismatch repair, and an increase in MSI, suggesting a role of DNMT1 
in maintaining genetic stability (Brown and Robertson, 2007; Kim et al., 2004; Wang 
and James Shen, 2004). Supporting this observation, global DNA demethylation in 
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human colorectal cancer cells also resulted in chromosomal instability (Rodriguez et 
al., 2006). The in vitro treatment of cultured human lymphocytes with 5-azacytidine 
resulted in poor condensation of heterochromatic regions and micronucleation of 
acentric DNA fragments from chromosomes 1, 9 and 16 (Fauth et al., 1998). The 
incorporation of 5-azacytidine into the DNA leads to inhibition of cytosine 
methylation, which may influence the conformation of the DNA and impair binding 
of DNA-interacting proteins such as Topoisomerase II and those in the kinetochore 
complex (Stopper et al., 1997). As such, hypomethylation of large heterochromatic 
regions of the chromosomes may be associated with their micronucleation. Genotoxic 
agents such as methyl methanesulfonate (MMS), N-methyl-N-nitrosourea (NMU) and 
Topoisomerase II inhibitor Genistein (GEN) were also shown to induce micronuclei 
formation in mouse lymphoma cells (Lutz et al., 2005).  
 
1.7.3 Possible DNA content in the micronuclei   
Micronuclei formation is undoubtedly an important mechanism for chromosome loss 
during DNA damage (Ford et al., 1988; Garaj-Vrhovac et al., 1992). About 50% to 
60% of spontaneously derived micronuclei in human fibroblasts consists of acentric 
DNA fragments, probably arising from chromosomal breaks during DNA segregation 
(Hennig et al., 1988). Micronuclei can also be induced by the treatment of cultured 
cells with agents that induce DNA damage such as gamma-radiation (Hatayoglu and 
Orta, 2007), hydrogen peroxide, arsenite oxide (Low et al., 2008) and adriamycin 
(Dhawan et al., 2003), which have been successfully used in chemotherapy. 
Carcinogen-induced clastogenic micronuclei have been more widely studied despite 
the fact that both clastogenic and aneugenic chromosome alterations occur during 
carcinogenesis. However, it is important to point out that there are relatively few 
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genotoxic agents that induce solely one type of micronuclei. For instance, some 
clastogens that induce clastogenic micronuclei can also induce micronuclei containing 
kinetochore structures, indicating the loss of whole chromosome(s) (Dhawan et al., 
2003; Humpage et al., 2000). The DNA content in the micronuclei structures remains 
an area of great interest, and chromosome painting on human lymphocytes upon γ-
irradiation indicated the presence of (ribosomal) DNA from chromosomes 1, 7, 11, 
14, 17 and 21 in the micronuclei (Fimognari et al., 1997). Interestingly, the frequency 
of micronuclei formation also increased with prolonged culture of human 
lymphocytes and is attributed to an age-dependent micronucleation of the X and Y 
chromosomes (Catalan et al., 1998; Catalan et al., 1995). The content of micronuclei 
may be investigated by the use of electron microscopy imaging. 
 
1.7.4 Doxorubicin 
Doxorubicin, a benzanthroquinone drug of the anthracycline family (trade name 
adriamycin) that targets Topoisomerase II, is routinely employed as a 
chemotherapeutic agent in the treatment of several types of human malignancies 
(Potter and Rabinovitch, 2005). Doxorubicin exhibits a wide spectrum of cytotoxicity 
effects primarily as a Topoisomerase IIα poison (Burden and Osheroff, 1998; 
Gewirtz, 1999). The planar three-ring structure stabilizes the Topoisomerase II-DNA 
cleavable complex by DNA intercalation and enhances cleavage of DNA at both 
strands in a Topoisomerase II-dependent manner. In addition, doxorubicin can also 
react with cellular formaldehyde to form DNA adducts (Cutts et al., 2005; Swift et al., 
2006). This prevents the DNA double strand breaks from rejoining, thereby allowing 
the replication and transcriptional machineries to readily disrupt this complex and 
render the DNA breaks permanent (Potter and Rabinovitch, 2005). The production of 
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DNA double strand breaks and the generation of reactive oxidative species by 
doxorubicin activate an ATM-dependent DNA damage response leading to the 
phosphorylation of histone H2AX on serine 139 and activation of downstream targets 
such as the NHEJ or HR pathways (Burma et al., 2001; Kurz et al., 2004; Rogakou et 
al., 1998). Increased sister chromatid exchanges and chromosomal aberrations has 
also been observed in Chinese hamster ovary cells treated with doxorubicin (Bean et 
al., 1992). This could probably account for the genotoxic effect of doxorubicin, which 
induces both clastogenic and aneugenic micronuclei formation in human cells 
(Dhawan et al., 2003; Eom et al., 2005; Jagetia and Nayak, 1996).  
 
The generation of micronucleated cells induced by doxorubicin assault in human 
HeLa cells was associated with a decrease in cell survival. Moreover, Eom et al 
showed that cell death inflicted by doxorubicin treatment is preceded by 
micronucleation (Eom et al., 2005). Interestingly, enzymatic studies have shown that 
doxorubicin can inhibit the enzymatic activity of DNMT1 via DNA intercalation in 
mammalian cell lines, which leads to conditional apoptosis in HCT116 cell lines 
(Yokochi and Robertson, 2004). This finding suggests that DNMT1 may act as a 
mediator for drug-induced cytotoxicity. As such, it would be interesting to investigate 
the possible involvement of DNMT1 in the generation of micronuclei upon DNA 
damage. Understanding the mechanism behind such chromosomal impairments may 
provide a clue to genomic instability, a hallmark in carcinogenesis. 
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1.8 Research Objectives  
 
DNA methylation is vital for proper chromatin structure and function in mammalian 
cells and the importance of DNA methylation can be further inferred by its 
involvement in several aspects of cellular processes. It is therefore necessary to ensure 
regulated expression of DNA methyltransferases (DNMTs), the enzymes that catalyze 
DNA methylation, to ensure proper coordination of methylation activities with 
biological processes. Aberrant DNA methylation has been frequently associated with 
tumorigenesis (Kanai and Hirohashi, 2007). However, though much study has been 
carried out in understanding how these abnormal methylation events, in the form of 
hypo- and hyper-methylation of genes, can affect the genomic stability of the cells, 
the question pertaining to how DNMT expression is altered remains unresolved.  
 
DNMT1 is the major maintenance DNA methyltransferase responsible for 
maintaining DNA methylation patterns of newly-synthesized DNA in dividing cells. 
As such, the expression levels must be tightly controlled in the cell cycle, particularly 
in the S phase of actively-dividing cells. De-regulated DNMT1 expression leads to 
serious consequences to the cells and this is evident by the abnormalities in DNMT1 
expression in breast cancer cells (Agoston et al., 2005) and colorectal carcinogenesis 
(Zhu et al., 2007). Interestingly, DNMT1 expression is frequently observed to be 
inversely related to p21WAF1 in mammalian cells. Although p21WAF1 has been shown 
to inhibit DNA methylation, its inverse relationship with DNMT1 expression suggests 
a potential link between the two proteins at the regulatory level. In my thesis, I aimed 
to elucidate the underlying mechanism(s) on how DNMT1 can be regulated in 
mammalian cells, and how this can relate to its relationship with p21WAF1. This may 
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hopefully provide some insights to how de-regulated DNMT expression, and hence 
cancer progression, can be corrected in mammalian cells. 
 
Genomic instability leading to carcinogenesis is highly prevalent in cancer and 
transformed cells, and can be broadly classified into microsatellite instability (MIN) 
associated with mutator phenotype, and chromosome instability (CIN) recognized by 
gross chromosomal abnormalities (Charames and Bapat, 2003). Chemotherapeutic 
agents, such as gamma radiation (Hatayoglu and Orta, 2007) and adriamycin 
(Dhawan et al., 2003), can give rise to such chromosomal impairments in the form of 
micronuclei structures in mitotic cells (Emri et al., 2000). However, what remains 
unclear is whether the induction of micronuclei upon exposure to such 
chemotherapeutic agents is a general characteristic to both normal and cancerous cell 
types during treatment. My study on elucidating the proteins and mechanisms 
involved in doxorubicin-mediated micronuclei formation could represent an 
opportunity to uncover the ‘mystery’ on how cancer cells are selectively targeted 
during cancer therapy. In addition, DNMT1 was recently identified as a major target 
for doxorubicin in mediating ‘conditional’ apopotosis in human cancer cells (Yokochi 
and Robertson, 2004). The involvement of DNMT1 in drug-induced cytotoxicity 
proved to be an area of great interest, especially so as DNMT1 is often up-regulated in 
cancer cells (Kanai and Hirohashi, 2007). My work in elucidating the role(s) of 
DNMT1 in doxorubicin-mediated micronuclei formation will hopefully address the 
involvement of DNMT1 in cancer treatment. This study will inevitably leads to more 
clues in supporting the use of drug targeting DNMT1 and/or micronucleation in 
cancer treatments.    
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Chapter 2: MATERIALS AND METHODS 
 
2.1 Mammalian cell cultures 
Unless otherwise stated, all mammalian cells were purchased from the ATCC and 
cultured using the recommended protocol. Wild-type (WT), p53-/-, DNMT1+/+ and  
DNMT1-/- HCT116 cell lines were provided by Prof B. Vogelstein (Sidney Kimmel 
Comprehensive Cancer Center, Johns Hopkins) and cultured in McCoy’s Medium 
(GIBCO) supplemented with 10% FBS (heat-inactivated, Hyclone, USA), 2mM L-
glutamine and penicillin-streptomycin (0.5units/ml penicillin and 10ng/ml 
streptomycin) (Sigma Chemicals and GIBCO-BRL). Hygromycin (0.1mg/ml) was 
used for selection of the DNMT1-/- HCT116 cells. MRC5.SV40 was provided by Dr 
P. Karan (ICRF, UK) and cultured in MEM supplemented with 10% FBS, 1mM 
minimum essential amino acids, 1mM sodium pyruvate, L-glutamine and penicillin-
streptomycin. All cells were cultured in a 37oC humidified incubator with 5% CO2. 
 
2.2 Antibodies 
Antibodies 2e10 mAb, 1C7 mAb, D12 mAb, 3G5 pAb and 5MeC pAb specific for 
DNMT1 were courtesy of Dr Linda Chuang. Anti-DNMT1 N-Terminal, anti-BRCA1 
(AB1) and anti-phospho S15-p53 were from Calbiochem. Anti-p300 (C20), anti-p53 
(DO1), anti-PCNA (PC10), anti-RB (IF8), anti-SP1 (PEP2), anti-c Myc (9e10), anti-
E2F1, anti-B23 (goat) and anti-MRE11 were all purchased from Santa Cruz. 
Monoclonal antibodies for Actin (clone C4) and p21WAF1/CIP1 (clone 70) were from 




2.3 Bacterial strain 
E. coli strain XL1-Blue was used for all transformations with LB media.  
 
2.4 Drugs and Chemicals 
MMS, TSA, caffeine and protease inhibitor cocktail P8340 (PI) were purchased from 
Sigma-Adrich (USA). MMS was prepared in DMSO and TSA was prepared in 
ethanol. Caffeine was directly dissolved in culture media before used. H2O2 was 
obtained from Dr Hue Kian Oh. Doxorubicin (Dox) was purchased from Calbiochem 
and dissolved in sterile distilled water. 5AzadC was bought from Fluka Chemicals 
and resuspended in sterile distilled water. Nutlin-3 was purchased from Alexis 
Biochemicals and dissolved in ethanol as recommended. 
 
2.5 Drug treatments 
Unless otherwise stated, mammalian cells were treated with the respective dosage of 
drugs prepared in complete medium (MMS, TSA and 5AzadC) at 37oC and harvested 
post-treatment at the time-points stated. For the H2O2 and Dox treatments, cells were 
treated with the respective dosage of the drugs at 37oC for 1 hr, washed twice with 
PBS, and recovered in complete medium at 37oC. The cells were then harvested post-
treatment at the time-points stated.  
 
2.6 Harvesting of mammalian cells 
The used medium was collected in a 50ml centrifuge tube (Falcon). Cells were 
washed twice with PBS and incubated with 2ml 25% Trypsin in PBS at 37oC for 3 
min. The trypsin was then inactivated by the addition of the used medium and the 
cells were resuspended by pipetting. The cell suspension was transferred to the 50ml 
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centrifuge tube (Falcon) and centrifuged at 1,500 rpm for 7 min at 4oC. The cell 
pellets were washed once with ice-cold PBS and centrifuged at 1,500 rpm for 5 min at 
4oC. Cell pellets were stored in -80oC until further analysis.  
 
2.7 Flow cytometry analysis 
The cells were collected by centrifugation at 1,500rpm, 4oC for 7 min and washed 
once with PBS. Cell pellets were resuspended and fixed with ice-cold 80% ethanol in 
PBS at -20oC for 24 hr. The cell suspension was centrifuged at 1,500 rpm for 5 min at 
4oC, and incubated with 50μg/ml propidium iodide and 20μg/ml RNase at 37oC for 30 
min. A Becton Dickinson FACScan machine (CellQuest) was used to count 21,000 
events and the data were analyzed using WinMDI and ModFit Program. 
 
2.8 Cell viability and cell proliferation assays 
About 5 X 105 cells were plated onto each well in a 6-well plate and incubated at 
37oC for 48 hr. Cells were treated with 5μM Dox for 1 hr, washed twice with PBS, 
and recovered in complete medium at 37oC. The cells were harvested post-treatment 
at the time-points stated and resuspended with 500μl of the used media. The cell 
suspension was transferred to a polystyrene tube and cell viability was measured by 
the tryphan blue staining method using a Cell Viability Analyzer (Vi-CELL XR 2.03, 
Beckman Coulter). The average cell viability count and proliferation efficiency from 
triplicate experiments was plotted on a line graph.  
 
2.9 Lactate Dehydrogenase (LDH) cell death assay 
Cells were plated onto a 96-well plate and cultured at 37oC for 48 hr until the cells 
reached about 80% confluency. Cells were treated with 5μM Dox for 1 hr, washed 
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twice with PBS, and recovered in complete medium at 37oC. At the time-points 
stated, the supernatant was collected to a 96-well plate. The cells were then lysed with 
equal volume of lysis buffer (0.1% Triton X-100 prepared in medium without 10% 
FBS) at room temperature for 15 min with shaking, after which, the lysate was 
collected to a 96-well plate. To measure the NADH concentration as a function of the 
lactate dehdrogenase (LDH) activity, 10μl of the supernatant and lysates were 
incubated with 200μl of the freshly prepared KP Buffer (4.58g K2HPO4 x 3H2O in 
500ml distilled H2O titrated against 0.66g of KH2PO4 in 500ml distilled H2O and 
adjusted to pH 7.5) supplemented with 500μl of NADH (8.5mg/ml dissolved in 0.1% 
NaHCO3) and 500μl of Pyruvate (3.4mg/ml in KP Buffer). The kinetic of the 
absorbance at 340nm was immediately measured using a TECAN plate reader. The 
cytotoxicity (% cell death) was determined by calculating the LDH activity in the 
supernatant versus the total LDH activity in the supernatant and lysates.  
 
2.10 Purification of total RNA 
Total RNA was extracted using the QIAshredder and RNeasy kit from QIAGEN 
(Germany) using the recommended protocol. 
 
2.11 Reverse transcription and PCR 
1μg RNA was primed with 5 pmoles 18 mer poly-dT primer at 70oC for 10 min and 
chilled on ice for 5 min. A reaction mixture containing 2μl 10X M-MuLV reverse 
transcriptase buffer, 100mM DTT, 0.5mM of each dNTP, 100 units of reverse 
transcriptase enzyme (NEB) and 20 units of RNase Inhibitor (Roche) was added to 
each sample and incubated at 42oC for 50 min. The reaction was heat inactivated at 
70oC for 15 min. RT-PCR was carried out in a 25μl volume using 2.5μl of 10X 
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MgCl2-free buffer, 2mM MgCl2, 0.2mM of each dNTPs, 10 pmol of forward and 
reverse primers (Table 1), 0.75 units Taq DNA Polymerase in Storage Buffer B 
(Promega) and 1μl of the prepared cDNA. The PCR cycle was carried out at an initial 
denaturation of 94oC for 3 min, followed by amplification with 5 cycles of 94oC for 
30 sec, 60oC for 30 sec and 72oC for 1 min and 25 cycles of 94oC for 30 sec, 55oC for 
30 sec and 72oC for 1 min, and a final extension at 72oC for 5 min.   
 
Primers for RT-PCR Sequences 
GAPDH 
 
F:   5’ ACATCGCTCAGACACCATGG 3’ 
R:   5’ GTAGTTGAGGTCAATGAAGGG 3’ 
DNMT1 F:   5’ GTGAAGGAGAAATTGAATCTCTT 3’  
R:   5’ GCCTCTCCATCGGACTTG 3’ 
p300 F:   5’ AGATGGCCCACGTGCAAATTT 3’ 
R:   5’ GAGACCTGAGAGTCCGCAAAA 3’ 
E2F1 F:   5’ ACCTGGAAACTGACCATC 3’ 
R:   5’ TACGAAGGTCCTGACACG 3’ 
Sp1 F:   5’ GCACAAACGTACACACACAGG 3’ 
R:   5’ CAGATCTGCCACCTGCATGAC 3’ 
p21 F:   5’ CCTGACGGATCCATGTCAGAACCGGCT 3’ 
R:   5’ CCTGACGAATTCTTAGGGCTTCCTCTT 3’ 
p53 F:   5’ CCTGAAAACAACGTTCTGTCCCCC 3’ 
R:   5’ CTTGTAGATGGCCATGGCGCGGACGCG 3’ 
 
Table 1:  Forward and reverse primers used for RT-PCR of the cDNA preparation; F for 
forward primers and R for reverse primers in the 5’ to 3’ direction. 
 
 
2.12 Purification of genomic DNA 
Genomic DNA was extracted from cell pellets using the QIAamp® DNA Blood Mini 
Kit (QIAGEN) using the recommended protocol and eluted in TE Buffer (10mM 
TRIS.CL pH 8.0 and 1mM EDTA pH 8.0). 
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2.13 DNA agarose gel electrophoresis 
6x DNA loading dye (0.008% bromophenol blue, 0.008% xylene cyanol FF and 30% 
glycerol) was added to DNA to obtain a final concentration of 1x mix. The sample 
was loaded onto an agarose gel (BRL) made in 1x TAE buffer with 0.5μg/ml 
ethidium bromide and electrophoresed at maximum current and constant voltage of 
120V in 1x TAE for 30 min at room temperature. The DNA was viewed under ultra-
violet lamp (Sambrook et al., 1989). 
 
2.14 Methylation-sensitive McrBc restriction digestion 
Genomic DNA was normalized against the PCR band for β-Globin. The PCR for β-
Globin was carried out in 25μl using 2.5μl 10X MgCl2-free buffer, 2mM MgCl2, 
0.2mM of each dNTPs, 10 pmol of forward (5’ TGGGTTTCTGATAGGCACTGACT 
3’) and reverse primers (5’ ATTCGTCTGTTTCCCATTCTAA 3’), 0.75 units Taq 
DNA Polymerase in Storage Buffer B (Promega) and 50ng genomic DNA. The PCR 
cycle was carried at an initial denaturation of 94oC for 3 min, followed by 
amplification with 25 cycles of 94oC for 30 sec, 55oC for 30 sec and 68oC for 45 sec, 
and a final extension at 68oC for 5 min. For global methylation status, 1μg genomic 
DNA was digested in 25μl volume containing 12 units of McrBc (NEB), 2.5μl of 10x 
buffer 2 (NEB), 0.25μl of 100x BSA (10mg/ml) and 0.25μl of 100x GTP (100mM) at 
37oC for 1 hour followed by inactivation at 65oC for 15 min. The reaction is then 
cooled to room temperature. After the addition of 6x loading dye to obtain a final 
concentration of 1x, the sample was electrophoresed in a 1% agarose gel.  
 
2.15 Cell lysis 
Cell pellets were lysed in 5X volume of modified RIPA buffer (50mM Tris pH 8.0, 
0.3M NaCl, 10mM EDTA pH 8.0, 1% NP40, 50mM NaF, 0.1% SDS, 0.5% sodium 
deoxycholate and 0.2mM PMSF, sonicated at 50% power output), 3X volume of 
NP40 buffer (50mM Tris pH 8.0, 0.3M NaCl, 1mM ETDA pH8.0, 10% Glycerol, 
0.5% NP40, 5mM NaF, 0.5mM Na3VO4, 10mM β-Glycerophosphate, 1mM DTT, 
0.2mM PMSF and 1:500 PI, resuspended and incubated on ice for 20 min) or 2X 
volume of non-SDS buffer (50mM Tris pH 7.5, 0.3M NaCl, 1mM EDTA pH 8.0, 3% 
Glycerol, 0.02% NP40, 50mM NaF, 1mM DTT and 0.2mM PMSF, sonicated at 50% 
power output). The modified RIPA and NP40 lysates were centrifuged at 14,000 rpm 
for 20 min at 4oC (Ultracentifuge 5417R, Eppendorf) and the non-SDS lysates were 
centrifuged at 30,000rpm for 30 min at 4oC (OptimaTM Ultracentrifuge, Beckman 
Coulture) to recover the supernatant. All protein concentrations were measured using 
the RC-DC kit (Bio-Rad, USA). The modified RIPA and NP40 lysates were used for 
Western blot analysis while the non-SDS was used for immunoprecipitation assay. 
 
2.16 Western blot analysis 
SDS-PAGE gels were prepared using 30% acrylamide/bis solution (Bio-Rad). 
Proteins were transferred to PVDF membranes (Bio-Rad) in transfer buffer (25mM 
Tris-base, 192mM glycine and 0.03% SDS) using the Bio-Rad transfer system set at 
100V and 350mA for 2 hr or 30V and 100mA for overnight at 4oC. The membranes 
were blocked with 5% skimmed milk (Anlene) in TBST buffer (20mM Tris.HCL pH 
8.0, 0.15M NaCl and 0.05% Tween-20) at room temperature for 30 min and then 
washed thrice with TBST buffer. Following that, the membranes were probed with 
specific primary antibodies at 37oC for 1 hr or at 4oC for overnight, washed thrice 
with TBST buffer and then probed with the respective secondary antibodies at 1:4000 
(anti-mouse IgG-HRPO, DAKO) or 1:20,000 (anti-rabbit IgG peroxidase conjugate, 
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Sigma) at 37oC for 1 hr. The membranes were washed thrice with TBST and probed 
with ECLTM Western blotting detection reagents (Amersham). Protein signals were 
visualized using hyperfilms (Amersham) developed with a Kodak X-omatic automatic 
developer. The protein signal was quantified using QuantityOne465 Program (Bio-
Rad) and plotted into a line graph. 
 
2.17 DNA manipulations 
Restriction digestions of DNA were performed using restriction enzymes from New 
England Biolabs (NEB, USA) according to the standard protocol at 37oC for 1 hour 
and inactivation at 65oC for 15 min. Ligation was carried out using T4 DNA Ligase 
(GIBCO, USA) using 9:1 ratio of inserts to vector at 16oC overnight. The ligation 
products were transformed into 100μl of XL1-Blue cells by incubation on ice for 30 
min, followed by heat shock at 42oC for 1 min, and then incubation on ice for another 
5 min. The transformed cells were recovered with 500μl of LB medium 
(supplemented with 20mM glucose) at 37oC for 1 hour and then cultured on LB agar 
plates (1.5% agar in LB supplemented with 100μg/μl ampicillin) at 37oC overnight. 
Clones were picked and cultured in 5ml of LB medium (supplemented with 100μg/μl 
ampicillin) with shaking at 37oC overnight. Plasmid preparations were carried out 
using QIAprep Spin columns (QIAGEN, USA) and positive clones were identified by 
restriction digestions.    
 
2.18 Mammalian expression plasmids 
The pXJ41-p21WAF1 plasmid expressing full-length human p21WAF1 cDNA and pXJ 
HA-p300 plasmid expressing full-length human p300 cDNA tagged to HA were 
provided by Dr Linda Chuang. pXJ40 Flag-E2F1 plasmid expressing full-length
                                   
 
Diagram 3: Circular map of pXJ41-neo vector. ORI, origin of replication; HCMV, human 
cytomegalovirus promoter; neo, mammalian cell resistance to G418 antibiotic; Amp, gene 
conferring ampicillin resistance in E. coli; SV40 poly A site is the signal for termination of 





                      
 
 
Diagram 4:  Circular map of pGL3-Basic vector. luc+, cDNA encoding the modified firefly 
luciferase gene; Ampr, gene conferring ampicillin resistance in E. coli; f1 ori, origin of replication 
derived from filamentous phage; ori, origin of replication in E. coli. Arrows within the Ampr and 
luc+ indicate the direction of transcription. 
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human E2F1 cDNA tagged to Flag, pXJ40 HA-Sp1 plasmid expressing full-length 
Sp1 cDNA tagged to HA- and pCMV-βGal were provided by Dr Hue Kian Oh 
(Manser et al., 1997). All other mammalian expression plasmids were cloned as 
described. 
 
2.19 Cloning of full length DNMT1 into pXJ40-Flag vector 
The pM-DNMT1 plasmid carrying the full length DNMT1 sequence was obtained 
from Dr Linda Chuang. The full length DNMT1 sequence was released from the pM 
vector by restriction digestion using EcoRI restriction enzyme (NEB). Blunt ends 
were generated on the digested DNA (10μg) using 50 units of T4 DNA Polymerase 
(NEB), 5μl of 10x T4 DNA Polymerase buffer, 0.2mM of each dNTPs and 0.5μl of 
100x BSA in a reaction volume of 50μl, and incubated at 12oC for 20 min followed 
by inactivation at 75oC for 10 min. The samples were then purified using Gel 
Extraction kit (QIAGEN, Germany) and cloned into mammalian expression vector 
pXJ40-Flag (Courtesy of Dr Hue Kian Oh) by blunt-end ligation. Positive clones were 
identified by restriction digestion and sequenced using T7 primers (5’ 
TAATACGACTCACTATAGGG 3’) for the T7 promoters. 
 
 
2.20 Cloning of DNMT1 promoter construct into pGL3-Basic vector 
                   
Diagram 5:  Schematic diagram of DNMT1 promoter spanning 340bp upstream of the ATG site. 
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The DNMT1 proximal promoter region (McCabe et al., 2005) was amplified by PCR 
from the total genomic DNA of MCF7 cells using the forward and reverse primers 
(Table 2) spanning 340bp upstream of the ATG site of the DNMT1 gene (Diagram 5). 
The PCR products were purified using the Gel Extraction kit (QIAGEN, Germany) 
and cloned into pGL3-Basic vector (Diagram 4) (Promega, USA) at the Kpn1-HindIII 
site to yield the pGL3-DNMT1Pro construct. Positive clones were identified by 




hDNMT1pro-F (Kpn1) 5’ TATTGGTACCCTTCTCGCTGCTTTATCCC 3’ 
hDNMT1pro-R (HindIII) 5’ TATTAAGCTTCTCGGAGGCTTCAGCAGA 3’ 
 
Table 2:  Primers used for amplification of human DNMT1 proximal promoter sequence for 
cloning into pGL3-Basic vector; F, forward primer and R, reverse primer. The recognition sites 
for the restriction enzymes are underlined. 
 
 
2.21 Preparation of competent cells 
An overnight culture of E. coli cells (in LB) was inoculated in 200ml of LB. The 
culture was then shaken at room temperature for about 5 hr. The cells were then 
pelleted by centrifugation at 2,500rpm, 4oC for 12 min. The cell pellets were 
resuspended with 1/3 of the original volume of chilled solution RF1 (100mM KCl, 
50mM MnCl2.4H2O, 30mM Potassium acetate, 10mM CaCl2.6H2O, 15% glycerol 
(v/v), adjusted to pH 5.8 with 0.2M acetic acid and filtered) and allowed to stand at 
4oC overnight. The cells were then centrifuged as before, resuspended in ice-cold RF2 
(10mM MOPS, 10mM KCl, 75mM CaCl2.6H2O, 15% glycerol (v/v), adjusted to pH 
6.8 with KOH and filtered) at 1/12.5 of the original volume, and aliquoted into pre-
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chilled micro-centrifuge tubes. The tubes were snap-frozen in liquid nitrogen and 
stored in -80oC until transformation. 
 
2.22 Transfection 
Unless otherwise stated, all transfection was carried out using SuperFect® transfection 
reagent (QIAGEN, Germany) under the recommended protocol. For Western blot 
analysis, mammalian cells were plated on 10-cm culture dish for 48 hr to achieve 60% 
confluency and then transfected with 10μg of the respective mammalian expression 
plasmids using 40μl of SuperFect® transfection reagent in serum-free media at 37oC 
for 2 hr. Cells were washed with PBS twice, recovered in complete medium at 37oC 
and harvested at 48 hr post-transfection for further analysis. For luciferase reporter 
assays, mammalian cells were plated on a 6-well culture dish for 48 hr to achieve 60% 
confluency and then transfected with a total of 2.3μg of mammalian expression 
plasmids using 8μl of SuperFect® transfection reagent in serum-free media at 37oC for 
2 hr. Cells were washed twice with PBS, recovered in complete medium at 37oC and 
harvested at 48 hr post-transfection for further analysis. 
 
2.23 Luciferase reporter assay 
MCF7 cells were cultured in 6-well dishes for 48hr and transfected with 0.5μg of 
DNMT1 promoter reporter plasmid, 0.5μg of mammalian expression plasmids (pXJ 
HA-p300, pXJ40 Flag-E2F1, pXJ40 HA-Sp1 and pXJ41-p21WAF1) and 0.3μg of 
pCMV-βGal as internal control using SuperFect® transfection reagent as described 
(QIAGEN, Germany). pCMV control vector (courtesy of Dr Hue Kian Oh) was used 
to top up the total DNA concentration to 2.3μg. Cells were harvested at 48 hr post-
transfection and lyzed with 1x Passive Lysis Buffer (Promega, USA) at room 
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temperature for 30 min. Protein concentration was quantitated using the Bradford 
Assay. The β-galactosidase activity was quantitated by incubating 50μl lysate in 50μl 
of 2X β-galactosidase buffer (150mM Na2HPO4, 45mM Na2VO4, 2mM MgCL2, 
100mM Mercaptoethanol and 1.33mg/ml ONPG) at 37oC for 1 hr and measured at 
420nm using a microplate reader spectrophotometer (BIO-RAD). Luciferase activity 
was quantitated using the Luciferase Assay System, Promega, USA, measured using a 
Luminometer (Turner Design) and normalized against the β-galactosidase activities 
for equal transfection efficiency. The average values for triplicate experiments were 
plotted in a histogram. 
 
2.24 siRNA experiments 
The siRNA-DNMT1 (h), siRNA-E2F1 (h) and siRNA-p300 (h) oligonucleotides 
(scramble sequences) were purchased from Santa Cruz and reconstituted to 10μM in 
RNAse-free water. The siRNA-LacZ (sense 5’ rCrGUrArCrGrCrGrGrArAUrArCUU 
rCrGrATT and antisense 5’ UrCrGrArArGUrAUUrCrCrGrCrGUrArCrGTT) 
(PrOligo) was used as an internal control, and empty transfection was used as a mock 
for the experiment. Mammalian cells were cultured in 10-cm culture plate for 48 hr to 
achieve 60% confluency and transfected with 100nmole of the respective siRNA 
using Oligofectamine® transfection reagent (QIAGEN, Germany) prepared in 
OptiMEM medium (GIBCO-BRL, USA) at 37oC for 5 hr according to the 
recommended protocol. The cells were washed with PBS twice and recovered in 
complete medium. Cells were harvested at 16, 36 or 48 hr post-transfection and lyzed 




2.25 Cell staining 
Cells coated on glass coverslips were washed briefly with PBS twice and fixed with 
3.7% paraformaldehyde in PBS for 15 min at room temperature. The fixing agent was 
then removed and the cells washed twice with PBS. Permeabilization was carried out 
with 0.1% Triton X-100 in PBS for 10 min at room temperature. Primary antibodies 
were then added at 1μg/100μl (D12 mAb specific for DNMT1, anti-B23 mAb, anti- 
phosphor S139-γH2AX mAb or anti-MRE11 mAb) of 1% Triton X-100 in PBS and 
incubated at 4oC overnight in a moist chamber. Following that, the cells were washed 
thrice with 0.1% Triton X-100 in PBS for 5 min each. Secondary antibodies 
conjugated with fluorescein or rhodamine (1:50 dilution in 1% Triton X-100 in PBS) 
(Sigma Chemicals, USA) was added onto the cells and incubated in dark for 1 hr at 
room temperature. The cells were then washed thrice with PBS, once with Hoechst 
33342 (1μg/ml in PBS) followed by thrice with PBS again. The slides were then 
mounted with PermaFluor (Lipshaw Immuno, USA) and viewed under oil immersion 
at 1250X magnification using a fluorescence microscope (AxioVision, camera from 
Carl-Zeiss, Germany). Confocal imaging was carried out using Olympus FluoView 
Version 1.6.  
 
2.26 Cell count for micronuclei frequency 
A total of about 200 cells were randomly viewed under oil immersion at 1250X 
magnification using a fluorescence microscope (AxioVision, camera from Carl-Zeiss, 
Germany). The number of cells exhibiting micronuclei structures was calculated as a 




2.27 Comet assay 
Cells coated on glass coverslips were treated with 5μM Dox (prepared in full media) 
for 1hr and recovered with fresh media for 24 hr. The alkaline Comet assay was 
carried out using the CometAssayTM Kit for single cell gel electrophoresis (Trevigen®, 
USA) according to the recommended protocol. The cells were then stained with 
SYBR Green I (provided in the CometAssayTM Kit) and viewed under the 
fluorescence microscope (AxioPlan 2 Imaging, Carl Zeiss). Tail moments were scored 
in at least 100 cells using the Comet Imager Software (Isis software, Metasystems, 
Germany) (courtesy of NUS). Extent of DNA damage was expressed as a measure of 
comet tail moments, which corresponds to the fraction of DNA in the comet tail. 
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Chapter 3: RESULTS 
 
3.1 Regulation of DNMT1 expression in the Cell Cycle 
DNA methyltransferase 1 (DNMT1), the major maintenance DNA methyltransferase, 
is necessary for maintaining DNA methylation patterns in newly synthesized DNA. 
DNMT1 is recruited to DNA replication sites through its interaction with PCNA, a 
processivity factor for DNA Polymerases δ and β (Iida et al., 2002). Interestingly, 
p21WAF1 has been shown to compete with DNMT1 for binding to its co-factor PCNA, 
thereby accounting for its ability to inhibit DNA replication and DNA methylation 
(Chuang et al., 1997).  
 
The regulation of DNMT1 gene expression is critical in coordinating DNMT1 activity 
with biological processes and therefore must be tightly regulated in the cell cycle to 
ensure proper methylation of newly-replicated DNA in S phase nuclei. Other than its 
ability to inhibit DNA methylation, a casual inverse relationship was frequently 
observed between p21WAF1 and DNMT1 expression, but the underlying mechanism is 
not resolved to date. DNMT1 and p21WAF1 may be linked in a regulatory pathway. 
Although DNMT1 has been shown to repress p21WAF1 transcription, it remains a 
question whether p21WAF1 can, on the other hand, negatively regulates DNMT1 in a 
feedback mechanism in addition to regulating DNA methylation events. This 
relationship, if confirmed, is of substantial importance, particularly during DNA 
damage when p21WAF1 is induced. In order to further validate the inverse relationship 
between DNMT1 and p21WAF1 and to elucidate the mechanism(s) involved, the 
regulation of DNMT1 expression and its relationship with p21WAF1 in the cell cycle 
was studied.  
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3.1.1 Inverse relationship between DNMT1 and p21WAF1 in the cell cycle 
 
3.1.1.1 DNMT1 expression in the cell cycle  
To study DNMT1 expression patterns in normal cell cycle, I used MRC5-non 
transformed (MRC5.NT), a human non-transformed lung fibroblast obtained from the 
ATCC. MRC5.NT was serum-starved for 48 hr to synchronize the cells at Go and 
early G1, after which media supplemented with 10% serum was added, and the cells 
were harvested at different time intervals upon release from the arrest. Non-
synchronized cells cultured in media supplemented with 10% serum for 48 hr were 
used as a control. This method of cell synchronization is commonly used for studying 
protein and mRNA expression levels in mammalian cell cultures without the need to 
introduce external factors such as chemical reagents that may possibly affect cell 
physiology (Jeanblanc et al., 2005). However, the drawback of this method is that 
different cell lines may require different duration of serum starvation for efficient cell 
cycle synchronization.  
 
The MRC5.NT cells showed a significant increase in Go/G1 cell population upon 
serum starvation as assessed by flow cytometry (see Go, Figure 1a). This coincides 
with the reduction in Cyclin D1 protein which is required for cell cycle progression, 
while actin expression remained relatively unchanged. The addition of media 
supplemented with 10% serum released the cells from the Go/G1 phase, as quantified 
by the gradual decrease in the percentage of G1 cells and corresponding increase in S 
and G2/M cells starting at 8 hr (Figure 1b). By about 26 hr, the cell cycle profile 
appeared similar to the control, suggesting the recovery of the cells from the arrest. 
The Western blots (Figure 1c) show that DNMT1 was significantly depleted in the






Figure 1: Cell cycle synchronization in MRC5 lung fibroblast non-transformed (MRC5.NT) cell 
line shows an inverse relationship between the expression of DNMT1 and p21WAF1. A. Flow 
cytometry analysis of synchronized cells; cells were arrested at Go/G1 upon serum starvation for 48 hr. 
B. Histogram of synchronized cell populations. C. Protein profiles (left) and mRNA profiles (right) of 
synchronized MRC5.NT cells (h; hours). D. Line graphs show the relative protein expression of 
DNMT1 and p21WAF1 (left), and p300, E2F1 and Sp1 (right) normalized against actin in the 
synchronized cells. (Collaboration with Dr Linda Chuang, IMCB).  
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cells at Go. The level gradually recovered upon serum addition, and this was 
correlated with the accumulation of an S phase cell population. The DNMT1 protein 
peaked at 24 hr which has the highest level of S phase cells, and this may be 
necessary for the role of DNMT1 in maintaining DNA methylation patterns of newly-
synthesized DNA during DNA replication (Ding and Chaillet, 2002). The protein 
expression of DNMT1 correlated with its mRNA profile suggesting that DNMT1 is 
transcriptionally regulated in the cell cycle (compare Figure 1b and 1c).  
 
An inverse relationship was observed between DNMT1 and p21WAF1 expression in the 
cell cycle, as quantified in the line graph (Figure 1d, left). The Go cells expressed low 
levels of DNMT1 and high levels of p21WAF1 proteins, while the gradual increase in 
DNMT1 following an accumulation of S phase cell population correlated with a 
gradual reduction in the level of p21WAF1 induction. Even though the inverse 
relationship between DNMT1 and p21WAF1 has been documented, the underlying 
mechanism remains unknown. The down-regulation of DNMT1 mRNA expression 
during p21WAF1 induction suggests the possibility that DNMT1 is indirectly regulated 
by p21WAF1 at the transcriptional level. The Western blots (Figure 1c, left) show that 
p21WAF1 induction resulted in the dephosphorylation of RB protein and consequently 
an increase in the G1 cell population, as assessed by flow cytometry (Figure 1a and 
1b). Hypo-phosphorylated RB binds E2F1 and inhibits its transcriptional activity at 
E2F1-responsive genes (Trouche et al., 1996). Similarly, p21WAF1 has also been 
shown to bind directly to E2F1 and its subunits, and this is associated with the 
inhibition of E2F1-dependent transcriptional activity via a pRB-independent pathway 
(Delavaine and La Thangue, 1999).   
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E2F1 and Sp1 are transcription factors commonly associated with the transcriptional 
activation of genes involved in S phase cell progression. Interestingly, binding sites 
for E2F1 and Sp1 have also been identified on the human DNMT1 promoter (McCabe 
et al., 2005). As shown in the Western blots (Figure 1c, left), low levels of E2F1 were 
detected in the non-cycling Go cells, and similar to DNMT1, the levels increased 
following an increase in the S phase cell population (compare Figure 1b and 1d, 
right); this agrees with the role of E2F1 in transcriptional regulation of genes in 
proliferating cells. Sp1 expression also follows a similar trend but is not as marked 
(Figure 1d, right); and this is probably due to the ubiquitious nature of Sp1/3 
transcription factors that constitutively bind to promoters of both genes involved in 
cell cycle progression and genes that inhibit cell cycle progression (Li et al., 2004; 
Suske, 1999). The expression profile of histone acetyltransferase p300, a known 
transcriptional co-activator for E2F1 and Sp1, correlated with that of E2F1 and Sp1, 
and this may be necessary for transcriptional co-activation of genes in S phase cells. 
Of note, acetylation of E2F1 by p300/CBP has been shown to be involved in the 
stabilization of the E2F1 protein; and hence depletion of p300 at Go may contribute to 
some extent the low level of E2F1. However, the decrease in E2F1 mRNA level in 
the Go cells (Figure 1c, right) suggests that transcriptional regulation may be the more 
obvious mechanism in the control of E2F1, which will not be discussed here. 
 
Several important observations have been made from this experiment. Firstly, the 
levels of DNMT1 and p21WAF1 expression have an inverse relationship in the cell 
cycle in human cells. Secondly, the down-regulation of DNMT1 occurs both at the 
transcriptional and translational levels. Thirdly, the human DNMT1 promoter was 
reported to be regulated via the pRB/E2F1 pathway; and p300 is a known co-activator 
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for both E2F1 and Sp1 transcriptional activities. Importantly, the expression of E2F1 
and p300, and to some extent Sp1, tightly correlates with DNMT1 expression. Lastly, 
p21WAF1 is known to inhibit the transcriptional activity of E2F1 via a pRB-dependent 
and pRB-independent mechanism. It remains to be answered whether p21WAF1 can 
also contribute to the down-regulation of p300 protein. Overall, these data provide 
important clues to a mechanistic explanation for the inverse relationship between 
DNMT1 and p21WAF1 expression. 
 
3.1.1.2 Inverse relationship between DNMT1 and p21WAF1 in DNA damage  
The cell synchronization studies on MRC5.NT provide a basis for understanding the 
relationship between DNMT1 and p21WAF1 in the normal cell cycle. In an attempt to 
determine if the inverse relationship still holds under adverse conditions, the protein 
profiles of DNMT1 and p21WAF1 were studied in human MRC5.NT and MCF7 (breast 
carcinoma cells) cells treated with different DNA-damaging agents. 
 
As observed in the Western blots (Figure 2), DNMT1 protein was depleted in a time-
course dependent manner in MRC5.NT cells treated with 5Gy of gamma radiation, 
and this coincides with p21WAF1 induction (Chuang et al., 2002). Similarly, the 
depletion of DNMT1 in MCF7 cells treated with 10Gy gamma radiation, 500μM 
MMS or 0.2mM H2O2 was correlated with an induction in p21WAF1 protein (Figure 3). 
These data demonstrate that DNMT1 shares an inverse relationship with p21WAF1 in 





Figure 2: Protein profiles of MRC5.NT cell line treated with 5Gy of gamma radiation for 
different time intervals (h; hours) shows the inverse relationship between DNMT1 and p21WAF1 
protein expression (Chuang et al, 2002).  





Figure 3: Protein profiles of MCF7 cell line treated with gamma radiation (10Gy), 
methylmethane sulfonate (MMS) (500μM) or H2O2 (0.2mM) for different time intervals (h; 
hours) shows the inverse relationship between DNMT1 and p21WAF1 protein expression. 
 
 
3.1.1.3 Inverse relationship between DNMT1 and p21WAF1 expression is 
independent of p53  
Even though p21WAF1 is ubiquitiously expressed in mammalian cells (Vidal and Koff, 
2000), its expression can be regulated at the transcriptional level by p53, particularly 
during a DNA damage response (el-Deiry et al., 1993). On the other hand, a p53 
consensus binding site was identified in exon 1 of human DNMT1 gene, and binding 
of p53 to this site represses DNMT1 transcription (Peterson et al., 2003). The inverse 
relationship between DNMT1 and p21WAF1 may therefore occur via p53 regulation, 
and this is further suggested by the wild-type p53 protein status in both MRC5.NT 
and MCF7 cell lines as what was reported. In order to address this question, the cell 
 68
 69
synchronization assay was repeated using wild-type p53 (parental) or p53-/- HCT116 
mammalian colorectal carcinoma cell lines.  
 
Both parental and p53-/- HCT116 cell lines were effectively arrested at Go/G1 upon 
serum starvation for 48 hr as assessed by flow cytometry (see Go, Figure 4a). The 
addition of media supplemented with 10% serum released the cells from Go/G1, as 
indicated by an increase in S phase cell population, particularly starting at 17.5 hr. 
Significant p21WAF1 protein induction was detected in the Go cells in both parental 
and p53-/- HCT116 cell lines (Figure 4b), suggesting that p21WAF1 can be up-regulated 
via p53-dependent and p53-independent mechanisms, as discussed earlier.  
 
Importantly, induction of p21WAF1 in the Go cells was correlated with reduction in 
DNMT1 expression, while the down-regulation of p21WAF1 at 17.5 hr was correlated 
with a recovery in DNMT1 expression, as quantified in the line graph (Figure 4c, left 
and right). Though the inverse relationship was not as obvious compared to 
MRC5.NT cells, which could be attributed to the difference in response of the cells to 
serum starvation, the general trend between DNMT1 and p21WAF1 proteins was 
similar. Sp1 expression was not significantly affected in the cell cycle probably due to 
the ubiquitious nature of Sp1/3 transcription factors as discussed earlier. On the other 
hand, it is unclear why E2F1 expression fluctuates throughout the cell cycle. It is 
likely that the stability of E2F1 is compromised in the absence of p300 in HCT116 
cell lines since acetylation of E2F1 by p300 stabilizes the protein (Ianari et al., 2004). 
However, more work is needed to address this postulation. Overall, the data suggest 
that DNMT1 shares an inverse relationship with p21WAF1 in the cell cycle independent 









Figure 4: Cell cycle synchronization in HCT116 parental (WT) and p53-knockout (p53-/-) cell 
lines shows lack of p53-dependence in the inverse relationship between DNMT1 and p21WAF1 
expression. A. Flow cytometry analysis of synchronized HCT116 WT and p53-/- cells; cells were 
arrested at Go/G1 upon serum starvation for 48 hr. B. Protein profiles of synchronized WT and p53-/- 
cell lines (h; hours). C. Line graphs show the relative protein expression of DNMT1 and p21WAF1 
normalized against actin in the synchronized HCT116 cells. 
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3.1.1.4 Transient over-expression of DNMT1 does not inhibit p21WAF1 
The inverse relationship between DNMT1 and p21WAF1 could be explained in two 
ways. Firstly, DNMT1 may act as an inhibitor of p21WAF1 so as to ensure negligible 
p21WAF1 expression during normal growth and cell division. Secondly, p21WAF1 may, 
on the other hand, act as an inhibitor of DNMT1 expression. The latter is indicated by 
the role of p21WAF1 in inhibiting E2F1-dependent transcriptional activity. 
Nevertheless, the effect of over-expressing DNMT1 was studied to determine which 
of these mechanisms operates. 
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Figure 5: MCF7 cells transfected with different concentrations of pXJ.Flag-DNMT1 plasmids 
shows DNMT1 over-expression does not increase p21WAF1 protein levels. A. Protein profiles of 
MCF7 cells transfected with control plasmids (48C) or with 1, 5 or 10μg of pXJ-DNMT1 plasmids for 
48 hr. B. Line graph shows the relative protein expression of DNMT1 and p21WAF1 normalized against 
PCNA in transfected MCF7 cells. 
 
 
MCF7 cells were transfected with different concentrations of a mammalian plasmid 
expressing full length DNMT1 cDNA (pXJ.Flag-DNMT1) for 48 hr, and the protein 
levels of DNMT1 and p21WAF1 were quantified. As shown in the Western blots 
(Figure 5a), DNMT1 protein was efficiently over-expressed in a concentration-
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dependent manner, particularly at 10μg, as indicated by the >2-fold induction of 
DNMT1 protein expression, which is further quantified in the line graph (Figure 5b). 
The increase in DNMT1 expression did not lead to the down-regulation of p21WAF1 
(or PCNA). The p53 protein level also remained unaffected. Taken together, this 
result provides no evidence that DNMT1 is an inhibitor of p21WAF1. 
 
3.1.1.5 siRNA-mediated depletion of DNMT1 does not induce p21WAF1 
The forced expression of DNMT1 did not lead to down-regulation of p21WAF1 protein 
(Figure 5). Though it is tempting to assume that DNMT1 lies downstream of p21WAF1 
in this context, it is also likely that p21WAF1 is already at the physiologically basal 
level and the observed increase in DNMT1 expression was unable to deplete p21WAF1 
any further. If this hypothesis is true, then the down-regulation of DNMT1 should 
lead to an increase in p21WAF1 protein. To examine this further, endogenous DNMT1 
was depleted by siRNA-mediated transfection in MCF7 (wild-type-p53) and H1299 
(p53-null human lung carcinoma) cell lines.  
 
The Western blots (Figure 6a) show that DNMT1 was efficiently depleted in both 
MCF7 and H1299 cell lines as early as 8 hr post-transfection, and by 48 hr post-
transfection, DNMT1 proteins were almost undetectable. While DNMT1 protein was 
depleted in a time-course dependent manner, the p21WAF1 protein level remained 
relatively unchanged, as quantified in the line graph (Figure 6b, basal level of p21WAF1 
set as 0). Similarly, p300 expression was not affected by DNMT1 knockdown. It 
could be argued that the p21WAF1 protein expression was already saturating in the 
MCF7 cells, and any decrease in DNMT1 was unlikely to lead to further p21WAF1 
protein induction. However, similar data were observed in H1299 cells which 
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displayed an almost negligible basal level of p21WAF1 protein (Figure 6b, right). Taken 






Figure 6:  MCF7 and H1299 cell lines transfected with si-RNA DNMT1 (si-DNMT1) for different 
times shows no changes in p21WAF1 protein levels. A. Protein profiles of MCF7 (left) and H1299 
(right) cells transfected with 100nM si-DNMT1 for 8, 32 or 48 hr; DNMT1 is efficiently depleted 
starting at 8 hr in both cell lines. B. Line graphs show the relative protein expression of DNMT1 and 
p21WAF1 normalized against actin in MCF7 (left) and H1299 (right) cells. 
 
 
3.1.1.6 Transient over-expression of p21WAF1 inhibits DNMT1  
To investigate whether p21WAF1 may act as an inhibitor of DNMT1 expression, the 
effect of over-expressing p21WAF1 by in vitro transfection was studied. Different 
concentrations of a mammalian plasmid expressing full-length p21WAF1 cDNA (pXJ-
p21WAF1) were transfected into MCF7 cells, which were harvested at 48 hr post-
transfection for analysis. Untransfected cells (48C) and cells transfected with empty 
vector (Mock) were used as controls.  
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As shown by flow cytometry (Figure 7a), the transfected MCF7 cells apparently 
became ‘cytostatic’ upon p21WAF1 over-expression, as suggested by the relatively 
unchanged cell cycle profile. This observation is unexpected since p21WAF1 is a 
known cell cycle inhibitor, and p21WAF1 induction should lead to apparent G1 cell 
cycle arrest. The Western blots (Figure 7b) show that transfection with 1μg of pXJ-
p21WAF1 plasmid was sufficient to over-express p21WAF1 protein by ~5-fold compared 
to the controls. The p53 protein level remained unchanged, and therefore it is unlikely 
to contribute to the up-regulation of the endogenous p21WAF1. An increase in the 
concentration of plasmids led to an increase in p21WAF1 expression, suggesting that 
the transfection efficiency was concentration-dependent. The up-regulation of 
p21WAF1 coincides with marginal down-regulation of c-Myc protein which is a known 
transcription repressor for p21WAF1 (Gartel et al., 2001). This observation may be due 
to the ability of p21WAF1 to repress c-Myc transcription by associating with STAT3 
and E2F1 at the c-Myc promoter upon DNA damage-mediated p21WAF1 induction 
(Vigneron et al., 2006). 
 
Interestingly, transient over-expression of p21WAF1 led to a decrease in DNMT1 in a 
dose-dependent manner (Figure 7b and 7c, top), whereas the expression levels of 
PCNA and actin remained unchanged. These data indicate that the inverse 
relationship between DNMT1 and p21WAF1 is not dependent on PCNA expression, 
even though p21WAF1 can compete with DNMT1 for binding to PCNA (Chuang et al., 
1997). Similar to the cell synchronization assay in MRC5.NT cells (Figure 1c), pRB 
was depleted following an increase in p21WAF1 expression (and decrease in DNMT1) 
(Figure 7b). It is likely that the depletion in pRB is the direct consequence of p21WAF1 
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Figure 7: MCF7 cell line transfected with different concentrations of pXJ-p21WAF1 plasmids 
shows over-expression of p21WAF1 inhibits DNMT1 and p300 proteins. A. Flow cytometry analysis 
of transfected MCF7 cells showing the ‘cytostatic’ effect of p21WAF1 over-expression on the cell cycle 
profile. B. Protein profiles of MCF7 cells transfected with control plasmid or with 1, 2.5, 5, 7.5 or 10μg 
of pXJ-p21WAF1 plasmids for 48 hr. C. Line graphs show the relative protein expression of DNMT1 and 
p21WAF1 (top) and p300, E2F1 and Sp1 (bottom) normalized against actin in transfected MCF7 cells. 
 
 
Nevertheless, a mechanistic explanation for the inverse relationship between DNMT1 
and p21WAF1 can be explained by the effect of p21WAF1 on the transcription factor 
E2F1 and co-activator p300. This is supported by the observation that p21WAF1 over-
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expression also resulted in a significant down-regulation of p300 protein (Figure 7b 
and 7c, bottom). While the mechanism for the apparent down-regulation of p300 by 
p21WAF1 is unclear at present, the data imply that p21WAF1 may potentially inhibit 
DNMT1 expression by down-regulating p300 protein, either directly or indirectly. 
Over-expression of p21WAF1 also caused a substantial down-regulation of Sp1 (Figure 
7b and 7c, bottom). Since Sp1 is a known transcription factor for DNMT1, the down-
regulation of Sp1 may have contributed to some extent the low level of DNMT1 
protein, similar to p300. Unlike p300 and Sp1, E2F1 expression is marginally 
depleted by p21WAF1 over-expression (Figure 7b and 7c, bottom). Rather, E2F1 
expression was up-regulated at higher concentrations of pXJ-p21WAF1 (see 10μg, 
Figure 7c, bottom), but the exact reason for this observation is unclear. 
 
3.1.1.7 TSA-mediated induction of p21WAF1 results in inhibition of DNMT1 
It is well established that treatment of mammalian cells with Trichostatin A (TSA), a
histone deacetylase (HDAC) inhibitor, efficiently promotes p21WAF1 gene de-
repression and cell cycle arrest. The up-regulation of p21WAF1 upon TSA treatment 
involves the recruitment of transcription factors Sp1/Sp3 to the p21WAF1 proximal 
promoter region (Sowa et al., 1999a; Xiao et al., 1999) and histone acetylation by 
p300 (Xiao et al., 2000). As presented in the data above, the transfection of MCF7 
cells with pXJ-p21WAF1 led to the transient over-expression of exogenous p21WAF1 
protein (Figure 7). However, in order to study the cellular response upon induction of 
the endogenous p21WAF1 protein, mammalian cell lines were treated with different 
non-toxic concentrations of TSA for 24 hr to induce p21WAF1.  
 
MCF7 breast carcinoma cells and MCF-10A non-tumorigenic breast cells behaved 
differently in the cell cycle when treated with different doses of TSA for 24 hr (Figure 
8a). The RT-PCR shows that p21WAF1 mRNA induction was evident only from 200nM 
of TSA in MCF7 cells, whereas p21WAF1 mRNA induction was not significant in 
MCF-10A cells at this same dose of TSA (Figure 8c). Treatment of MCF7 and MCF-
10A cells with TSA induced p21WAF1 protein in a dose-dependent manner, while the 
protein levels of PCNA and actin remained unchanged (Figure 8b). Significant 
p21WAF1 protein induction was detected in the MCF7 cells treated with 100nM TSA, 
and the induction increased by >2-fold at 200nM and 300nM TSA, suggesting that 
200nM TSA may be the maximum dose that elicits p21WAF1 induction. On the other 
hand, negligible p21WAF1 protein induction was observed in MCF-10A cells, except 
for a relatively weak induction at 300nM TSA (Figure 8b, right).  
 
Moreover, whereas up-regulation of p21WAF1 by TSA correlated with down-regulation 
of DNMT1 in MCF7 cells, the reduction in DNMT1 expression occurred prior to 
p21WAF1 induction in MCF-10A cells (see 100nM TSA, Figure 8b). One likely 
explanation for these observations is that the p21WAF1 induction in MCF-10A cells 
may have occurred at a much earlier time, but had declined by 24 hr. Nevertheless, 
TSA-mediated p21WAF1 induction was associated with the down-regulation of 
DNMT1 protein and mRNA levels in both cells (Figure 8b and 8c, and Figure 9a). It 
is also noteworthy that p300 and Sp1 proteins (similar to DNMT1) were down-
regulated by TSA in a dose-dependent manner in both cell lines (see p300, Figure 9a 











Figure 8:  MCF7 and MCF-10A cell lines treated with 100, 200 or 300nM Trichostatin A (TSA) 
for 24 hr shows TSA-mediated p21WAF1 induction leads to down-regulation of DNMT1 
expression. A. Flow cytometry analysis shows MCF7 and MCF-10A cells behaved differently upon 
TSA treatment. B Protein profiles (left) and C. mRNA profiles (right) of MCF7 and MCF-10A cells 









Figure 9:  MCF7 and MCF-10A cell lines treated with 100, 200 or 300nM Trichostatin A (TSA) 
for 24 hr shows TSA-mediated p21WAF1 induction leads to down-regulation of DNMT1 
expression. A. Line graphs show the relative protein expression of DNMT1, p21WAF1 and p300 
normalized against actin in MCF7 (left) and MCF-10A (right) cells. B and C. Line graphs show the 
relative protein expression of E2F1 and Sp1 respectively normalized against actin in MCF7 (left) and 
MCF-10A (right) cell lines. 
 
 
The TSA experiments provide some additional evidence for my novel finding that 
p21WAF1 inhibits DNMT1 protein and mRNA levels. To provide further evidence, the 
experiment was repeated by treating MCF7 and MCF-10A cells with 200nM TSA for 
different times. Since no obvious difference in p21WAF1 protein induction was 
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observed with 200nM and 300nM TSA (at least in MCF7 cells), 200nM TSA was 
chosen as the optimal concentration.  
 
The flow cytometry analysis (Figure 10a) show that MCF7 and MCF-10A cells 
behaved differently when treated with 200nM TSA, particularly at 12 hr of treatment. 
As shown in the Western blots (Figure 10b), treatment with 200nM TSA led to the 
rapid induction of p21WAF1 protein at 12 hr following TSA treatment in MCF7 cells, 
but earlier at 6 hr in MCF-10A cells, while the protein levels of actin remained 
unchanged. The p21WAF1 induction in MCF7 cells was maintained at a high level even 
after 48 hr. In contrast, p21WAF1 induction in MCF-10A cells was not sustained as it 
was depleted to a basal level at 24 hr. This can be explained by the selective recovery 
of c-Myc expression (a known transcriptional repressor of p21WAF1 gene) at 24h 
following TSA treatment in MCF-10A cells (Gartel et al., 2001) (see 24 hr, Figure 
10b). The induction of p21WAF1 did not correlate with p53 expression in both cell 
lines, since a significant amount of p21WAF1 was already detected before p53 
induction was observed, suggesting that TSA-induced up-regulation of p21WAF1 
occurs via p53-independent mechanism (see 12 hr for MCF7 and 6 hr for MCF-10A, 
Figure 10b). In fact, TSA treatment correlated with the down-regulation of p53 
protein and mRNA levels at 12 hr of treatment in MCF7 cells and at 6 hr of treatment 
in MCF-10A cells, which recovered at 48 hr.  
 
It has been widely accepted that p21WAF1 can halt the cell cycle in the G1 phase by 
inhibiting the phosphorylation of RB by CDK complexes. The hypo-phosphorylated 
RB associates with E2F1 to form the RB/E2F1 complex, and hence prevents the 







Figure 10: MCF7 and MCF-10A cell lines treated with 200nM Trichostatin A (TSA) for different 
times shows TSA-mediated p21WAF1 induction leads to down-regulation of DNMT1 expression. A. 
Flow cytometry analysis shows MCF7 and MCF-10A cells behaved differently upon TSA treatment. B. 
Protein profiles and C. mRNA profiles of MCF7 (left) and MCF-10A (right) cells with no treatment or 









Figure 11:  MCF7 and MCF-10A cell lines treated with 200nM Trichostatin A (TSA) for 
different times shows TSA-mediated p21WAF1 induction leads to down-regulation of DNMT1 
expression. A. Line graphs show the relative protein expression of DNMT1, p21WAF1 and p300 
normalized against actin in MCF7 (left) and MCF-10A (right) cells treated with TSA for different 
times (h; hours). B. Line graphs show the relative protein expression of E2F1 and C. Sp1 normalized 
against actin in MCF7 (left) and MCF-10A (right) cells treated with TSA for different times. 
 
 
earlier (Delavaine and La Thangue, 1999). The RB protein seems to be hypo-
phosphorylated at 24 hr of TSA treatment in MCF7 cells, as suggested by the 
increased in protein mobility following p21WAF1 induction, and this is associated with 
a significant reduction in RB protein level (Figure 10b). On the other hand, RB 
protein was only slightly reduced in MCF-10A cells (which displayed a relatively 
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higher level of endogenous RB protein as compared to MCF7 cells); and this can be 
attributed to non-sustainable p21WAF1 induction in MCF-10A cells upon TSA 
treatment (compare RB levels in MCF7 and MCF-10A cells, Figure 10b, right). 
 
In both cells, TSA-mediated p21WAF1 induction was also associated with the down-
regulation of c-Myc, an E2F1-responsive gene involved in apoptosis (Figure 10b) 
(Trouche et al., 1996). In line with this, it has been reported that upon DNA damage, 
p21WAF1 can be recruited to the c-Myc promoter in association with STAT3 and E2F1, 
and this resulted in transcriptional repression of c-Myc expression (Vigneron et al., 
2006). Interestingly, the repression of c-Myc may be necessary for the up-regulation 
of p21WAF1 upon TSA treatment since c-Myc is also a known transcription repressor 
of p21WAF1 (Gartel et al., 2001). c-Myc can be recruited to the proximal region of 
p21WAF1 promoter, and previous work suggested that c-Myc associates with Sp1/3 
(Gartel et al., 2001), MIZ1 (Wu et al., 2003), MAX (Mao et al., 2003) or DNMT1 
methyltransferase 3 (DNMT3) (Brenner et al., 2005) to repress p21WAF1 transcription. 
Nevertheless, the controversial findings from these reports imply that c-Myc employs 
a multitude of pathways to repress p21WAF1 transcription. In view of this, TSA-
mediated p21WAF1 induction in MCF-10A decreased to a basal level at 24 hr following 
TSA treatment, and this can be attributed to the recovery of c-Myc protein expression, 
as discussed earlier. 
 
Similar to previous experiments, TSA-mediated p21WAF1 induction correlated with the 
down-regulation of DNMT1 expression in both MCF7 and MCF-10A cells, as shown 
in the Western blots (Figure 10b) and line graphs (Figure 11a). However, DNMT1 
reverted back to its unstimulated level at about 48 hr in MCF-10A cells, and this can 
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be explained by the non-sustainable TSA-mediated p21WAF1 induction starting from 
24 hr of TSA treatment. The depletion of DNMT1 protein was correlated with 
depletion in its mRNA, suggesting that TSA treatment inhibits DNMT1 at the 
transcriptional level (Figure 10c). In line with this, TSA-mediated p21WAF1 induction 
was also associated with a significant reduction in E2F1 which is a known 
transcription factor for DNMT1 (Figure 11b). In addition, Sp1 is down-regulated, at 
least in MCF-10A cells, in a similar trend to DNMT1 (Figure 11c, right). It is 
noteworthy that the down-regulation of DNMT1 consistently coincides with the 
down-regulation of p300 similar to previous experiments (see p300, Figure 11a), 
implying that p300 might have a significant role in regulating DNMT1 expression. 
 
                                                
Figure 12:  Protein profiles of MCF7 cells co-treated with TSA and Mg132 shows that the 
reduction of DNMT1 protein upon TSA treatment cannot be rescued by proteosomal inhibitor, 
suggesting that the DNMT1 reduction occurs at the transcriptional level. 
 
To further ascertain that TSA treatment inhibits DNMT1 at the transcriptional level, 
MCF7 cells were treated with 200nM TSA for 18 hr after which the cells were treated 
with the proteosomal inhibitor Mg132 for another 6 hr (total of 24 hr). Even though 
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Mg132 alone effectively increases p21WAF1 as well as c-Myc protein levels, the co-
treatment with TSA and Mg132 was unable to ‘rescue’ the reduction in DNMT1 
protein, while the protein levels of PCNA and actin remained unaffected (Figure 12). 
Taken together, these data suggest that the down-regulation of DNMT1 upon TSA-
mediated p21WAF1 induction occurs at the transcriptional level.  
 
3.1.1.8 TSA-mediated induction of p21WAF1 is independent of p53                     
The TSA-mediated p21WAF1 induction in MCF7 and MCF-10A cell lines occurred in 
the absence of p53 induction. To directly investigate whether TSA-mediated p21WAF1 
induction (and DNMT1 down-regulation) can occur via a p53-independent 
mechanism, wildtype p53 (parental) and p53-/- HCT116 cell lines were treated with 
200nM TSA for different time intervals. The flow cytometry data (Figure 13a) show 
that the parental and p53-/- HCT116 cell lines were both arrested at G2 phase 
following 12 hr of TSA treatment. These G2 cell populations were unable to proceed 
through the cell cycle and re-enter G1. The consequence of this checkpoint failure 
leads to significant cell death, as indicated by the sub-G1 cell populations, which was 
noticeable by 24 hr following treatment in both cells (see 24 hr, Figure 13a). 
 
The Western blots (see HCT116 p53-/-, Figure 13b) show that significant p21WAF1 
induction was detected even in the absence of p53, suggesting a p53-independent 
mechanism in TSA-mediated p21WAF1 induction. Similarly, it has been reported that 
the induction of p21WAF1 expression by HDAC inhibitors such as sodium butyrate and 
suberoylanilide hydroxamic acid (SAHA) occurs through Sp1 sites via a p53-
independent mechanism (Huang et al., 2000; Xiao et al., 1997). The TSA-mediated 








Figure 13:  HCT116 parental (WT) and p53-knockout (p53-/-) cell lines treated with 200nM 
Trichostatin A (TSA) for different times shows the lack of p53-dependence for the down-
regulation of DNMT1 by TSA-mediated p21WAF1 induction. A. Flow cytometry analysis shows G2 
arrest at 12 hr of TSA treatment followed by noticeable cell death starting at 24 hr in both cell lines. B. 
Protein profiles and C. mRNA profiles of HCT116 parental (WT) and p53-/- cell lines with no treatment 









Figure 14:  HCT116 parental (WT) and p53-knockout (p53-/-) cell lines treated with 200nM 
Trichostatin A (TSA) for different times shows the lack of p53-dependence for the down-
regulation of DNMT1 by TSA-mediated p21WAF1 induction. A. Line graphs show the relative 
protein expression of DNMT1 and p21WAF1 normalized against actin in parental (WT) (left) and p53-/- 
(right) HCT116 cell lines treated with TSA for different times (h; hours). B. Line graphs show the 
relative protein expression of E2F1 and C. Sp1 normalized against actin in parental (WT) (left) and 
p53-/- (right) HCT116 cell lines treated with TSA for different times. 
 
 
based on the increase in p21WAF1 mRNA levels (Figure 13c) following a significant 
~10-fold reduction in the p21WAF1 transcriptional repressor c-Myc protein while actin 
remained relatively unaffected (Figure 13b).  
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It should be noted that HCT116 cell lines do not express the p300 co-activator. 
Surprisingly, TSA-mediated p21WAF1 induction still resulted in significant depletion 
of DNMT1 protein and mRNA levels in the HCT116 cell lines even though E2F1 
shows only a very marginal decline in the HCT116 cell lines in contrast to MCF7 and 
MCF-10A cells (compare Figure 10b and 13b, and Figure 11b and 14b). Importantly, 
p21WAF1 has been shown to bind E2F1 and inhibit its transcriptional activity without 
affecting its protein turnover (Delavaine and La Thangue, 1999). As such, TSA-
mediated induction of p21WAF1 may have resulted in a decrease in E2F1-dependent 
transcriptional activation on the DNMT1 promoter, which is further augmented in the 
absence of endogenous p300 protein (which would normally cooperate with E2F in 
the co-activation of promoters, though its role at the human DNMT1 promoter has not 
been reported to date). In addition, Sp1, a known transcription factor for DNMT1, is 
significantly down-regulated in a similar trend as DNMT1 protein in both HCT116 
cell lines upon TSA treatment (compare Figure 14a and 14c). 
 
The absence of endogenous p300 in HCT116 cell lines may have resulted in the 
selective depletion of Sp1 which was not as obvious in MCF7 and MCF-10A cells 
(compare Figure 11c and 14c). As such, it is arguable that the induction of p21WAF1 
upon TSA treatment may have led to the down-regulation of DNMT1 by different 
pathways; firstly, by the inhibition of p300 (and E2F1) in the MCF7 and MCF-10A 
cells; and secondly, by the selective inhibition of Sp1 in the absence of endogenous 
p300 in the HCT116 cell lines. Given the strong correlation between DNMT1 and 
p300 expression, it can be speculated that DNMT1 expression in cell lines which do 
not express p300 is comparatively lower than cell lines with p300. However, more 
experiments will be needed to support this speculation. Nevertheless, these results 
suggest that p21WAF1 inhibits DNMT1 transcription, and that the inverse relationship 
between p21WAF1 and DNMT1 is independent of endogenous p53 protein status. 
 
3.1.2 Transcriptional regulation of human DNMT1 promoter 
So far, my data demonstrate that p21WAF1 negatively regulates DNMT1 expression at 
the transcriptional level which has not been reported to date. In addition to the ability 
of p21WAF1 to inhibit the transcriptional activity of E2F1, my data strongly suggest 
that the down-regulation of DNMT1 by p21WAF1 over-expression is consistently 
associated with the reduction in p300 protein, at least in MCF7 and MCF-10A cell 
lines. The cell synchronization studies with MRC5.NT cells also showed that DNMT1 
expression is highly related to E2F1, p300 and Sp1. p300 does not carry any DNA 
targeting sequence, and hence p300 has to interact with a transcription factor to exert 
its function in transcriptional regulation. Indeed, in addition to its role as a histone 
acetyltransferase, p300 has been shown to act as co-activator for E2F1 and Sp1, both 
of which bind directly to the human DNMT1 promoter (McCabe et al., 2005). 
Although p300 has been shown to be involved in transcriptional co-activation of the 
mouse Dnmt1 promoter by Sp3 (Kishikawa et al., 2003; Kishikawa et al., 2002b), its 
exact role on human DNMT1 promoter has not been studied. In addition, the exact 
roles of E2F1 (and Sp1) in human DNMT1 expression needs further validation. 
Addressing how DNMT1 promoter is regulated by these proteins will provide further 
evidence to support the mechanistic outline on how p21WAF1 negatively regulates 
DNMT1 in mammalian cells.  
 
3.1.2.1 siRNA-mediated depletion of E2F1 results in down-regulation of DNMT1 
E2F1 is a known transcription factor that can bind to E2F-binding sites on the
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promoters of E2F-responsive genes such as c-Myc, DAP Kinase and DNA 
Polymerase, most of which are involved in cell cycle progression (Trouche et al., 
1996). To address the question as to whether E2F1 is indeed involved in the 
regulation of DNMT1 expression, the effect of depleting E2F1 on DNMT1 expression 
was studied. To deplete endogenous E2F1, the osteosarcoma cell line U2OS (p53-wt) 
was transfected with siRNA-E2F1 (Santa Cruz) by the oligofectamine transfection 
method (QIAGEN); and siRNA-lacZ (ProOligo) and Mock (oligofectamine only) 
were used as controls. U2OS was used for the experiment due to its relatively high 
transfection efficiency.  
 
The flow cytometry data show that the cell cycle profile of U2OS cells transfected for 
8, 32 or 48 hr with si-E2F1 was not noticeably affected compared to the Mock and 
siLacZ controls (Figure 15a). As shown in the mRNA profiles (Figure 15b), E2F1 
mRNA was partially depleted especially at 8 hr post-transfection, and this was 
reflected in a marked reduction in its protein expression (Figure 15c). The depletion 
of E2F1 led to the down-regulation of DNMT1 protein and mRNA levels by >50% in 
a time-course dependent manner, which was quantified in the line graph (Figure 15d), 
while RB and actin protein levels remained unaffected. These data suggest that E2F1 
is involved in the regulation of DNMT1 expression. 
 
The reduction in DNMT1 protein and mRNA was not, however, as great as 
anticipated, which might be due to the incomplete knockdown of E2F1 (Figure 15b). 
The DNMT1 promoter is a TATA-less promoter, and its transcription is consequently 
highly dependent on the binding of basal transcription factors and co-activators. The 
inability of the siRNA-E2F1 to completely down-regulate DNMT1 expression could 
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also possibly be explained by the constitutive binding of other transcription factors 
such as Sp1 and Sp3 (as well as co-activators not dependent on E2F1) to the DNMT1 
promoter even when E2F1 is depleted. Importantly, even though the binding sites for 
E2F1 and Sp1/3 are relatively close to each other, they can bind independently on the 
DNMT1 promoter (McCabe et al., 2005). Overall, these data suggest that E2F1 plays 
an important but not necessarily crucial role as a transcription factor for DNMT1.   
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Figure 15:  U2OS cells transfected with si-RNA to E2F1 (si-E2F1) for 8, 32 and 48 hr shows a 
decrease in DNMT1 expression by E2F1 knockdown. A. Flow cytometry analysis of U2OS after 
transfection with 100nM si-E2F1 for different times (h; hours). B. mRNA profiles and C. Protein 
profiles of U2OS show the down-regulation of DNMT1 expression following si-E2F1 transfection. D. 
Line graph shows the relative protein expression of DNMT1 and E2F1 normalized against actin in 
transfected U2OS cells. 
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3.1.2.2 siRNA-mediated depletion of p300 results in down-regulation of DNMT1 
To further examine the regulation of DNMT1 expression, siRNA-mediated transient 
depletion of p300 (and DNMT1) was carried out in MCF7 and H1299 cell lines by 
oligofectamine transfection for 48 hr. 
 
The flow cytometry data show that the cell cycle profiles of MCF7 and H1299 cells 
transfected with si-p300 and si-DNMT1 for 48 hr were not significantly altered 
compared to the Mock and siLacZ controls (Figure 16a). The mRNA profiles (Figure 
16b) show that both p300 and DNMT1 mRNA yields were depleted in MCF7 and 
H1299 cells; and this was correlated with a depletion in p300 and DNMT1 protein 
levels by ~ 80% and 100% respectively, as compared to the controls (Figure 16c), 
indicating the efficiency of the siRNA-mediated transfection. As observed in Figure 
16c, both E2F1 and Sp1 remained relatively unaffected by the p300 knockdown, 
indicating that even though the three proteins may function collaboratively in 
transcriptional regulation, the loss of p300 did not affect E2F1 and Sp1 protein yields. 
This result was further supported by the relatively high level of E2F1 and Sp1 in the 
HCT116 cell lines which do not express p300 protein (Figure 13b). Interestingly, 
compared to H1299 cells, p300 in MCF7 cells migrated slower in the acrylamide gel, 
suggesting that p300 in MCF7 may exist in a modified form. Indeed, p300 has been 
shown to be regulated at multiple levels that include post-translational modifications, 
as reviewed by Ghosh and Varga (Ghosh and Varga, 2007). However, DNMT1 down-
regulation occurred independently of the migration status of p300. More experiments 
are needed to achieve a more conclusive understanding of why p300 might be 
selectively modified in MCF7 cells, and what function(s) it could fulfill. 






Figure 16:  MCF7 and H1299 cell lines transfected with si-RNA to p300 (si-p300) and si-RNA to 
DNMT1 (si-DNMT1) for 48 hr shows p300 knockdown depletes DNMT1 expression. A. Flow 
cytometry analysis of MCF7 and H1299 cells transfected with 100nM of the respective si-RNAs for 48 
hr; cell cycle profiles were not significantly altered. B. mRNA profiles and C. Protein profiles of 
MCF7 (left) and H1299 (right) cells show the down-regulation of DNMT1 and p300 expression. D. 
Histograms show the relative protein expression of DNMT1 and p300 normalized against actin in si-
RNA transfected MCF7 (left) and H1299 (right) cells. 
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Importantly, p300 knockdown led to significant down-regulation of DNMT1 protein 
and mRNA levels in both MCF7 and H1299 cells (Figure 16b and 16c), suggesting 
that the regulation of DNMT1 by p300 is not dependent on endogenous p53. This 
result was further quantified in the histograms (Figure 16d), and provides strong 
evidence for the role of p300 as a transcriptional regulator for DNMT1 expression. In 
support, the depletion of endogenous DNMT1 by siRNA-mediated transfection did 
not alter the expression of p300 (Figure 6a), demonstrating that DNMT1 does not lie 
upstream of p300 protein. 
 
 
Figure 17:  Methylation-sensitive McrBc digestion of total genomic DNA upon si-RNA 
transfection in MCF7 and H1299 cell lines shows that the genomic methylation status of the cells 
was not altered by si-RNA-mediated p300 and DNMT1 knockdown. 1μg of genomic DNA was 
digested with 1.2units of McrBc enzyme at 37oC for 1 hr, and heat-inactivated at 65oC for 20 min. The 
digested samples (McrBc) and undigested samples (Ctrl) was run along a 1.2% agarose gel. 
 
 
Of note, even though DNMT1 expression was severely diminished upon si-p300 
transfection, particularly in MCF7 cells, the genomic methylation status of the cells 
was not affected, as determined using methylation-sensitive McrBc restriction 
digestion (Figure 17). McrBC is a GTP-dependent methylation-sensitive restriction 
endonuclease that cleaves close to a purine-methylated C (PuCpGs) in the context of a 
second PuCpG about 40bp to 2000bp apart (Stewart and Raleigh, 1998). As such, 
cleavage of genomic DNA with McrBC will produce a distinct digestion pattern or 
smear in different cell lines. Since the methylation of cytosines in mammals mainly 
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occurs in the context of CpG dinucleotides, McrBC is a useful tool for detection of the 
gross methylation status in DNA. However, the drawback of this method is that 
pyrimidine-methylated C (PyCpGs) is not recognized. Nevertheless, the McrBc assay 
show that the global methylation status of the cells was relatively unaffected upon si-
p300 transfection, as shown by the similarity in the cleavage patterns (Figure 17), 
which might be explained by the transient transfection experiment and the stability of 
DNA methylation. Overall, these data imply that p300 is an important transcription 
regulator for DNMT1 expression.  
 
To corroborate these results, the experiment was repeated as a time-course. MCF7 and 
H1299 cells were transfected with si-p300 for 16, 32 and 48 hr or 72 hr. Flow 
cytometry data (Figure 18a) show that while the cell cycle profile of MCF7 was not 
significantly affected, there was a slight increase in the G1 cell population in H1299 
cells at 48 hr post-transfection. Nevertheless, p300 mRNA was substantially depleted 
as early as 16 hr post-transfection with si-p300 in both cell lines (Figure 18b), which 
was correlated with a time-dependent depletion of p300 protein (Figure 18c).  
 
Consistent with my previous data, the expression of E2F1 and Sp1 proteins was not 
altered by the p300 knockdown in both MCF7 and H1299 cells (Figure 18c). In 
contrast, DNMT1 mRNA and protein were down-regulated in a time-dependent 
manner corresponding to a gradual depletion of p300, while actin remained relatively 
unchanged (Figure 18b and 18c). The data were quantified in the line graphs (Figure 
19), which strongly implies that p300 functions upstream of DNMT1. Taken together, 
these results demonstrate that p300 may serve as an important transcriptional co-








Figure 18:  MCF7 and H1299 cell lines transfected with si-RNA to p300 (si-p300) for 16, 32 and 
48 hr or 72 hr shows decline in DNMT1 protein associated with reduction in p300. A. Flow 
cytometry analysis of MCF7 and H1299 cells transfected with 100nM of si-p300 for different times (h; 
hours); cell cycle profiles were not significantly altered. B. mRNA profiles and C. Protein profiles of 
MCF7 (left) and H1299 (right) cells show the down-regulation of p300 and DNMT1 expression. 
(Continued in Figure 19). 
(Collaboration with Dr Hue Kian Oh, IMCB). 
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 Figure 19:  MCF7 and H1299 cell lines transfected with si-RNA to p300 (si-p300) for 16, 32 and 
48 hr or 72 hr shows decline in DNMT1 protein associated with reduction in p300. Line graphs 
show the relative protein expression of DNMT1 and p300 normalized against actin in si-p300 
transfected MCF7 (left) and H1299 (right) cell lines. 
 
3.1.2.3 Transcriptional regulation of DNMT1 promoter by E2F1, Sp1 and p300 
The human DNMT1 promoter is a TATA-less promoter and therefore its 
transcriptional activity is highly dependent on transcription factors that bind to 
sequences adjacent to the initiation start sites (McCabe et al., 2005). To examine the 
importance of E2F1 and p300 for the transcriptional activity of the human DNMT1 
promoter, the basal promoter region of human DNMT1 gene was amplified from the 
genomic DNA of MCF7 cells and cloned into the reporter vector pGL3-Basic 
(Promega) to be used in a promoter-luciferase reporter assay. The DNMT1 promoter 
construct (pGL3-DNMT1Pro) contains the proximal promoter region of human 
DNMT1 spanning 340bp upstream of the ATG site, and has a single E2F-binding site 
and two consensus Sp1/3 sites (Diagram 6).  
                       
Diagram 6: Schematic diagram of human DNMT1 proximal promoter region spanning 340bp 
upstream of ATG site (0) cloned into pGL3-Basic vector. Binding sites for Sp1/3 (-214 and -111) 
and E2F1 (-50) are shown. 
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Mammalian expression vectors carrying E2F1, Sp1, p300 and p21WAF1 cDNA were 
transfected into MCF7 cells using superfect transfection reagent (QIAGEN) and the 
protein profiles of the cells were studied at 48 hr post-transfection. Western analysis 
using specific antibodies showed that the proteins were efficiently over-expressed 
with the respective mammalian expression vectors in the MCF7 cells at 48 hr post-
transfection (Figure 20).  
 
 
                                 
Figure 20:  Protein profiles of MCF7 cells transfected with the respective plasmids for 48 hr. 
 
 
After confirming expression of the plasmids, MCF7 cells were co-transfected with 
pGL3-DNMT1Pro and with vectors harboring E2F1, Sp1, p300 or p21WAF1 cDNA. A 
vector expressing β-galactosidase was transfected, and β-galactosidase expression 
was used as a marker to measure the transfection efficiencies. Luciferase activity was 
then measured at 48 hr post-transfection and normalized against the β-galactosidase 
















































Figure 21:  Luciferase reporter assays of human DNMT1 promoter (DNMT1-Pro) in MCF7 cells 
transfected for 48 hr in the absence of exogenous p21WAF1 (no p21WAF1) or co-transfection with 
exogenous p21WAF1 (with p21WAF1). Luciferase activity from triplicate experiments normalized against 
0.25 OD of β-Galactosidase activity (β-Gal) shows the transcriptional activity of E2F1 and Sp1, and 
the co-activational activity of p300, on the DNMT1 proximal promoter, which are effectively inhibited 
by p21WAF1.  
 
 
The transcriptional activity of the DNMT1 promoter was significantly enhanced in the 
MCF7 cells when challenged with vectors expressing E2F1, Sp1 or p300 (black bars, 
Figure 21). Since p300 does not have a DNA-binding domain, the transactivation of 
the DNMT1 promoter by p300 was likely due to the transcriptional co-activation 
activity with the endogenous transcription factors. In agreement with this observation, 
the co-expression of p300 with E2F1 or with Sp1 resulted in enhanced transactivation 
of the DNMT1 promoter as compared to transfection with E2F1 or Sp1 alone 
(compare E2F1 and Sp1 with E2F1+p300 and Sp1+p300 respectively, Figure 21). 
These data demonstrate that p300, E2F, and Sp1 are all involved in transactivation of 
human DNMT1 promoter, and reveal interplay among these proteins in the regulation 
of the DNMT1 promoter.  
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Consistent with the p21WAF1 transient over-expression and TSA-mediated 
experiments, the transcriptional activity of the DNMT1 promoter was reduced by 
p21WAF1 over-expression (compare no p21WAF1 and with p21WAF1, Figure 21). As 
shown in the histogram (Figure 21), p21WAF1 over-expression not only depleted p300 
and to some extent Sp1 proteins (as shown in Figure 7, 8 and 10), but was also able to 
suppress the transcriptional activity of E2F1, Sp1 and co-activity of p300 on the 
human DNMT1 promoter (compare no p21WAF1 and with p21WAF1, Figure 21). These 
data provide additional evidence of how p21WAF1 negatively regulates DNMT1 
expression via an indirect mechanism. The experiment was repeated in H1299 cells 
and similar data were obtained (data not shown), suggesting that the activity of E2F1, 
Sp1 and p300 on DNMT1 promoter is independent of p53 protein status. Taken 
together, these results demonstrate the direct involvement of E2F1, Sp1 and p300 in 
the transcriptional regulation of the human DNMT1 promoter, which is partially 
inhibited by p21WAF1.   
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3.1.3 Discussion 
An inverse relationship between DNMT1 and p21WAF1 expression levels under normal 
physiological conditions and in the DNA damage response was demonstrated in this 
thesis. Although hypermethylation is associated with transcriptional silencing of the 
p21WAF1 promoter, several lines of evidence originally supported the association of 
DNMT1 with transcriptional repression of p21WAF1 expression, which could have 
provided an explanation for the inverse relationship (as discussed previously, Page 
29). Particularly, anti-sense knockdown of DNMT1 in human non-small cell lung 
carcinoma A549 cells led to the re-expression of p21WAF1 by a mechanism 
independent of DNA methylation and histone deacetylation (Milutinovic et al., 2004). 
Instead, the author showed that mutation of the Sp1 sites on the p21WAF1 promoter not 
only inhibits Sp1 binding but also abolishes the activation of p21WAF1 transcription by 
DNMT1 knockdown, suggesting that the mechanism for DNMT1-mediated 
transcriptional repression involves the suppression of CpG-rich Sp1 sites without 
affecting the methylation status of the promoter (the p21WAF1 promoter is not 
methylated in A549 cells). Supporting this, an independent study also showed that 
disruption of DNMT1 expression in A549 cells using siRNA was accompanied by an 
increase in p21WAF1 levels (Oridate and Lotan, 2005). 
 
However, contrary to these findings, my study shows that the over-expression of 
DNMT1 or knockdown of DNMT1 by siRNA-mediated transfection did not lead to 
significant changes in p21WAF1 expression in human breast cancer cells (Figure 5a and 
6a). Although it is tempting to assume that the contradicting observation may be due 
to the transient nature of the transfection experiments or that DNA methylation, if 
any, is a stable event, the different cell types used may also be a crucial factor. Two 
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consecutive studies showed that DNMT1 knockdown in A549 cells triggers a cascade 
of genotoxic stress checkpoint proteins via an ATR-dependent manner, and induces 
an intra-S phase arrest to inhibit DNA replication (Milutinovic et al., 2003; 
Unterberger et al., 2006). Since the ATR pathway has also been shown to be involved 
in the activation of p53 and p21WAF1 in the response to nucleoside analogue-induced 
DNA damage in A549 cells (Wang et al., 2008), the concomitant increase in p21WAF1 
expression observed by Milutinovic et al and Oridate et al might be an indirect 
consequence of the intra-S phase arrest, rather than the direct effect of DNMT1 
knockdown. Supporting this argument, the data presented in my thesis show that 
siRNA knockdown of DNMT1 effectively depletes DNMT1 expression but did not 
alter the cell cycle profile of MCF7 cells. This favors the notion that the expression of 
p21WAF1 is not affected by DNMT1, at least in MCF7 cells. 
 
In addition to its ability to inhibit DNA methylation events, p21WAF1 may also be 
linked to DNMT1 in a regulatory pathway, but the underlying mechanism is not yet 
resolved. Here, I report the novel discovery that the over-expression of p21WAF1 by in-
vitro transfection and TSA-mediated induction resulted in a decrease in DNMT1 at 
the protein and mRNA levels. These data strongly suggest that p21WAF1 lies upstream 
of DNMT1 in the inverse relationship, and potentially negatively regulates DNMT1 
expression. Importantly, this observation was consistently accompanied by a decrease 
in E2F1 and p300 protein levels (Figure 9a, 9b, 10a and 10b). Both p300 and E2F1 
were identified in my study as important transcriptional regulators of DNMT1, which 
might prove to be a crucial link in understanding one important regulatory mechanism 
for the inverse relationship between DNMT1 and p21WAF1.  
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An E2F1 consensus binding site has been identified on the human DNMT1 promoter 
(Bigey et al., 2000). Following that, McCabe et al showed that the 340bp region 
upstream of the ATG start site in the human DNMT1 promoter can be transactivated 
by E2F1 and repressed by active pRB (McCabe et al., 2005). Through the used of 
small interfering RNA (siRNA) to knock down the endogenous E2F1 levels, my study 
further demonstrates the importance of E2F1 in transcriptional regulation of human 
DNMT1 expression, which was antagonized by p21WAF1 (Figure 21). In addition, 
E2F1 transactivates the human DNMT1 promoter, which was further enhanced in the 
presence of the p300 co-activator (Figure 21). Although the E2F1 protein level was 
not significantly affected by p21WAF1 over-expression (Figure 7b), p21WAF1 does 
exhibit obvious inhibitory effects on the transcriptional activity of E2F1 as well as on 
the co-activation activity of p300 on the DNMT1 promoter (Figure 21). In line with 
this, p21WAF1 is known to negatively regulate the transcriptional activity of E2F1 via a 
CDK/pRB-dependent and independent pathways to inhibit transcription of genes 
involved in G1/S transition (Delavaine and La Thangue, 1999). This p21WAF1-E2F1-
DNMT1 pathway may play a pivotal role in regulating DNMT1 expression during 
cell cycle progression. 
 
DNMT1 transcription is reported to be down-regulated by the histone deacetylase 
inhibitor apicidin, and this involves the recruitment of pRB and an HDAC complex to 
the E2F-binding site on the DNMT1 promoter (You et al., 2008). Similarly, TSA has 
been shown to down-regulate the expression of DNMT3b in human endometrial cells 
(Xiong et al., 2005). Collectively, these data imply that the pRB-E2F pathways may 
be involved in regulating DNMT1 at multiple levels in humans. Indeed, the loss of 
RB is a common event in human cancers; and embryonic fibroblasts derived from 
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mice with disruptions in the RB family genes are immortal and exhibit properties of 
transformed cells (Dannenberg et al., 2000; Sage et al., 2000). The de-regulation of 
E2F transcriptional activity as a consequences of the alterations in the p16(INK4a)-
cyclin D1-Rb pathway is a hallmark of human cancer (Johnson and Degregori, 2006; 
Markey et al., 2007). Similarly, de-regulated DNMT1 expression has been reported in 
several human cancer cells (De Marzo et al., 1999; el-Deiry et al., 1991). As such, 
this E2F1-DNMT1 axis (as demonstrated in my thesis) might contribute to some 
extent the aberrant DNA methylation frequently observed in tumor malignancy. 
 
With the exception of HCT116 colon carcinoma cells which lack p300, the co-
activation of human DNMT1 transcription by p300 also seems to play a crucial role, 
and this has not been documented to date. The importance of p300 for DNMT1 
expression was further demonstrated by the drastic reduction in DNMT1 expression 
upon knockdown of endogenous p300 proteins (Figure 16c and 18c). Also, the down-
regulation of DNMT1 expression upon transient and TSA-mediated p21WAF1 
induction was consistently accompanied by reduction of p300 (Figure 8b and 10b). 
This observation is surprising since TSA-mediated up-regulation of p21WAF1 was 
shown to involve the recruitment of transcription factors Sp1/Sp3 (Sowa et al., 1999a; 
Xiao et al., 1999) and histone acetylation by p300 (Xiao et al., 2000) of the p21WAF1 
proximal promoter region. Although my study indicates that p21WAF1 potentially 
inhibits p300 at the transcriptional level, as shown in MCF7 and MCF-10A cells 
(Figure 10c), it is still unclear whether this involves a direct or indirect mechanism.  
 
The relationship between p21WAF1 and p300 is further complicated by the ability of 
p21WAF1 to inhibit p300 co-activation activity on the human DNMT1 promoter (Figure 
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21). These data are rather controversial, since p21WAF1 has been shown to stimulate 
the activity of p300 by the de-repression of the transcriptional repression CRD1 (cell 
cycle regulatory domain 1) domain located within amino acids 995 to 1044 of p300 
protein (Snowden et al., 2000). Using a series of p21WAF1 constructs harboring 
mutations in the binding regions for cyclin A/D and CDK2/4, Gregory et al showed 
that the induction of p300 activity by p21WAF1 is independent of its ability to inhibits 
cyclin/CDK activity (Gregory et al., 2002). Although the exact mechanism for this 
regulation is obscure, the use of N-terminal p21WAF1 GST proteins characterized the 
direct binding of p21WAF1 to some members of the class I and II HDACs (Garcia-
Wilson and Perkins, 2005). Since sumoylation-mediated repression of CRD1 involves 
the recruitment of HDAC6, this finding may hopefully hold the key to understanding 
how p21WAF1 de-represses CRD1 (Girdwood et al., 2003). However, this idea remains 
ambiguous, since Gregory et al (Gregory et al., 2002) were unable to detect an 
association between p21WAF1 and HDAC6 in mammalian cells.  
 
Nevertheless, the discrepancy in the results may be attributed to the different systems 
used in the studies. The authors fused the p300 protein to the Gal4 DNA-binding 
domain and utilized the Gal4 E1B reporter plasmid, which contains the TATA box 
from adenovirus to examine the activity of p300. On the other hand, I studied the 
activity of p300 with regards to the co-transactivation of human DNMT1 promoter 
fused to the pGL3-Basic plasmid. The Gal4 system excludes any effects from 
endogenous p300 and therefore it is unable to address the direct involvement of 
endogenous p300 in transcriptional regulation with regards to gene promoters. 
Furthermore, it cannot be ruled out that the use of Rous sarcoma virus-p21WAF1 by the 
authors compared to my use of pXJ-p21WAF1 constructs contributed to the differences 
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in the results. Nevertheless, my study clearly supports the novel idea that p300 acts as 
a crucial target for p21WAF1-dependent down-regulation of DNMT1, which may have 
significant implications for the DNA damage response. Thorough investigation is 
needed to elucidate the exact mechanism for the inhibition of p300 by p21WAF1 
protein.   
 
My data are consistent with the idea that the down-regulation of DNMT1 by p21WAF1 
occurs by a mechanism involving the inhibition of the transcriptional activity of 
E2F1, as well as the co-activation activity of p300 (which also regulates E2F1), on the 
human DNMT1 promoter. However, a twist in the tale comes with my observation 
that DNMT1 is still effectively down-regulated upon TSA-mediated up-regulation of 
p21WAF1 in HCT116 cell lines, which do not express endogenous p300. In HCT116 
cells, regardless of p53 status, TSA caused down-regulation of Sp1 but not E2F1 in a 
time-dependent manner, and the reduction in Sp1 coincided with the reduction in 
DNMT1 (Figure 13b). In MCF7 and MCF-10A cells under similar conditions, the 
opposite was true – E2F1 was strongly down-regulated by TSA, but Sp1 was only 
modestly (if at all) reduced (Figure 8b and 10b). Since I showed that Sp1 is involved 
in transcriptional regulation of DNMT1 expression (Figure 21), the TSA-induced loss 
of Sp1 expression alone can account for the decline in DNMT1 mRNA and protein in 
the absence of p300. It remains to be determined whether the absence of p300 in 
HCT116 cells is related to the different effects of TSA on E2F1 and Sp1 expression 
compared with MCF7 and MCF-10A cells; and it will be important to determine if 
another factor (or p300-related coactivator) can compensate for the loss of p300 in 
HCT116 cells.  
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These results are further supported by the ability of p21WAF1 to inhibit the 
transcriptional activity of Sp1 on the DNMT1 promoter in a p53-independent manner 
(Figure 21 and data not shown). Importantly, the down-regulation of Sp1 proteins 
does not seem to agree with the early work by Xiao et al demonstrating that the Sp1 
site is essential for TSA-mediated induction of p21WAF1 in NIH3T3 murine cells (Xiao 
et al., 1999). However, further work by Sowa et al using MG32 osteosarcoma cells 
showed that although the Sp1 site is crucial for the up-regulation of p21WAF1 
expression, Sp3, but not Sp1, is responsible for mediating the transactivation of the 
p21WAF1 promoter upon TSA treatment (Sowa et al., 1999b). If this report is accurate, 
then an investigation of the mechanism underlying the TSA-mediated depletion of 
Sp1 may be important in understanding how DNMT1 may be negatively regulated by 
p21WAF1 in the absence of p300. 
 
Taken together, my study indicates that the expression of human DNMT1 is tightly 
regulated by a complex interplay of proteins that includes the transcription factors 
E2F1 and Sp1, and the co-activator p300. These proteins are potential targets for 
p21WAF1 under physiological conditions, which may be necessary to ensure properly 
regulated DNMT1 expression and DNA methylation especially during cell cycle 
progression. The details of this relationship may provide the molecular basis for 
understanding the coordination of DNMT1 expression with other critical biological 
processes such as those that occur during the DNA damage response.  
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3.2 The Role(s) of DNMT1 in Doxorubicin-mediated micronuclei formation 
Aside from normal cellular processes, there is an increasing body of evidence to 
indicate that DNMT1 plays a role in the DNA damage response (Mortusewicz et al., 
2005). Although Yokochi et al demonstrated the potential involvement of DNMT1 in 
doxorubicin (Dox)-inflicted cytotoxicity (Yokochi and Robertson, 2004), it remains 
unclear whether DNMT1 is also involved in mediating micronucleation frequently 
observed upon doxorubicin assault. In addition, whether such genotoxic effects is a 
general characteristic of both normal and cancer cell types remains to be investigated. 
 
3.2.1 Doxorubicin mediates selective depletion of DNMT1 in non-transformed 
cell lines 
In an attempt to investigate the effect of Dox on mammalian cell lines, the non-
tumorigenic breast cell line MCF-10A (representative of normal cells) and breast 
carcinoma cell line MCF7 (representative of cancer cells) were briefly treated with 
5μM Dox and harvested at different time intervals. Since DNMT1 has been identified 
as a potential target for Dox-mediated DNA damage, studying DNMT1 expression 
may provide some clue in understanding the response elicited by the two cell lines. 
 
Flow cytometry data (Figure 22a) show that MCF-10A was mainly arrested at G2 
while MCF7 was arrested at the G1 and G2 phases upon 48 hr of treatment with 5μM 
Dox. The Western blots (Figure 22b) show that Dox induced p53, and consequently 
p21WAF1, in both cell lines at 6 hr of treatment. Even though p53 induction was not 
sustainable in MCF7, as shown by its drastic reduction at 24 hr as compared to MCF-
10A cells, the p21WAF1 induction remained relatively high, suggesting that the 










Figure 22: MCF-10A and MCF7 cell lines treated with 5μM Dox for different times shows the 
preferential depletion of DNMT1 and p300 expression in the non-transformed MCF-10A cells. A.  
Flow cytometry analysis shows G2 arrest in MCF-10A cell line (left) and G1 and G2 arrest in MCF7 
cell line (right) at 48 hr of 5μM Dox treatment (h; hours). B. Protein profiles and C. mRNA profiles of 
MCF-10A (left) and MCF7 (right) cell lines with no treatment or treatment with 5μM Dox for 6, 24 or 
48 hr. (Continued in Figure 23). 
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 Figure 23: MCF-10A and MCF7 cell lines treated with 5μM Dox for different times shows the 
preferential depletion of DNMT1 and p300 expression in the non-transformed MCF-10A cells. 
Line graphs showing the depletion of DNMT1 and p300 protein expression normalized against actin in 
MCF-10A cells (left) but not in MCF7 (right) cells.  
 
 
Interestingly, DNMT1 was largely depleted in MCF-10A cells, while it was only 
marginally affected in MCF7 cells. Furthermore, DNMT1 protein expression 
correlated with the mRNA profiles (Figure 22c), suggesting that DNMT1 is 
transcriptionally regulated during the Dox-mediated DNA damage response. As 
quantified in the line graphs (Figure 23), the down-regulation of DNMT1 in MCF-
10A cells coincides with the reduction of p300, which is an essential transcription co-
activator for DNMT1 (except in p300-null HCT116 cell lines as discussed 
previously), while actin remained relatively unaffected. Overall, these results imply 
that DNMT1 is selectively depleted in non-transformed cell line (MCF-10A), and this 
may be due to a decrease in the transcription of its mRNA.  
 
To further validate this observation, parallel experiments were carried out in normal 
lung fibroblasts MRC5.NT and its SV40-counterpart MRC5.SV40 cell line. The flow 
cytometry data (Figure 24a) show that MRC5.NT and MRC5.SV40 cells behaved 
differently when treated with 5μM Dox for different time intervals. MRC5.SV40 cells 








Figure 24: MRC5.NT and MRC5.SV40 cell lines treated with 5μM Dox for different times shows 
the preferential depletion of DNMT1 and p300 expression in the non-transformed MRC5.NT 
cells. A. Flow cytometry analysis shows MRC5.NT (left) and MRC5.SV40 (right) cell lines behaved 
differently when treated with 5μM Dox treatment (h; hours). B. Protein profiles and C. mRNA profiles 
of MRC5.NT (left) and MRC5.SV40 (right) cell lines with no treatment or treatment with 5μM Dox for 




Figure 25:  MRC5.NT and MRC5.SV40 cell lines treated with 5μM Dox for different times shows 
the preferential depletion of DNMT1 and p300 expression in the non-transformed MRC5.NT 
cells. Line graphs showing the depletion of DNMT1 and p300 protein expression normalized against 
actin in MRC5.NT cells (left) but not in MRC5.SV40 (right) cells.  
 
 
was not observed in MRC5.NT cells. Strikingly, DNMT1 protein was significantly 
depleted in MRC5.NT cells as early as 12 hr of treatment while negligible changes 
were observed in MRC5.SV40 cells even at 48 hr of treatment (Figure 24b), similar to 
MCF-10A and MCF7 cells respectively. Furthermore, the protein expression 
correlates with the mRNA profiles (Figure 24c), suggesting that DNMT1 is 
transcriptionally regulated during Dox-mediated DNA damage. Again, the down-
regulation of DNMT1 coincides with the reduction of p300 as quantified in the line 
graphs (Figure 25), while actin remained relatively unaffected.  
 
Taken together, these data show that Dox leads to the selective depletion of DNMT1 
and p300 in the non-transformed cell lines (MCF-10A and MRC5.NT) while these 
proteins remained relatively unaffected in the transformed cell lines (MCF7 and 
MRC5.SV40).  
 
3.2.2 Doxorubicin induces micronuclei formation in transformed cell lines 
To understand the difference in the responses of transformed and non-transformed 
cell lines to Dox treatment, the DNA damaging effects elicited by Dox were studied. 
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Dox is known to induce DNA double-strand breaks (DSBs) in mammalian cells which 
lead to the activation of an ATM-dependent DNA-damage response (Kurz et al., 
2004). ATM-dependent phosphorylation of the SQ motif at serine 139 of gamma-
histone.H2AX (γH2AX) is one of the earliest responses to DSBs and may be essential 
for the recruitment of repair factors to DNA damage sites (Burma et al., 2001; 
Rogakou et al., 1998). Indeed, treatment with 5μM Dox initiated a time-course 
induction in the phosphorylated serine 139-γH2AX (H2AX) staining at nuclear foci 
indicative of DSBs in both MCF-10A and MCF7 cell lines (Figure 26a). Consistently, 
MCF7 had more H2AX foci than MCF-10A cells, particularly at 48 hr of treatment.    
 
In addition to mediating the DNA damage response, Dox has been shown to induce 
both clastogenic and aneugenic micronuclei in mitotic cells (Dhawan et al., 2003); 
and the frequency of micronuclei induction has been recommended as a test procedure 
for evaluating the mutagenicity of chemicals. Interestingly, 5μM Dox was found to 
induce micronuclei structures in MCF7 cells as early as 24 hr of treatment (Figure 26b 
and enlarged image in Figure 27a). Surprisingly, these micronuclei structures were 
not detected in MCF-10A cells even after 48 hr of treatment. Of note, the formation of 
micronuclei in MCF7 cells coincides with a relatively stable DNMT1 (and p300) 
protein expression while the absence of micronuclei in MCF-10A cells coincides with 
a significant depletion in DNMT1 (and p300) protein expression (Figure 22). This 
data highlighted the observation that DNMT1 expression levels positively correlates 
with micronucleation. In addition, micronucleation in MCF7 cells was preceded by an 
increase in cell size (Figure 27b). Although micronuclei form during mitosis (whereby 
the cells would have already replicated their DNA and hence should be bigger), their 
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Figure 26: MCF-10A and MCF7 cell lines treated with 5μM Dox for different times shows the 
selective induction of micronuclei structures in MCF7 cells upon Dox-mediated DNA damage. A. 
MCF-10A (left) and MCF7 (right) cell lines treated with 5μM Dox for 6, 24 or 48 hr and stained with 
phosphorylated serine 139-γH2AX (H2AX) and Hoechst 33342 (DNA) shows the time-dependent 
induction of phosphorylated serine 139-H2AX foci upon Dox treatment (h; hours). B.  Cell staining of 
MCF-10A (left) and MCF7 (right) cell lines with D12 mAb specific for DNMT1 (DNMT1) and 
Hoechst 33342 (DNA) shows the selective induction of micronuclei structures (indicated by the 
arrows) in MCF7 cells with 5μM Dox starting at 24 hr of treatment. The DNMT1 staining in MCF-10A 
cells was very weak after 24 hr of Dox treatment and was digitally enhanced to enable the 
identification of the DNMT1 protein in the nucleus. (Continued in Figure 27). 
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Figure 27: Formation of micronuclei in MCF7 cells upon Dox treatment coincides with an 
increase in cell size. A. MCF7 cells with no treatment (24C) or treatment with 5μM Dox for 24 hr (24h 
Dox) and stained with Hoechst 33342 shows the formation of micronuclei structures (indicated by the 
arrows) from the nucleus (enlarged image). B. Histogram showing the diameter (microns) of MCF7 
cells with no treatment (white bar) or treatment with 5μM Dox (black bar) for different times. 
 
To ascertain if the difference in response between the two cell lines is due to varying 
degrees of Dox-mediated DNA damage, the Comet assay was carried out. This assay 
has been widely used to measure DNA damage in the form of single-strand breaks, 
DSB and protein-associated strand breaks, and therefore it can potentially detect the 
range of DNA damage mediated by Dox (Collins, 2004). As shown in the histogram 
(Figure 28), though Dox can induce substantial amount of DNA damage in both cell 
lines, the level of DNA damage was relatively higher in MCF7 cells (see longer tail 




 Figure 28: Comet assay on MCF-10A (yellow bars) and MCF7 cells (green bars) with no 
treatment (24C) or treatment with 5μM Dox for 24 hr (Dox) shows a higher level of DNA 
damage, as determined by the longer average tail moment randomly scored in 200 cells, in MCF7 
as compared to MCF-10A cells.  
 
 
The results obtained to this point imply that Dox-mediated DNA damage induced 
micronuclei formation in the tumorigenic/transformed but not the non-
tumorigenic/non-transformed cell lines. In parallel experiments, MRC5.NT and 
MRC5.SV40 cell lines were treated with 5μM Dox for different time intervals. 
Similar to MCF-10A and MCF7 cell lines, treatment with 5μM Dox initiated a time-
dependent induction in the phosphorylated serine 139-γH2AX (H2AX) staining at 
nuclear foci indicative of DSBs in both MRC5.NT and MRC5.SV40 cell lines (Figure 
29a). In addition, micronuclei were detected in MRC5.SV40 cells as early as 24 hr of 
treatment, but not in MRC5.NT cells even after 48 hr of treatment (Figure 29b and 
30a). Similar to MCF7 cells (Figure 27b), micronucleation in MRC5.SV40 cells also 
coincides with an increase in cell size as compared to the control (Figure 30b). 
 
Taken together, I hypothesized that normal or non-tumorigenic cells might be more 
efficient in the repair of DNA lesions as compared to tumor cells and consequently, 






Figure 29:  MRC5.NT and MRC5.SV40 cell lines treated with 5μM Dox for different times shows 
the selective induction of micronuclei structures in MRC5.SV40 cells upon Dox-mediated DNA 
damage. A. MRC5.NT (left) and MRC5.SV40 (right) cell lines treated with 5μM Dox for 6, 24 or 48 
hr and stained with phosphorylated serine 139-γH2AX (H2AX) and Hoechst 33342 (DNA) shows the 
time-dependent induction of phosphorylated serine 139-H2AX foci upon Dox treatment (h; hours). B.  
Cell staining of MRC5.NT (left) and MRC5.SV40 (right) cell lines with D12 mAb specific for DNMT1 
(DNMT1) and Hoechst 33342 (DNA) shows the selective induction of micronuclei structures 
(indicated by the arrows) in MRC5.SV40 cells with 5μM Dox starting at 24 hr of treatment. The 
DNMT1 staining in MRC5.NT cells was very weak after 24 hr of Dox treatment and was digitally 
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Figure 30: Formation of micronuclei in MRC5.SV40 cells upon Dox treatment coincides with an 
increase in cell size. A. MRC5.SV40 cells with no treatment (24C) or treatment with 5μM Dox for 24 
hr (24h Dox) and stained with Hoechst 33342 shows the formation of micronuclei structures (indicated 
by the arrows) from the nucleus (enlarged image). B. Histogram showing the diameter (microns) of 




3.2.3 Doxorubicin-mediated micronuclei formation is a general phenomenon in 
transformed cell lines 
A panel of mammalian cell lines treated with 5μM Dox for 24 hr was studied to 
further validate that Dox induces micronuclei formation in transformed cell lines only, 
and that the down-regulation of DNMT1 in non-transformed cell lines may be one of 
the reason for the lack of micronuclei induction in these cells. 
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Figure 31: Mammalian cell lines treated with 5μM Dox for 24 hr shows the preferential depletion 
of DNMT1, which correlates with the absence of micronuclei, in the non-tumorigenic cell lines 
(IMR90, MCF-10A and MRC5.NT). A. Protein profiles of DNMT1, p53, phosphorylated S15-p53 
(pS-p53) and actin in mammalian cell lines treated with 5μM Dox for 24 hr; the respective protein 
loading is normalized against that of MCF7 cells. B. Table showing the relative DNMT1 protein 
expression normalized against actin and the formation of micronuclei structures in the mammalian cell 
lines upon Dox treatment. 
 
 
The Western blots (Figure 31a) show that Dox-mediated DNA damage led to the 
phosphorylation of p53 proteins (pS-p53) in all the cell lines studied, with the 
exception of IMR90 cells which showed negligible level of p53 induction, and H1299 
and HCT116 p53-/- cell lines which are both p53-null. Interestingly, DNMT1 was 
significantly depleted in the non-transformed cell lines IMR90 (breast), MCF-10A 
(breast) and MRC5.NT (lung). On the other hand, DNMT1 protein was marginally 
affected in the panel of transformed cell lines tested (Figure 31a and 31b). The protein 
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expression of DNMT1 was normalized against actin, and quantified as a percentage 
relative to the control cells. As shown in the table (Figure 31b), the significant 
reduction of DNMT1 in the non-transformed cell lines coincides with the absence of 
micronuclei upon Dox treatment. Taken together, the data suggest that the induction 
of micronuclei by Dox is a general phenomenon confined to mammalian transformed 
cell lines, is associated with retention of DNMT1 expression, and is not dependent on 
p53 status. 
 
A few key observations were made from the experiments so far. Firstly, Dox 
selectively depletes DNMT1 protein and mRNA levels in the non-transformed cell 
lines, and this was associated with a reduction of co-activator p300 protein, at least as 
shown in MCF-10A and MRC5.NT cell lines. Secondly, Dox-mediated DNA damage 
induces micronuclei formation accompanied by an increase in cell size in the 
transformed cell lines only. Lastly, DNMT1 expression levels positively correlates 
with micronucleation, and that the down-regulation of DNMT1 in the non-
transformed cell lines may be the reason for the lack of micronuclei formation in these 
cells, thus implying that DNMT1 is necessary for the Dox-mediated micronucleation. 
It will therefore be interesting to elucidate the importance of DNMT1, as well as other 
proteins, in such Dox-induced chromosomal abnormalities.   
 
3.2.4 Doxorubicin retards proliferation in both transformed and non-
transformed cell lines 
Although cancer cells were once thought to be unable to undergo senescence, a 
senescence-like phenotype characterized by polyploidization and inability to 
proliferate has been observed in cancer cells subjected to anti-cancer treatments (Shay 
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and Roninson, 2004), including Dox at low doses (Eom et al., 2005). To determine 
whether Dox leads to growth retardation and whether this is true only of the cancer 
cells (hence possibly contributing to micro-nucleation), two pairs of cell lines 
MCF7/MCF-10A and MRC5.SV40/MRC5.NT were treated with 5μM Dox for 





Proliferation assay of MCF-10A cells treated with 5μM DOX























   
Proliferation assay of MCF7 cells treated with 5μM DOX






















Figure 32: MCF-10A and MCF7 cells treated with 5μM Dox shows that Dox inhibits 
proliferation in both non-transformed and transformed cell lines. Line graphs showing the cell 
number (X106/ml) of MCF-10A (A) and MCF7 (B) cell lines with no treatment (■) or treatment with 




Proliferation assay of MRC5.NT cells treated with 5μM DOX






















Proliferation assay of MRC5.SV40 cells treated with 5μM DOX























Figure 33: MRC5.NT and MRC5.SV40 cells treated with 5μM Dox shows that Dox inhibits 
proliferation in both non-transformed and transformed cell lines. Line graphs showing the cell 
number (X106/ml) of MRC5.NT (A) and MRC5.SV40 (B) cell lines with no treatment (■) or treatment 
with 5μM Dox (▲) for different times (h; hours). 
 
 
As shown in the line graphs (Figure 32 and 33), the doubling times for MCF7, MCF-
10A and MRC5.SV40 cells were about 24 hr, while that of MRC5.NT cells were 
about >36 hr. Although Dox has been shown to induce senescence-like phenotypes in 
cancer cells commonly determined by the expression of SA-β-Galactosidase activity 
at pH 6.0, its comparative effect on normal or non-transformed cells has not been 
reported. Surprisingly, treatment with 5μM Dox effectively retards the proliferation of 
both transformed (see Figure 32b and 33b for MCF7 and MRC5.SV40, respectively) 
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and non-transformed (see Figure 32a and 33a for MCF-10A and MRC5.NT, 
respectively) cell lines as compared to the controls. Two key observations were made 
from this experiment. Firstly, the data clearly demonstrate that the reported ability of 
Dox to inhibit proliferation is not limited to cancer cells. Secondly, even though Dox 
can inhibit proliferation of both transformed and non-transformed cell lines, 
micronucleation was only detected in the transformed cell lines. This implies that 
Dox-induced growth retardation is not by itself a crucial event leading to 
micronucleation in the case of the transformed cell lines.  
 
By definition, cell division is a pre-requisite to the formation of micronuclei since 
micronuclei can only be formed during telophase. If the proliferative ability is greatly 
compromised in the transformed cell lines, how is it possible for micronuclei to form 
in the absence of cell division? It is likely that micro-nucleation proceeds via 
endoreduplication, a process whereby cells undergo the next round of DNA 
replication without entering mitosis (and this can be determined by the presence of 
multiple centromeres in the cells), similar to the observations made by Sliwinska et al 
(Sliwinska et al., 2008). Since no mitosis took place, this event was not detected by 
the proliferation assay. Additionally, it is possible that cells underwent telophase but 
did not proceed through to cell division. Both events, coupled with an increase in cell 
size, are characteristics of cancer cells undergoing DNA damaged-induced 
senescence-like morphological changes, which is distinguishable from cellular 
senescence (by the lack of telomere shortening). Whether endoreduplication or 
endomitosis took place is still unclear and is not the present focus, but it will be 
interesting to determine the answer to this question in the future. Nevertheless, my 
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data clearly show that Dox inhibits proliferation of both non-transformed and 
transformed cell lines even though micronucleation was only detected in the latter. 
 
3.2.5 Doxorubicin induces micronuclei formation in transformed cell lines in a 
dose and time-dependent manner 
To further assess the effect of Dox on transformed or cancer cell lines with regards to 
micronucleation, MCF7 cells were treated with different doses of Dox or with 5μM 
Dox for different time intervals, and the frequency of micronuclei formation was 
randomly scored in 200 cells. The basal level of micronuclei in the control cells was 
very low (Figure 34a). On the other hand, increasing number of cells with micronuclei 
structures were detected at 2.5μM, 3.75μM, 5μM and 6.25μM of Dox. Of note, the 
cells exhibited slightly fewer micronuclei at 7.5μM Dox as compared to 6.25μM Dox. 
There are a few possible reasons for this observation; firstly, 5μM to 6.25μM Dox 
may be the optimal concentration for inducing micronuclei structures in these cells, 
and any increase in the dose may not lead to any further increase in micronuclei 
frequency at 24 hr. Secondly, 7.5μM Dox may be too lethal for MCF7 cells such that 
most cells bypass forming micronuclei and die directly. However, more experiments 
are needed to confirm this idea.  
 
In addition to a dose-dependent response, treatment of MCF7 cells with 5μM Dox for 
different time intervals resulted in a time-dependent increase in micronuclei frequency 
(Figure 34b). Taken together, these data show that Dox induces micronuclei 
formation in transformed cell lines, at least in MCF7 cells, in a dose and time-
dependent manners. Since substantial numbers of micronuclei can be detected at 24 hr 
of treatment with 5μM Dox, this dose was subsequently used for further studies. 
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Figure 34: MCF7 cells treated with different doses of Dox or with 5μM Dox for different times 
shows that Dox induces micronuclei structures in transformed cell lines in a dose and time-
dependent manner. A. Histogram showing percentage of micronucleated cells in MCF7 with no 
treatment (24C) or treatment with 2.5, 3.75, 5, 6.25 or 7.5μM Dox for 24 hr. B. Histogram showing 




3.2.6 Induction of micronuclei correlates with decrease in cell viability and 
increase in cell death in transformed cell lines 
It is believed that DNA damage-induced polyploidization is a common feature of 
cancer cells undergoing aberrant mitosis due to an inherent genomic instability. It 
remains a question as to whether micronuclei formation is a ‘good’ or ‘bad’ event. 
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Since micronuclei formation results in the loss of chromosomal DNA fragments 
which may eventually lead to a genetic imbalance, excessive micronuclei should in 
theory lead to drastic effect on the physiological status of the cells that survive. 
Alternatively, micronuclei might be beneficial in the sense that they might trigger the 
death of cells that would otherwise become genetically unstable. To address this 
question, the effect of Dox on cell survival was investigated. 
 
MCF-10A and MCF7 cell lines were treated with 5μM Dox for different time 
intervals, and this resulted in time-dependent accumulation of micronucleated cells in 
MCF7, while negligible micronucleated cells were detected in MCF-10A even at 144 
hr of treatment (Figure 35a). Interestingly, excessive micronuclei induction in MCF7 
cells eventually led to a progressive decrease in the cell viability (measured using the 
tryphan blue extrusion method), which correlates with an increase in cell death 
(measured using the LDH assay) as early as 48 hr of treatment. Of note, significant 
cell death was already detected in MCF7 cells even when the cell viability was 
apparently not much affected (compare the cell viability and cell death at 48 hr in 
MCF7 cells, Figure 35b and 35c). One reason for this observation could be due to the 
limitations of the tryphan blue extrusion method (using the Vi-Cell Analyzer) to 
detect dying cells that might have ruptured into fragments; these cells were not 
detected as a single event or count. Comparatively, Dox did not lead to significant 
changes in the cell survival rate of MCF-10A cells. These data imply that even though 
Dox treatment inhibits proliferation in both transformed and non-transformed cell 
lines (Figure 32 and 33), the selective induction of micronuclei in the transformed cell 
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Figure 35: Induction of micronuclei correlates with a decrease in cell viability and increase in cell 
death in MCF7 cells. A. Line graph showing the percentage of micronucleated cells randomly scored 
in 200 cells in MCF-10A (■) and MCF7 (▲) cell lines treated with 5μM Dox for different times. B.  
Line graph showing the cell viability (%) of MCF-10A (■) and MCF7 (▲) cell lines treated with 5μM 
Dox for different times; the cell viability was measured using the tryphan blue exclusion method. C. 
Histogram showing the frequency of cell death (%) in MCF-10A (left) and MCF7 (right) cell lines 
treated with 5μM Dox for different times; cell death was measured using the LDH assay. 
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Figure 36: Induction of micronuclei correlates with a decrease in cell viability and increase in cell 
death in MRC5.SV40 cells. A. Line graph showing the percentage of micronucleated cells randomly 
scored in 200 cells in MRC5.NT (■) and MRC5.SV40 (▲) cell lines treated with 5μM Dox for 
different times. B.  Line graph showing the cell viability (%) of MRC5.NT (■) and MRC5.SV40 (▲) 
cell lines treated with 5μM Dox for different times; the cell viability was measured using the tryphan 
blue exclusion method. C. Histogram showing the frequency of cell death (%) in MRC5.NT (left) and 
MRC5.SV40 (right) cell lines treated with 5μM Dox for different times; cell death was measured using 
the LDH assay. 
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To further validate these observations, the experiments were repeated with the 
MRC5.NT and MRC5.SV40 cell lines. Similarly, treatment with 5μM Dox led to 
time-dependent accumulation of micronucleated cells in MRC5.SV40 but not in 
MRC5.NT cells (Figure 36a). The increase in micronuclei frequency correlated with a 
decrease in cell viability and increase in cell death in the MRC5.SV40 cells (Figure 
36b and c), similar to MCF7 (Figure 35). On the other hand, loss of viability was not 
detected in the MRC5.NT cells even at 144 hr of treatment (Figure 36b). Dox 
treatment of these non-transformed cells did result in a modest increase in cell death 
in the cytotoxicity assay (Figure 36c), which was, however, substantially lower and 
did not increase over time as compared with its transformed counterpart 
(MRC5.SV40).  
 
Collectively, these data show that the selective induction of micronuclei in the 
transformed cell lines strongly correlates with a decrease in cell viability and increase 
in cell death, which was not detected in the non-transformed cell lines. These findings 
may have significant implications in the use of micronuclei detection as an in vitro 
genotoxicity test for the evaluation of (potential) chemotherapeutic drugs. 
 
3.2.7 Doxorubicin-mediated micronuclei structures are sites of DNA damage 
Even though Dox can induce both clastogenic and aneugenic micronuclei in 
mammalian cells, the precise contents of the micronuclei structures are not known. 
Since Dox-induced micronuclei are absent in non-tumorigenic cells (MCF-10A and 
MRC5.NT), micronuclei may be sites of DNA damage that contain DNA from 
“defective” repair events leading to their extrusion from the nucleus in response to 
Topoisomerase poisons such as Dox. In addition, the selective depletion of DNMT1
  
 
Figure 37: Immunostaining of MCF7 cells treated with 5μM Doxorubicin for 24 hr and viewed 
under the fluorescent microscope or by confocal imaging shows the specific localization of H2AX 
(A), Nucleophosmin/B23 (B), DNMT1 (C) and MRE11 (D) in the micronuclei structures while RB 
staining (E) was not detected. The cellular DNA is stained with Hoechst 33342 (DNA) and 




in non-tumorigenic cell lines (MCF-10A and MRC5.NT) and the detection of a sub-
fractions of DNMT1 in the micronuclei structures in tumorigenic cell lines (MCF7 
and MRC5.SV40) may suggest that DNMT1 is involved in the Dox-mediated DNA 
damage response.  
 
As mentioned previously, phosphorylated serine 139-γH2AX is a common marker 
used for identifying DNA damage in cells. The immunostaining (Figure 37a) show 
that phosphorylated serine 139-γH2AX (H2AX) was localized in the micronuclei 
upon Dox-mediated DNA damage. In addition, MRE11, which is a component of the 
mismatch repair (MMR) complex, was also detected in the micronuclei structures 
(Figure 37d). Since both H2AX and MRE11 are involved in the DNA damage 
response, the data imply that Dox-mediated micronuclei structures are potentially 
sites of DNA damage. As shown in Figure 37b, nucleophosmin/B23 staining was also 
identified in the DNA-containing micronuclei structures. This preliminary finding is 
surprising because even though it has been demonstrated that Dox-mediated DNA 
damage leads to the translocation of nucleophosmin/B23 from the nucleolus to the 
nucleus (Chan et al., 1987), the direct link between nucleophosmin/B23 and 
micronuclei has not been documented. This novel observation implies that 
micronuclei possibly contain components from the nucleolar compartment which are 
translocated during Dox-mediated DNA damage. Of note, my unpublished data also 
show that nucleophosmin/B23 can associate with DNMT1 in the cellular and 
nucleolar fractions of cells treated with Dox in co-immunoprecipitation experiments, 
and that both proteins co-localize in micronuclei structures (data not shown). 
However, more work is needed to ascertain the link between nucleophosmin/B23 and 
DNMT1 in the DNA damage-induced micronucleation.  
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Similar to what has been observed previously in MCF7 and MRC5.SV40 cells, 
DNMT1 was consistently detected in the micronuclei structures (Figure 37c). The 
localization of DNMT1 was specific since RB, which serves as a negative control, 
was not detected in the micronuclei (Figure 37e). Though there are increasing reports 
suggesting the involvement of DNMT1 in the DNA damage response, the possible 
role(s) of DNMT1 in micronucleation is not known to date. This novel observation 
indicates for the first time the direct involvement of DNMT1 in such DNA damage-
induced chromosomal impairments in mammalian cells. 
 
3.2.8 Depletion of DNMT1 by 5AzadC treatment attenuates Dox-mediated 
micronuclei formation  
Given that micronuclei contain a significant amount of DNA based on DAPI staining, 
Dox treatment must induce substantial DNA damage in the genome leading to 
excision or recombinant repair where large DNA fragments are excised. One of the 
most crucial aspects for excision and recombination repair, where large fragments of 
DNA are re-synthesized, is to ensure that DNA methylation patterns of the repaired 
(or re-synthesized) DNA is faithfully restored. This activity of DNMT1 in the DNA 
damage response has long been observed in a few key points. Firstly, DNMT1 has 
high affinity for damaged DNA (Smit, 1999). Secondly, DNMT1 can interact with the 
DNA replication and repair factor PCNA (Iida et al., 2002). Thirdly, DNMT1 possess 
the ability to locate at DNA ends and has been shown to be recruited to DNA 
damaged sites (Mortusewicz et al., 2005). Lastly, the induction of micronuclei in 
transformed cell lines is correlated with the lack of significant DNMT1 (and p300) 
depletion. As such, DNMT1 is a potential candidate for further studies of its role in 
micronucleation.  
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To test whether DNMT1 plays a role in the induction of micronuclei in response to 
Dox, MCF7 and MCF-10A cells were co-treated with different combinations of 5μM 
Dox and 2.5μM 5AzadC for 24 hr (Table 3 below). 5Aza-2-deoxycytidine (5AzadC) 
is a cytosine structural analogue that has been shown to induce rapid loss of DNMT1 
upon repeated replications (Santini et al., 2001). The 5AzadC treatment was carried 
out using a concentration of 2.5μM, which has previously been found to effectively 
deplete the endogenous DNMT1 in mammalian cell lines without having adverse 
effects on the cell cycle (data not shown). Indeed, the flow cytometry data (Figure 
38a) show that 5AzadC treatment alone did not lead to significant alteration in the cell 
cycle profiles of both MCF7 and MCF-10A cells. 
  
Treatments Descriptions 
 24C No treatment 
 DOX 5μM Dox for 1hr and harvested at 24 hr post-treatment 
 5AzadC 2.5μM 5AzadC for 24 hr 
 DOX – 5AzadC Dox for 1hr, followed by 5AzadC for 24 hr 
 5AzadC – DOX 
5AzadC for 1 hr, followed by Dox and 5AzadC for 1 hr, and finally 
with 5AzadC for 22 hr 
 DOX + 5AzadC Dox and 5AzadC for 1hr, followed by 5AzadC for 23 hr 
 
Table 3:  Description of the different combinations of treatments with 5μM Doxorubicin and 
2.5μM 5AzadC for 24 hr in MCF7 and MCF-10A cell lines. 
 
 
As observed in the Western blots (Figure 38b), DNMT1 protein was effectively 
depleted by 5AzadC in both MCF7 and MCF-10A cells. On the other hand, DNMT1 
was selectively depleted by Dox in MCF-10A but not MCF7 cells, as discussed 
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previously. Interestingly, the co-treatment of cells with Dox/5AzadC showed that Dox 
can at least partially block the depletion of DNMT1 by 5AzadC only in MCF7 cells. 
Although this result is surprising, it indicates that Dox induced significant alteration 
of DNMT1 properties in the MCF7 cells such that DNMT1 became less sensitive to 
the effect of 5AzadC. This could possibly come about if the recruitment of DNMT1 to 
DNA damage sites (i.e. micronuclei structures) during Dox-mediated DNA damage in 







Figure 38: MCF7 and MCF-10A cell lines treated with 5μM Doxorubicin and 2.5μM 5AzadC for 
24 hr shows that Dox can selectively block the 5AzadC-mediated DNMT1 degradation in MCF7 
cells. A.  Flow cytometry analysis shows that MCF7 (top) and MCF-10A (bottom) behaved similarly in 
the co-treatment. B. Protein profiles of MCF7 (left) and MCF-10A (right) cells with no treatment (24C) 
or treatment with a combination of 5μM Dox and 2.5μM 5AzadC for 24 hr. (Continued in Figure 39). 
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Figure 39:  MCF7 and MCF-10A cell lines treated with 5μM Doxorubicin and 2.5μM 5AzadC for 
24 hr shows the depletion of DNMT1 by 5AzadC attenuates Dox-mediated micronuclei formation 
in MCF7 cells. A.  Immunostaining with DNMT1-specific D12 mAb (DNMT1) and Hoechst 33342 
(DNA) shows the induction of micronuclei structures in MCF7 cells (top), which was absence in MCF-
10A cells (bottom). B. Histogram showing the percentage of micronucleated cells randomly scored in 
200 cells in MCF7 (white bar) and MCF-10A (black bar) cell lines treated with 5μM Dox for 24 hr.  
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To ascertain whether the depletion of DNMT1 by 5AzadC can affect Dox-mediated 
micronucleation, immunostaining was carried out in MCF7 and MCF-10A cell lines, 
and the percentage of micronucleated cells was randomly scored in 200 cells. As 
anticipated, Dox induced micronucleation in MCF7 but not in MCF-10A cells. 
Although 5AzadC was reported to induce micronuclei formation in human cancer 
cells (Stresemann et al., 2006), micronuclei were not detected in both cell lines treated 
with 5AzadC alone (Figure 39a). One explanation for the controversy in the data can 
be explained by the used of different cell lines; Stresemann et al used TK6 (human 
lymphoblastoid) cells as compared to the used of MCF7 and MCF-10A cells in this 
experiment. In addition, even though Stresemann et al used a lower concentration of 
5AzadC (up to 0.5μM), the duration of the 5AzadC treatments was also significantly 
different, which could have contributed to the difference in the data. Importantly, co-
treatment of MCF7 cells with any of three combinations of Dox and 5AzadC inhibited 
a fraction of the endogenous DNMT1 (as observed by about 70% reduction in 
DNMT1 levels, Figure 38b), and this correlates with up to 50% reduction in 
micronucleated cells as compared to treatment with Dox alone (Figure 39b). These 
data imply that DNMT1 may play a significant role in intiating micronucleation upon 
DNA damage, at least in MCF7 cells. 
 
3.2.9 Knockout of DNMT1 attenuates Dox-mediated micronuclei formation 
5AzadC can lead to the formation of both DNMT1- and DNMT3-DNA adducts 
during DNA replication. Interestingly, it has previously been shown that 5AzadC 
mediates cell death and apoptosis in embryonic stem cells primarily through 
DNMT3a and DNMT3b (Oka et al., 2005). In contrast, DNMT1, but not DNMT3a 
and DNMT3b, was selectively degraded via a proteasomal pathway upon 5AzadC 
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treatment in mammalian cell lines (Ghoshal et al., 2005). The effect of 5AzadC was 
further complicated by the recent report suggesting that 5AzadC induces the 
formation of double-strand DNA breaks that involves both DNMT1 and DNMT3b 
(Palii et al., 2008). The controversial data leads to the argument that the attenuation of 
Dox-mediated micronuclei formation by 5AzadC could be exerted by its effect on 
DNMT3a and DNMT3b rather than DNMT1 alone. 
 
To address this argument, DNMT1+/+ and DNMT1-/- (knockout by homologous 
recombination) HCT116 cell lines were treated with 5μM Dox for different time 
intervals. The Western blots (Figure 40b) show the absence of DNMT1 protein in the 
DNMT1-/- HCT116 cells. The knockout of DNMT1 in the DNMT1-/- HCT116 cells 
was further confirmed with the immunostaining data (Figure 41a) which showed 
negligible DNMT1 staining in the DNMT1-/- cells as compared to DNMT1+/+ 
counterpart. Interestingly, even though Dox induced micronucleation in both 
DNMT1+/+ and DNMT1-/- HCT116 cell lines at 24 hr of treatment (Figure 40c), the 
percentage of micronucleated cells randomly scored in 200 cells revealed that the 
DNMT1-/- cells display significantly fewer micronuclei as compared to the DNMT1+/+ 
cells (Figure 41a). As the cell cycle profiles of DNMT1+/+ and DNMT1-/- HCT116 
cell lines appeared similar (Figure 40a), we are certain that the difference in 
micronuclei frequency is not attributed to the cell cycle stages. Since a deficit in 
DNMT1 attenuated Dox-mediated micronuclei formation in the DNMT1-/- HCT116 
cells, the data strongly imply that DNMT1 may be responsible for promoting 
micronucleation, which agrees with the data from previous experiment. However, if 
DNMT1 is the sole player for mediating the micronucleation process, one would 









Figure 40:  HCT116 DNMT1+/+ and DNMT1-/- cell lines treated with 5μM Dox for different times 
shows fewer micronuclei formation in the absence of DNMT1. A. Flow cytometry analysis shows 
HCT116 DNMT1+/+ (top) and DNMT1-/- (bottom) cell lines behaved similarly when treated with 5μM 
Dox treatment for 6, 24 or 48 hr (h; hours). B. Protein profiles of HCT116 DNMT1+/+ (left) and 
DNMT1-/- (right) cell lines with no treatment (C) or treatment with 5μM Dox for different times. C. 
Immunostaining was carried out using DNMT1-specific D12 mAb (DNMT1) and Hoechst 33342 
(DNA); micronuclei structures were detected in both cell lines treated with 5μM Dox for 24 hr. 
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Figure 41:  HCT116 DNMT1+/+ and DNMT1-/- cell lines treated with 5μM Dox for 24 hr shows 
that loss of DNMT1 attenuate Dox-mediated micronuclei formation but was unable to ‘rescue’ 
cell viability. A. Histogram showing the percentage of micronucleated cells randomly scored in 200 
cells in HCT116 DNMT1+/+ (white bar) and DNMT1-/- (black bar) cell lines treated with 5μM Dox for 
24 hr. B. Line graph showing the cell viability (%) of HCT116 DNMT1+/+ (■) and DNMT1-/- (▲) cell 
lines treated with 5μM Dox for different times; the cell viability was measured using the tryphan blue 
exclusion method. C. Histograms showing the frequency of cell death (%) in DNMT1+/+ (left) and 
DNMT1-/- (right) HCT116 cell lines treated with 5μM Dox for different times; the cell death was 
measured using the LDH assay.  
 








































question, it is necessary to point out that there are controversial data regarding the 
activity of DNMT1 in DNMT1-/- HCT116 cells. Most importantly, Egger et al 
identified a truncated DNMT1 isoforms in the DNMT1-/- HCT116 cells, which retain 
some activity of the full-length DNMT1 protein (Egger et al., 2006). As such, 
complete inhibition of micronuclei in these cells was not expected. In addition, 
DNMT1 may play an important, but not crucial role, in promoting micronucleation.  
 
As shown previously, micronuclei induction correlates with decrease in cell viability 
and increase in cell death in MCF7 (Figure 35a and 35b) and MRC5.SV40 (Figure 
36a and 36b) cell lines. In addition, Dox-mediated micronuclei formation was 
significantly inhibited in the absence or partial loss of DNMT1 in HCT116 cells 
(Figure 41a). From these findings, one would expect to see some rescue of cell 
viability in the DNMT1-/- HCT116 cells as compared to the DNMT1+/+ counterpart 
when treated with Dox. However, the decrease in cell viability in the Dox-treated 
DNMT1-/- HCT116 cells was actually slightly greater than that in DNMT1+/+ cells at 
the different time intervals studied. Of note, there was a huge increase in Dox-induced 
cell death in the DNMT1-/- HCT116 cells, which reached about 100% at 144 hr of 
treatment, compared to 60% in DNMT1+/+ HCT116 cells (Figure 41c). The 
explanation for these results apparently contradicts with the MCF7 and MRC5.SV40 
data, and could lie in the lethal effect of the partial loss of full length DNMT1 in 
HCT116 cells, thus causing a relatively high level of basal cell death in the untreated 
DNMT1-/- HCT116 cells (compare control of DNMT1+/+ and DNMT1-/- HCT116 
cells, Figure 41c).  
 
Importantly, if the high basal numbers of dying cells (Figure 41c) is subtracted from
the Dox-treated values, then the highest increase in Dox-induced cell death in the 
DNMT1-/- cells (45%) is actually lower than the values for the DNMT1+/+ cells (60%). 
This method of calculation now suggests that loss of DNMT1 partially rescues the 
cells from Dox cytotoxicity. However, loss of DNMT1 was not able to completely 
abolish the cytotoxicity effect of Dox due to the relatively high level of micronuclei 
that was still detected in the DNMT1-/- cells; micronuclei formation probably needs to 
be inhibited to a low threshold before significant beneficial effect, if any, on viability 
can be observed.      
 
Collectively, these data suggest that reduction in or partial loss of DNMT1 reduces 
Dox-mediated micronuclei formation in some transformed cell lines, including MCF-
7, MRC-5.SV40 and HCT116. Moreover, attenuating DNMT1 expression was 
associated with loss of viability in MCF-7 and MRC-5.SV40 cells, but whether 
DNMT1 contributes to cell death in HCT116 remains inconclusive and cannot be 
fully answered because deletion of DNMT1 itself compromises cell viability. 
 
3.2.10 Knockdown of DNMT1 by siRNA-mediated transfection attenuates Dox-
mediated micronuclei formation 
In another direct approach to understanding the involvement of DNMT1 in Dox-
mediated micronucleation, MCF7 cells were transfected with siRNA to DNMT1 for 
8, 32 or 48 hr using Oligofectamine Transfection Reagent (Invitrogen) to deplete the 
endogenous DNMT1 expression. Empty transfection (Mock) and transfection with 
siRNA to LacZ were used as controls.  
 







Figure 42: SiRNA-mediated DNMT1 knockdown leads to inhibition of micronuclei formation in 
MCF7 cells. A. Protein profiles of MCF7 cells with no transfection (Mock) or transfected with 100nM 
si-LacZ (siLacZ) or 100nM si-DNMT1 (siDNMT1) for 8, 32 or 48 hr (h; hours). B. Immunostaining 
was carried out using DNMT1-specific D12 mAb (DNMT1) and Hoechst 33342 (DNA) on transfected 
MCF7 cells with no treatment (MCF7 24h Control, top) and transfected MCF7 cells treated with 5μM 
Dox for 24 hr (MCF7 24h Dox, bottom); micronuclei structures are indicated by the arrows. 
(Continued in Figure 43). 
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Figure 43: Si-RNA mediated DNMT1 knockdown leads to inhibition of micronuclei formation in 
MCF7 cells. Histogram showing the percentage of micronucleated cells randomly scored in 200 cells 
in transfected MCF7 cells with no treatment (white bar) or treatment with 5μM Dox for 24 hr (black 
bar). 
 
a time-dependent manner as compared to the controls. In addition, the
immunostaining (Figure 42b) shows that majority of the endogenous DNMT1 protein 
was depleted upon transfection with si-DNMT1 for 24 hr. The transfected cells were 
then treated with 5μM Dox for another 24 hr to examine their response with regards 
to micronuclei induction. As expected, treatment with Dox induced significant 
numbers of micronucleated cells in the Mock, si-LacZ and si-DNMT1-transfected 
MCF7 cells (Figure 43). Strikingly, the percentage of micronucleated cells randomly 
scored in 200 cells revealed that DNMT1 knockdown was able to suppress the 
micronuclei frequency by more than 50% as compared to the controls (compare si-
DNMT1 with Mock treated with 5μM Dox for 24 hr, Figure 42). The drastic 
difference in the number of micronucleated cells is not dependent on the cell cycle 
stages since DNMT1 siRNA did not alter the cell cycle profiles (Figure 16a). Taken 
together, the data from the DNMT1 knockout and knockdown experiments in the 
HCT116 and MCF7 cell lines provide further evidence that DNMT1 plays a 
prominant role in promoting micronuclei formation upon Dox-mediated DNA damage 
in tumorigenic or transformed cell lines, which has not been reported to date.  
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3.2.11 Discussion  
The detection of micronuclei is widely used as an in vitro genotoxicity test in drug 
evaluation. Numerous studies on micronuclei have been carried out in both murine 
and human cells; and they mainly centered around the use of DNA-damaging agents 
that induce double strand DNA breaks. A recent report shows that UVA irradiation 
from sunlight can also induce the formation of micronuclei which may contribute to 
chromosomal aberration associated with skin carcinogenesis (Wischermann et al., 
2008). Similarly, adriamycin, a chemotherapeutic agent, has been reported to increase 
sister chromatid exchanges and chromosomal aberrations which may potentially 
contribute to micronuclei induction (Bean et al., 1992). In line with this, Dox, a 
derivative of adriamycin, has been shown to induce micronucleation in human HeLa 
cell lines (Jagetia and Nayak, 1996). My results further compare the genotoxic actions 
of Dox on normal and cancer cell lines which has not been reported to date. 
 
The comparison study in my thesis shows that Dox selectively induces senescence-
like morphological changes characterized by multi-nucleation, swelling of cells, 
followed by a reduction in cell viability in cancer or transformed cell lines (MCF7 and 
MCR5-SV40), which was not observed in normal or non-transformed cell lines 
(MCF-10A and MRC5.NT) even though substantial DNA damage was detected. 
Importantly, the appearance of micronuclei in the cancer cell lines is associated with 
an increase in the G2 cell population, particularly at 24 hr of treatment (Figure 22a 
and 24a). This is expected since micronuclei are essentially chromatin-containing 
bodies that lag in anaphase due to the failure of sister chromatids to segregate 
properly, and are extruded into the cytoplasm during telophase (Lindholm et al., 
1991). The detection of multiple micronuclei in a single cell suggests that the 
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micronuclei may contain acentric chromosomes or chromatid fragments instead of 
whole chrosomosomes or chromatids, since it is unlikely for a single cell to lose 
multiple whole chromosomes and yet maintain cell viability to some extent. However, 
it is unclear whether micronuclei formation is a normal (e.g. repair-related) or 
defective event. This question can possibly be addressed by the excessive formation 
of micronuclei in transformed cell lines, which eventually leads to a decrease in cell 
viability and an increase in cell death, suggesting that micronuclei probably harbor 
“defective” repair events leading to their extrusion from the nucleus. This does not 
come as a surprise since micronuclei formation no doubt results in the loss of 
chromosomal DNA fragments, which may eventually lead to genetic imbalances and 
ultimately result in cell death. In agreement with this, Jagetia et al also reported that 
the induction of micronuclei with adriamycin is inversely correlated with cell survival 
in HeLa cell lines (Jagetia and Nayak, 1996).  
 
A recent report suggests that the formation of micronuclei induced by nocodazole, a 
chemotherapeutic agent which interferes with the formation of mitotic spindles, 
involves the interplay between caspase-3 and microtubule integrity (Decordier et al., 
2008). The author showed that the frequency of nocodazole-induced micronuclei in 
caspase-3-deficient MCF7 cells is significantly lower as compared to MCF7 stably 
transfected with functional caspase-3 gene (MCF7casp3+). It was postulated that, similar 
to lamin B (Kottke et al., 2002) and nuclear pore complex protein Nup153 (Buendia 
et al., 1999), components of the nuclear envelope could be potential targets for 
caspase-3 in micronuclei formation, and caspase-3-dependent cleavage of these 
components resulted in micronuclei formation. However, though caspase-3 may be 
involved in micronuclei formation, it may not be an essential factor since significant 
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amount of nocodazole-induced micronuclei (about 40%) were still detected in the 
parental MCF7 cells. My data further demonstrate that substantial micronuclei were 
induced in MCF7 cells lacking functional capsase-3 activity upon Dox treatment. 
Aside from the difference in the drug used, both results support the involvement of 
caspase-3-independent mechanism in DNA damage-induced micronucleation. 
 
Decordier et al further demonstrated that apoptosis is induced at a threshold 
concentration of nocodazole, which contributes to the elimination of the 
micronucleated cells, when there is excessive chromosome loss and non-disjunction 
(Decordier et al., 2008). On the other hand, Eom et al reported that cell death induced 
by Dox can occur by two different regulatory mechanisms – apoptosis and mitotic 
catastrophe (Eom et al., 2005). Though the mechanism remains to be elucidated, both 
studies support that the formation of micronuclei eventually leads to cell death. In line 
with these, my data consistently show that several days after treatment with Dox, cell 
survival was greatly compromised following micronuclei induction in the transformed 
cell lines. The lack of obvious cell death in the early hours of treatment might be 
explained by the use of sub-lethal dosage of Dox. My analyses were based on the pre-
treatment of cells with Dox for 1 hr as compared to the continuous exposure of cells 
to Dox used in many other studies. The advantage of this experimental design allows 
the study of cells during the process of Dox-mediated multi-nucleation before 
significant cell death is triggered, which might otherwise interfere with the analysis.  
 
I discovered that Dox induces micronucleation in tumorigenic cell lines only, but the 
mechanism has yet to be elucidated. Interestingly, the absence of micronuclei 
formation in non-tumorigenic cell lines is consistently associated with significant 
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depletion in DNMT1 expression that appears to be in part caused by the reduction of 
p300, as discussed in my earlier results (Section 3.1). Although it is still not clear how 
p300 was selectively targeted for degradation, work by Poizat et al showed that Dox 
treatment in cardiac cells activates the p38 MAPK pathway which phosphorylates and 
degrades p300 (Poizat et al., 2005). The novel finding by Poizat et al may provide a 
mechanistic explanation for the depletion of p300 protein, and consequently DNMT1, 
as observed in non-tumorigenic cell lines. On the other hand, my work showed that 
DNMT1 (and p300) expression is relatively unaffected in the panel of tumorigenic 
cell lines that form micronuclei. This interesting finding suggests that DNMT1 may 
be a crucial factor involved in the selective demise of cancer cells, but not normal 
cells, during Dox treatment. Several lines of evidence presented in my thesis further 
show that DNMT1 contributes to Dox-mediated micronuclei formation i.e. 
chromosomal instability in tumorigenic cell lines. The mechanism is unknown, but 
may possibly involve DNMT1 targeting components of the nuclear envelope similar 
to what has been suggested for caspase-3, or by interfering with microtubule 
assembly. Since dysregulated DNMT1 expression is often associated with 
tumorigenesis (Agoston et al., 2005; Peng et al., 2005), the expression levels of 
DNMT1 in the tumor cells may therefore be a crucial factor in determining the 
cytotoxic effect of chemotherapeutic drugs, particularly Dox, which agrees with the 
observation in my thesis. Of note, DNMT1 has also been shown to be a potential 
target for cancer therapy of tumor cells exhibiting oxidative multimodality-resistant 
phenotype (MMRP) (Mishra et al., 2008).  
 
Given the importance of DNMT1 in promoting micronucleation, one would expect 
few, if any, micronuclei following the complete loss of DNMT1. However, 
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micronuclei were still detected in the Dox-treated DNMT1-/- HCT116 cells. This can 
be explained in two ways. First, a truncated DNMT1 that has part of the N-terminal 
regulatory domain deleted, but retains the C-terminal catalytic domain was identified 
in the DNMT1-/- HCT116 cells (Egger et al., 2006). This truncated protein possesses 
DNA methylation activity which might potentially contribute, at least partially, to 
DNMT1 activity during the Dox-mediated DNA damage response. In agreement with 
this postulation, Spada et al further showed that this truncated DNMT1 protein, 
though lacking the PCNA-binding domain, displayed only twofold reduced post-
replicative DNA methylation maintenance activity (Spada et al., 2007). Secondly, 
although DNMT1 contributes to micronuclei formation, other mechanisms may also 
be involved in HCT116 cells. Compensatory effect(s), if any, of other DNMTs (i.e. 
DNMT3a and 3b) in the partial absence of DNMT1 under my experimental conditions 
may also have contributed to micronucleation in the DNMT1-/- HCT116 cells. Of 
note, the link between DNMT3a/3b and micronuclei formation has not been 
documented, and will prove to be an important area for future study. Nevertheless, my 
data demonstrate that the partial loss of DNMT1 in DNMT1-/- HCT116 cells still 
attenuates micronuclei formation significantly, further supporting the idea of DNMT1 
being one of the molecular targets for Dox in cancer therapy. 
 
In addition, Yokochi et al demonstrated that the treatment of DNMT1+/+ HCT116 
cells with a certain dosage of Dox induced apoptotic cell death (Yokochi and 
Robertson, 2004). This conditional apoptosis was not observed in DNMT1-/- HCT116 
cells, implying a role for DNMT1 in targeting human cancer cells for cell death, at 
least in this context. My data show a strong positive correlation between DNMT1 and 
micronucleation. However, under my experimental conditions where micronuclei was 
 148
induced, although the loss of DNMT1 in DNMT1-/- HCT116 cells slightly attenuates 
Dox-mediated micronuclei formation, it seemed unable to ‘rescue’ cells to a 
significant extent from the ultimate cell death. This might mean that the frequency of 
micronucleation needs to be inhibited to a low threshold before beneficial effect, if 
any, on cell viability can be observed. In addition, DNMT1 has been shown to be 
important for cell survival, and that loss of DNMT1 compromises the viability of 
mammalian cells, as reviewed by Brown et al (Brown and Robertson, 2007). The 
indispensable role of DNMT1 in maintaining cell viability is conserved in both mice 
and humans, as mice deficient in DNMT1 die during embryogenesis (Li et al., 1992), 
and mouse fibroblasts lacking DNMT1 die within a few divisions (Jackson-Grusby et 
al., 2001). As such, the (partial) loss of full length DNMT1 in HCT116 cells may 
have compromised cell viability, as shown by the relatively high level of basal cell 
death (Figure 41c), which inevitably resulted in more dying cells upon DNA damage. 
Nevertheless, by subtracting the basal level of cell death from the DNMT1+/+ and 
DNMT1-/- HCT116 cell lines, my data show that the (partial) loss of DNMT1 in 
HCT116 cells appears to have resulted in a lower level of cell death upon Dox-
mediated DNA damage (Figure 41c). Taken together, these data further highlighted 
the functional role(s) of DNMT1 in micronucleation and cell death in the response to 
DNA damage, at least in transformed or cancer cells.   
 
The data in my thesis clearly demonstrate that DNMT1 contributes to 
micronucleation, and the loss of DNMT1 attenuates micronuclei formation in the 
cancer or transformed cell lines. On the other hand, Chen et al showed that complete 
deletion of DNMT1 in the HCT116 DNMT1-/- cells (which still displayed some 
DNMT1 activity) using Cre-LoxP inducible knockout strategy leads to mitotic 
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defects, formation of multiple micronuclei and eventual cell death via mitotic 
catastrophe (Chen et al., 2007a; Rhee et al., 2000). The controversy regarding the role 
of DNMT1 in micronucleation arises due to the differences in the system studied. 
DNMT1 may be necessary for promoting micronucleation in cells in response to 
drug-induced DNA damage. However, under normal physiological conditions, the 
complete loss of DNMT1 leads to genomic inbalance as a result of aberrant 
hypomethylation or methylation-independent defects (such as DNA replication). Due 
to the complexity of the different roles played by DNMT1 in mammalian cells, these 
inevitable leads to mitotic failure and cell death, which could be significantly different 
from the DNA damage-induced response elicited by Dox treatment. 
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Chapter 4: CONCLUSIONS, IMPLICATIONS AND FUTURE 
DIRECTIONS 
 
Conclusions   
In conclusion, my findings provide the first mechanistic explanation for the inverse 
relationship observed between DNMT1 and p21WAF1 proteins in mammalian cells that 
are independent of DNA methylation. I showed that DNMT1 transcription is 
dependent on E2F1 and Sp1. In addition, I identified p300 as a crucial transcriptional 
co-activator for E2F1 and Sp1 in regulating human DNMT1 expression. Interestingly, 
other than negatively regulating E2F1 transcriptional activity, I showed that p21WAF1 
can potentially inhibit p300 levels and functions, and thus negatively regulates 
DNMT1 expression. However, in the absence of p300 (HCT116 cell lines), Sp1 was 
selectively inhibited by p21WAF1 (in contrast to p300-expressing cell lines), and 
thereby likely contributes to the down-regulation of DNMT1 expression. Although 
this is a very interesting finding, the exact mechanism whereby p21WAF1 can 
selectively target Sp1 in the absence of p300 needs further investigation. 
Nevertheless, the novel p21WAF1-E2F1/p300-DNMT1 pathway, as summarized in 
Diagram 7 below, may play a pivotal role to ensure DNMT1 expression and DNA 





                   
 
Diagram 7: Speculative model illustrating the mechanism(s) involved for the inverse relationship 
observed between DNMT1 and p21WAF1 in mammalian cells. 
 
 
Following this, I found that Dox-mediated DNA damage induces p21WAF1, and this 
leads to the selective depletion of p300, and consequently DNMT1, in the non-
tumorigenic cell lines. Although these data further emphasize the physiological 
significance of the relationship between DNMT1 and p300 proteins, it remains to be 
investigated how p300, and consequently DNMT1, is targeted for depletion in the 
non-transformed cell lines. Regardless, I found that the higher stability of DNMT1 
(and p300) in the transformed or cancer cell lines coincides with micronucleation, 
which consistently leads to a reduction in cell viability and an increase in cell death 
(Diagram 8). With the strong positive link between DNMT1 and micronuclei 
formation, I further investigated the role of DNMT1 and discovered that although 
DNMT1 plays an important role in micronuclei induction and its expression appears 
to correlate with cell death, it is unclear to what extent complete absence of full length 
DNMT1 can ‘rescue’ HCT116 cells from cell death. Nevertheless, my data 
demonstrate for the first time a mechanistic link between DNMT1 and multi-
nucleation during the DNA damage response in the mammalian cell lines. 
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Diagram 8: Speculative model illustrating the response of non-tumorigenic (normal) and 
tumorigenic (cancer) cell lines to the treatment with the Topoisomerase II poison (doxorubicin); 
the stability of DNMT1 in the cancer cell lines contributes to micronucleation. 
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Implications and Future Directions 
Eukaryotic gene expression is tightly regulated at the chromatin and transcription 
levels to maintain cellular homeostasis. The E2F family of transcription factors play 
pivotal roles in the regulation of gene expression, and E2F-responsive elements have 
been identified in many genes involved in cell cycle control and DNA synthesis, 
including DNMT1 (Muller et al., 1997). Although the ability of p21WAF1 to inhibit the 
transcriptional activity of E2F1 either directly or indirectly has been documented 
(Delavaine and La Thangue, 1999), it is still unclear how p21WAF1 affects E2F1 and 
consequently down-regulates DNMT1 (under the conditions described in my thesis). 
The p21WAF1 protein has been shown to associate with STAT and E2F1 transcription 
factors and be recruited to the promoters of c-myc and cdc25A genes following DNA 
damage by Topoisomerase inhibitors such as Dox (Vigneron et al., 2006). The ability 
of p21WAF1 to associate with DNA prompts further investigation of whether p21WAF1 
can potentially suppress DNMT1 directly via E2F/Sp1 sites.  
 
One approach would be to mutate the E2F sites on the DNMT1 promoter and evaluate 
whether DNMT1 expression is affected by p21WAF1. Chromatin immunoprecipiation 
assay could also be carried out to determine if p21WAF1 associates with the DNMT1 
promoter, particularly upon Dox-mediated DNA damage when p21WAF1 is induced. If 
this is true, is p21WAF1 recruited to the E2F/Sp1 sites via direct binding with E2F1 
and/or Sp1 proteins, similar to what was reported for the c-myc and cdc25A promoter? 
This question can be addressed by carrying out an immunoprecipitation assay to 
determine if p21WAF1 can indeed associate with E2F1 and/or Sp1, and whether RB 
could also be involved in this relationship. 
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Although unable to bind directly to DNA, the cofactor p300 exists as an important 
component of the transcription machinery in mammalian cells. Whereas the 
contribution of p300 in transcription regulation has been documented extensively, its 
direct contribution to DNMT1 expression, as demonstrated in my thesis, was never 
studied. A key finding in my study identifies p300 as a potential downstream target 
for p21WAF1, which may emerge as a novel mechanism for the control of DNMT1 
expression in mammalian cells. p21WAF1 has been shown to physically interact with 
p300 in vitro and that p21WAF1 co-localizes and associates with p300 at DNA damage 
sites induced by UV irradiation in human fibroblasts, as demonstrated by 
immunostaining and imuunoprecipitation assays (Cazzalini et al., 2008). As p21WAF1 
is significantly up-regulated during the Go or early G1 phase of the cell cycle (and 
this coincides with the down-regulation of p300 and DNMT1), it may be asked 
whether p21WAF1 can associate with p300 in a cell cycle dependent manner, and 
whether this association is maintained upon Dox treatment, particularly in normal and 
cancer cell lines. Some clues can be obtained by carrying out immunoprecipitations to 
determine the association of p21WAF1 and p300 in different cell cycle phases in 
synchronized cell extracts, as well as in untreated and Dox-treated cell extracts.  
 
Despite the many roles played by p300, the molecular basis for p300 regulation 
remains poorly understood. The transcriptional co-activity of p300 has been reported 
to be regulated at multiple levels, including post-translational modifications such as 
phosphorylation, acetylation and sumoylation, as reviewed by Ghosh and Varga 
(Ghosh and Varga, 2007). For example, Akt, also known as protein kinase B (PKB), 
is a downstream effector of phosphatidylinositol 3-kinase (PI3K) which exerts its 
function through phosphorylation of its substrate proteins at consensus sequence 
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RXRXXS/T (Obata et al., 2000). Akt was shown to interact and phosphorylate p300, 
and this activity of PI3K/Akt is necessary to prevent proteosomal degradation of p300 
and to maintain the cellular p300 steady-state levels (Chen et al., 2004). Conversely, 
PTEN, a dual lipid and tyrosine phosphatase that negatively regulates the PI3K/Akt 
pathway (Hlobilkova et al., 2006), was shown to mediate myostatin-induced p300 
degradation (Ji et al., 2008). Dox treatment has also been shown to induce the 
phosphorylation of p300 by p38 MAPK in cardiac cells, but this leads instead to its 
protein degradation rather than stabilization (Poizat et al., 2005). Nevertheless, the 
possible association of p21WAF1 with p300 may have contributed to some forms of 
modification to the p300 proteins which promote its degradation. Alternatively, 
p21WAF1 may indirectly promote p300 degradation via a secondary pathway. Either 
way, it is important to determine if p300 can undergo modifications (eg. 
phosphorylation or ubiquitination) prior to its degradation upon p21 over-expression 
(by transient transfection, TSA-mediated induction or DNA damage-induced 
conditions). This question can be addressed by carrying out immunoprecipitations 
using phospho-specific antibodies (once they become commercially available), and 
then probing for p300 in the immuno-complexes.  
 
In addition, possible cross-talk between p21WAF1 and the p38 MAPK pathway (which 
has been shown to be responsible for p300 phosphorylation and subsequent 
degradation upon Dox treatment) will be worth investigating, particularly in this 
context. One experimental approach would be to determine if inhibition of the p38 
MAPK pathway in p21WAF1 over-expression or upon Dox treatment could rescue p300 
degradation. Specific inhibitors for p38 MAPK such as SB202190 or SB203580 have 
been widely used (Muniyappa and Das, 2008). Alternatively, MAP kinase 
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phosphatases (MKPs) such as DUSP16/MKP-7 are able to selectively target the 
dephosphorylation and inactivation of p38 isoforms in mammalian cells (Owens and 
Keyse, 2007). One obvious advantage of inhibition rather than activation of the p38 
MAPK pathway (by osmotic shock, insulin etc) is that the induced activation of p38 
MAPK pathway may introduce other secondary factors that can potentially affect 
p300 turnover. Nevertheless, understanding how p21WAF1 suppresses p300, either 
directly or indirectly, may provide further insights into the inverse relationship 
between DNMT1 and p21WAF1, as well as the significance of p300 in transcriptional 
regulation (of DNMT1) in mammalian cells during the DNA damage response.  
 
Multi-nucleation is a hallmark of cancer cell lines undergoing DNA damage-induced 
senescence (Chang et al., 1999). Although it is understood that polyploidization is the 
result of aberrant mitosis due to failure in the cell cycle checkpoints, the route to 
multi-nucleation is poorly recognized. My discovery that DNMT1 contributes, to a 
significant extent, to the induction of micronuclei provides an explanation for the 
absence of DNA damage-induced micronuclei formation in the non-tumorigenic cell 
lines; since DNMT1 (and p300) is significantly depleted in these cells. Though this 
observation is an important clue in understanding the difference in the response of 
tumor and non-tumorigenic cells to Dox treatment, the mechanism underlying the 
selective depletion of DNMT1 in normal cells remains to be elucidated.  
 
Of note, even though I showed that p21WAF1 induction leads to the depletion of p300, 
and consequently DNMT1 expression (Figure 1c, 7b and 10b), the higher level of 
p21WAF1 induction in MCF7 compared to MCF-10A cells upon Dox treatment did not 
lead to the anticipated reduction of p300 and DNMT1; rather, p300 and DNMT1 
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appears to be more stable in the MCF7 cells. This observation can be explained in two 
ways. Firstly, even though an inverse relationship was observed between DNMT1 and 
p21WAF1 in the cell cycle and in DNA damage response (Figure 1b, 2 and 3), the 
cellular response to Dox treatment may be more complex than expected, since Dox 
not only acts as a Topoisomerase II poison, but also has a wide spectrum of 
cytotoxicity effects (Swift et al., 2006). As such, the ‘classical’ inverse relationship 
between DNMT1 and p21WAF1 was not maintained. Secondly, since DNMT1 and 
p300 mRNAs are down-regulated to a higher extent in non-transformed cells, I 
speculate that Dox somehow induces differential modifications of p300 in non-
tumorigenic cells compared with tumor cells (which may or may not be attributed to 
p21WAF1), which leads to greater p300 destabilization and degradation in the non-
tumorigenic cells. In another view, it is also likely that p300 is preferentially modified 
and stabilized in tumor cells which make it more resistant to the effect of Dox-
mediated p21WAF1 induction. Both postulations can be supported by the somewhat 
different mobilities of p300 isoforms in the Dox-treated cells (see the shift in p300 
protein bands particularly at 6hr of treatment with Dox as compared to the controls, 
Figure 22b). Nevertheless, how p21WAF1 affects p300, both in the cell cycle and upon 
Dox-mediated DNA damage, remains an important question that needs urgent 
investigation. 
 
Other than its major targets such as Topoisomerase II and DNA Polymerases, Dox has 
been shown to be a potent inhibitor of DNMT1 activity via DNA intercalation 
(Yokochi and Robertson, 2004). I speculate that this DNMT1-DNA-Dox complex 
may be perceived by the cellular DNA repair machinery as a lethal form of DNA 
damage adducts, similar to what has been reported for the cytotoxicity of 5AzadC 
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(Juttermann et al., 1994), which then facilitates the removal of this complex in the 
form of micronuclei structures. Several attempts had been taken to visualize this 
process by treating cells transfected with DNMT1 constructs tagged to GFP with Dox 
at a dosage known to induce micronuclei, and viewing the live cells with time-lapse 
microscopy. However, due to low transfection efficiencies and difficulty in the 
experimental design, no concrete data have been obtained yet. An alternative 
mechanism could likely be explained by the potential role of DNMT1 in DNA repair, 
as suggested by its involvement in the MMR pathway (Guo et al., 2004; Kim et al., 
2004). Micronuclei contain damaged DNA, and DNMT1 may possibly be involved in 
initiating the ‘extrusion’ of these chromosomal aberrations in an attempt to reduce 
mutations. Nevertheless, this idea remains elusive, and more investigations on the 
exact role(s) of DNMT1 in micronuclei formation will be needed. 
 
A key finding in my study characterized the contribution of DNMT1 to DNA 
damage-induced micronucleation of cancer cells. However, DNMT1 knockout was 
unable to rescue cells from ultimate cell death. Instead, slightly more cell death was 
actually detected in the DNMT1 knockout cells due to the high basal level of dying 
cells. This highlights the fact that other than its involvement in DNA damage-induced 
micro-nucleation, DNMT1 plays important roles in other cellular processes (such as 
maintaining DNA methylation patterns during DNA replication). Though DNMT1-/- 
HCT116 cells are essentially hypomorphs expressing truncated, yet active, DNMT1 
proteins (Egger et al., 2006), the reduced DNMT1 activity in these cells probably 
enhances genomic instability and compromises cell viability, as reviewed by Brown et 
al (Brown and Robertson, 2007). Whether DNMT1 directly promotes micronuclei 
formation by interfering with the division of the spindle microtubules, or whether 
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DNMT1 promotes some forms of stress or an aberrant signaling-induced senescence 
(STASIS) phenotype in the cancer cells, and that multi-nucleation is simply the 
downstream effect, is yet another issue awaiting further investigation. I have 
attempted to over-express DNMT1 in MCF7 cells to determine if DNMT1 up-
regulation can further enhance the micronucleation process and accelerate cell death 
upon Dox treatment. My preliminary findings (data not shown) show that DNMT1 
over-expression increased the frequency of micronuclei formation slightly. The data 
are encouraging even though the increase in micronuclei formation is marginal; this is 
likely due to that DNMT1 protein levels in MCF7 cells may have already reached 
saturation, and any further induction of DNMT1 is unable to promote further 
micronuclei formation in the response to Dox treatment. Due to the limitation of this 
experimental approach, I am currently utilizing the DNMT1-deficient cells (DNMT1-/- 
HCT116) in ‘gain-of-function’ experiments (data not shown). Thus, restoring 
expression of DNMT1 and its derivatives with mutations in specific functional 
domains (Diagram 1, page 27) should give further clues to the interaction partners and 
mechanisms of DNMT1 in Dox-mediated micronucleation. My preliminary data need 
further confirmation and therefore are not shown in this thesis. 
 
It has been proposed that apoptosis may be triggered by aberrant chromosomal 
segregation during the metaphase/anaphase transition (Castedo et al., 2004). 
However, it is still unclear whether the ultimate cell death following Dox treatment is 
caused by apoptosis or necrosis. Apoptotic or necrotic event can be distinguished by 
staining with PI/Annexin V staining and analyzed by FACS analysis - apoptotic cells 
stain either positive or negative for PI and positive for Annexin while necrotic cells 
stain positive for PI and negative for Annexin. Alternatively, cells may undergo 
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aberrant mitoses upon Dox treatment, which leads to cell death via mitotic 
catastrophe. Indeed, this seems to be a more likely mechanism since sub-lethal dosage 
of Dox was shown (in my thesis) to lead to growth arrest, enlarged cell size and multi-
nucleation, which are characteristic of cancer cells undergoing DNA damaged-
induced senescence-like morphological changes associated with mitotic catastrophe, 
as defined by Roninson et al (Roninson et al., 2001). These cells will then undergo 
cell death preceding massive micronucleation. This form of senescence-like 
phenotype, also termed as STASIS (stress or aberrant signaling-induced senescence), 
can be identified by an increase in SA-β-Gal expression detectable by 5-bromo-4-
chloro-3-indolyl β-D-galactoside (X-Gal) staining at pH 6.0, but is distinguished from 
normal replicative senescence by the lack of telomere shortening (Shay and Roninson, 
2004). Of note, cells undergoing mitotic catastrophe do not form DNA ladders (He et 
al., 2002) or distinct DNA breaks detectable by TUNEL staining (Chang et al., 1999), 
and these have proven to be a useful techniques for differentiating mitotic catastrophe 
and apoptosis. These experimental approaches may be useful in elucidating the exact 
mechanism for the cytotoxic effect of Dox in the context of STASIS. However, 
although mitotic catastrophe is fundamentally different from apoptosis and/or 
necrosis, some research groups have suggested that cell death via mitotic catastrophe 
may be preceded by apoptosis or necrosis, or both. This no doubt adds further 
complications to this issue. 
 
If Dox-induced micronucleation is indeed caused by aberrant mitosis, it remains a 
question whether it is the result of cells undergoing a second round of DNA 
replication without entering mitosis (endoreduplication) or cells being forced through 
a second round of mitosis without DNA replication (endomitosis) due to a defect in 
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the mitotic spindle checkpoints (Sliwinska et al., 2008). Identifying the number of 
centrosomes in the micronucleated cells or the staining patterns of both gamma- and 
beta-tubulins may provide some clues to this question. Nevertheless, how is it 
possible for a Topoisomerase II poison, which essentially induces double-strand DNA 
breaks, to induce spindle damage? This question could probably be addressed by Eom 
et al, who demonstrated that low dose of Dox down-regulates several mitosis-
associated proteins including Mad2 and BubR1 (Eom et al., 2005). The crosstalk 
between the DNA damage checkpoint and spindle checkpoint is further supported by 
the impairment in G2/M cell cycle arrest upon Dox-induced DNA damage response in 
BubR1-/- cells (Fang et al., 2006). Understanding how Dox potentially activates 
mitotic spindle damage may greatly enhance the efficacy of this drug in 
chemotherapy. It may also be worthwhile to investigate the potential involvement of 
DNMT1 in this spindle checkpoint response. Fluorescence In-Situ Hybridization 
(FISH) may also be carried out using chromosome-specific probes to identify the 
chromosomes distribution in the micronucleated nuclei of these treated cells. 
 
The translocation of nucleophosmin/B23 from the nucleolar to the micronuclei 
structures (Figure 36) and its association with DNMT1 in-vivo (my data not shown) 
may be an important finding. How might a nucleolar protein that participates in 
ribosomal biogenesis take part in micronuclei formation induced by the cellular 
damage response? This may imply major nucleolar reorganization due to dispersal of 
nucleolar components in response to Dox, which can be addressed using nucleolar 
markers such as Fibrillarin and Ki-67. The nucleolus is the site of ribosome subunit 
biogenesis in eukaryotic cells and has been proposed as a DNA damage response 
center (Horn and Vousden, 2004). Ribosomal genes are synthesised in multiple gene 
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copies (>500) in the nucleolus, and only a fraction of these genes are transciptionally 
active, while the remainder are epigenetically suppressed by CpG methylation of their 
promoters (Majumder et al., 2006). If the nucleolus is indeed a site for the DNA 
damage response, then the extensive number of ribosomal and repetitive genes will 
definitely be affected during DNA damage, especially in this context. How is DNMT1 
involved in DNA damaged-mediated nucleolar translocation to micronuclei? In 
addition to the ability of DNMT1 to associate with B23 even after Dox insult (data 
not shown), work by Espada et al showed that DNMT1 may be necessary for the 
maintenance of nucleolar organization (Espada et al., 2007). These findings suggest 
future investigations to determine whether Dox-mediated nucleolar translocation is 
augmented by DNMT1 protein.  
 
My preliminary results from MCF7 and E6-transformed MCF7 (MCF7-E6) cell lines 
in addition to what has already been reported suggest that p53 may suppress 
micronucleation in mammalian cells. The involvement of p53, if confirmed, on the 
mechanisms, physiological significance and relationship to DNMT1 (and 
nucleophosmin/B23) will be worth looking into. Possibly, in-vivo 
immunoprecipitations can be carried out to determine the association of these 
proteins, if any, under normal conditions as well as upon Dox treatment in p53 wild-
type and p53-defective cell lines. The complexity of my findings would no doubt 
kick-start more investigation. 
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